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General Introduction
Guido J. Jenniskens 
Jacques H. Veerkamp 
Toin H. van Kuppevelt
Department o f Matrix Biochemistry, University 
Medical Center, NCMLS, Nijmegen, The 
Netherlands
Submitted.

For centuries, it has been recognized that skeletal muscle 
effectuates positioning and movement in multicellular 
organisms. Initial studies focused on tissue structure and 
histology, later studies on metabolism and electrophysiology. 
Nowadays, sophisticated research tools such as NMR, video 
speed confocal imaging of intracellular ion fluxes, and 
recombinant DNA techniques enable scientists to intervene in 
the cellular physiology and learn about muscle functioning at 
the cellular and subcellular level. In recent years, there has 
been an emerging interest in the composition of the extracellular 
matrix (ECM) and in the developmental and physiological roles 
of its constituents. In this review, we will focus on a single class 
of ECM-resident molecules and their emerging roles in muscle 
development and physiology: heparan sulfate proteoglycans. 
The emphasis will be on the structure and significance of the 
heparan sulfate moiety.
Skeletal muscle tissue
In higher organisms, three distinct types of muscle tissue can be 
distinguished: 1) smooth muscle, which is involuntary, 2) cardiac muscle, 
which is also involuntary and forms most of the heart, and 3) skeletal 
muscle, which owes its name to its attachment to bones and its impor­
tant role in the positioning and the voluntary (somatic) movement of the 
skeleton and which is also an important player in breathing (involuntary; 
diaphragm).
Morphology and physiology
Attachment of skeletal muscle to bony structures is achieved by ten­
dons, which are continuous with a sheet of connective tissue surrounding 
the muscle, the epimysium. Skeletal muscle is build up of hundreds to 
thousands of long cylindrical cells, called muscle fibers or myofibers, 
which are parallel ordered in fascicles (Fig. 1). A sheet of connective 
tissue, called the perimysium, which is continuous with the epimysium, 
surrounds the fascicles. The endomysium surrounds the separate 
myofibers. The sum of the connective tissue located between myofibers 
is often called interstitium, whereas the endomysial component that lies 
closest to the myofiber surface is referred to as basal lamina (BL; Sanes, 
1986; see further). The cell membrane surrounding a myofiber is called 
the sarcolemma.
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Figure 1. Connective tissue of skeletal muscle. (a)
Tendons that are connected to bones are continuous 
with the connective tissue of skeletal muscle. (b) The 
connective tissue is organized in three continuous 
layers: the epimysium encircles the whole muscle, the 
perimysium surrounds bundles of 10-100 individual 
myofibers, so called fascicles, and the endomysium 
separates individual myofibers from one another. Blood 
vessels and motor neurons are located within the 
perimysium and divide into a network of capillaries and 
nerve branches extending into the endomysium 
(Adapted from Torotora GJ and Reynolds Garabowski S 
(1996), Principles of anatomy and physiology, Harper 
Collins, New York. (with permission)).
Myofibrils
Myofibrils, the contractile elements of striated muscle, are 1-2 jam in 
diameter and are build up of thin filaments (actin complexed with 
troponin and tropomyosin) and thick filaments (myosin), which are 
arranged in sarcomeres, the basic functional units of muscle contraction 
(Fig. 2). Sarcomeres are bordered by Z discs, narrow areas of dense 
material, in which actin filaments are anchored in a regular pattern. 
Myosin filaments are orderly located between the actin filaments, 
overlapping with two opposite arrays of actin filaments to a greater or 
lesser extent (depending on the contractile state of the muscle). The 
regular arrangement of both types of filaments is causal for the striated 
appearance of skeletal muscle in microscopy. A darker area within each 
sarcomere, called the A band, consists mostly of the myosin filaments 
but also includes portions of the actin filaments. Alternating with A bands 
are the I bands, regions of lesser density which contain the rest of the 
actin filaments as well as the Z disc. In the center of the A band, the H 
zone represents the region where only myosin but no actin filaments are 
located. The M line is formed by proteins that connect adjacent myosin 
fibers and divides the H zone in two.
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Figure 2. Organization of skeletal muscle. (a)
Individual myofibers (muscle cells) are composed of 
multiple myofibrils and surrounded by the sarcolemma. 
(b) Myofibrils contain thin (actin) filaments and thick 
(myosin) filaments, arranged in sarcomeres, the basic 
contractile elements of skeletal muscle. (c) Narrow 
regions of dense material, called Z disks, separate 
sarcomeres. Actin filaments are anchored into the Z 
discs in a regular pattern, and overlap partially with 
myosin filaments. The alternating density of the highly 
arranged molecules is causal for the striated 
appearance of skeletal muscle. Dark A bands, 
consisting of the myosin filaments and parts of the 
actin filaments, alternate with I bands, which are 
composed of actin filaments and the Z disc. The H zone 
within the A band covers the region where only myosin 
filaments are located, and the M line comprises of 
proteins that connect adjacent myosin filaments 
(Adapted from Torotora GJ and Reynolds Garabowski S 
(1996), Principles of anatomy and physiology, Harper 
Collins, New York. (with permission)).
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Muscle contraction
Actin and myosin filaments function by shortening the distance between 
the Z disks (i.e. contraction) of a sarcomere, according to the sliding 
filament theory, first described in the mid-1950s (Huxley, 2000). In short, 
an increase in the sarcoplasmic calcium (Ca2+) concentration causes a 
change of shape in the troponin-tropomyosin complex, enabling myosin 
to bind to actin. Under the release of ADP, myosin undergoes a 
conformational change drawing the thick filament towards the H zone 
(power stroke). Next, ATP binds to myosin, causing it to detach from 
the actin filament. The subsequent hydrolysis of ATP to ADP reorients 
myosin to its original state, enabling a second power stroke if ATP is 
available and the sarcoplasmic Ca2+ concentration remains high. The 
sliding of actin and myosin filaments causes the shortening of sarcomeres, 
which in turn leads to the shortening of the muscle fibers and ultimately 
to the contraction of the muscle.
Neuromuscular junction
Originally, the trigger for muscle contraction comes from motor neurons, 
which communicate with muscle fibers through specialized regions 
called neuromuscular junctions (NMJs; Fig. 3). At NMJs, the axon termi­
nal of a single branch of an innervating motor neuron contacts a single 
myofiber. Both cells show specializations at these sites of synaptic con­
tact (Engel, 1994). The axon terminal is divided into a cluster of synaptic 
end bulbs, which contain large numbers of membrane vesicles filled with 
the neurotransmitter acetylcholine (ACh). When a nerve action potential 
reaches the synaptic end bulbs, ACh is secreted by fusion of the synaptic 
vesicles with the plasma membrane. ACh diffuses over the 50 nm wide 
synaptic cleft, which is filled with the synaptic BL (sBL; see below), bet­
ween the nerve terminal and the facing muscle sarcolemma where it 
binds to acetylcholine receptors (AChRs). AChRs are large ACh-binding 
cation channels inserted in the postsynaptic sarcolemma on top of surface- 
increasing invaginations, the junctional folds. Upon binding of ACh, the 
AChR chanel opens which leads to an influx of Na+ ions along its 
electrochemical gradient, creating an endplate potential (EPP; Fig. 4). 
Voltage gated Na+ channels (vgNa+Chs), present in the postsynaptic 
sarcolemma at the troughs of the junctional folds, sense the EPP and 
open to increase the Na+ influx thus causing an action potential (AP). 
Next, the AP travels along the sarcolemma. The ACh released in the 
synaptic cleft is quickly degraded by acetylcholine esterase (AChE), an 
enzyme located specifically within the sBL.
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Figure 3. Skeletal muscle 
innervation and the 
neuromuscular junction. (a) 
Axon terminals of 
innervating motor neurons 
contact individual 
myofibers in specialized 
regions called synapses.
(b) Here, synaptic end 
bulbs, filled with 
acetylcholine (ACh)- 
containing synaptic 
vesicles, which can fuse 
with the presynaptic 
memebrane, lay in shallow 
gutters formed by the 
muscle membrane. (c) The 
postsynaptic membrane 
contains many 
invaginations, junctional 
folds, on top of which 
acetylcholine receptors 
(AChRs) are located. Upon 
arrival of a neural action 
potential, ACh is released 
by exocytosis and diffuses 
over the synaptic cleft, 
where it binds to AChRs in 
the motor end plate 
(Adapted from Torotora GJ 
and Reynolds Garabowski S 
(1996), Principles of 
anatomy and physiology, 
Harper Collins, New York. 
(with permission)).
Sarcoplasmic reticulum and transverse tubules
Each myofibril is encircled by an elaborate tubular membrane system 
called the sarcoplasmic reticulum (SR; Fig. 5; Franzini-Armstrong, 1972). 
The SR is similar to the smooth endoplasmic reticulum of nonmuscle 
cells, and primarily functions as a Ca2+ store. Highly specialized ion 
pumps and ion channels in the SR membrane maintain a Ca2+ gradient 
such, that the cytosolic Ca2+ concentration ([Ca2+]t) is low (less than 10­
7M) when the muscle is in its relaxed state (Berchtold et al., 2000). In
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Figure 4. Excitation-contraction coupling In skeletal 
musde. Upon binding of ACh, AChRs open which leads 
to an influx of Na4 ions, creating o local endplate 
potential (EPP). Subsequently, voltage-tfated Na* 
channels (VgNa’Chs), present In the postsynaptic 
sarcolemma at the bottoms of the junctional foîds, 
open which increases the Na* Influx to form an action 
potential (AP). The AP oravels along the sarcotemma to 
trigger dlhydropyrtdine rcceptors (DHPRs) present In 
the T-tubule system, which in turn activate ryanodln 
receptors (RyRs) in the sarcoplasmic reticulum (SR). 
This activation reads to the release of Co2* into the 
cytosol, which causes muscle contraction through the 
sliding of myosin filaments over actin filaments. 
Sarcoplasmic reticulum calcium ATPoSCS (SERCAs), 
present in the SR membrane, pump Ca** back into the 
SRf wWch restores the muscle resting potential.
Scanned frcm the 
priri ed tioncf this 
pLblication
mammalian muscles, two spatially distinct forms of SR are present: the 
longitudinal SR extends the full length of the A band, w hereas the 
fenestrated SR is oriented along the I band. At each A-l band junction, 
tubular invaginations of the sarcolemma, catted transverse tubules (T- 
tubules), penetrate transversely towards the center o f the myofiber. The 
inside o f T-tubulcs is continuous with the extracellular environment and 
filled with extracellular fluid and ECM (Davis and O riso n , 19£4). On
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Figure 5. Skeletal muscle 
architecture: the 
sarcoplasmic reticulum, T- 
tubules, and the triad. 
Myofibrils (1) are encircled 
by the SR (2), an elaborate 
membrane system that 
connects to tubular 
invaginations in the 
sarcolemma present at the 
A-I band junction, the 
transverse tubules (T- 
tubules; 5, T). The terminal 
cisternae of the SR (3) 
together with the T-tubule 
membrane system are 
called triads (4), two of 
which are present per 
sarcomere. The SR over 
the I band is called the 
fenestrated SR, whereas 
the SR over the A band is 
called the longitudinal SR. 
6, sarcolemma; 7, basal 
lamina; 8, collagen fibrils 
(From Krstic RV (1979), 
General histology of the 
mammal, Springer-Verlag, 
New York. (with 
permission)).
both sides, T-tubules border the SR in specialized structures called ter­
minal cisternae. Together, the T-tubule and its bordering SR terminal 
cisternae are referred to as triad, two of which are present on each 
sarcomere.
Excitation-contraction coupling
Although both membrane systems are physically separated, highly 
specialized proteins enable the conversion of a sarcolemmal AP to SR 
Ca2+ release into the cytosol (Fig. 4). Dihydropyridine receptors (DHPRs) 
that are present in the T-tubular membrane are L-type Ca2+ channels 
containing a voltage sensor. Opposite to DHPRs, ryanodine receptors 
(RyRs, large tetrameric Ca2+ channels) are located in the SR membrane. 
When an AP travels along the sarcolemma of the T-tubule system, the
GENERAL INTRODUCTION 17
voltage sensor in the DHPR is activated, which causes the protein to 
undergo a conformational change. The sarcoplasmic loop between DHPR 
transmembrane domains 2 and 3 interacts with the large sarcoplasmic 
foot-domain of the RyR (Tanabe et al., 1990; El-Hayek et al., 1995; Nakai 
et al., 1998), causing this Ca2+ channel to open and release large amounts 
of Ca2+ into the cytosol, leading to muscle contraction. Upon release, 
Ca2+ is rapidly pumped back into the SR by sarcoplasmic reticulum Ca2+ 
ATPases (SERCAs). This cascade of AP-induced Ca2+ release and re­
uptake, which leads to temporal muscle contraction, is called excitation- 
contraction (e-c) coupling.
Skeletal muscle: development
Skeletal muscle tissue is derived from progenitor cells present in the 
embryonic mesenchyme of the somites (Fig. 6; Grinnel, 1995; Buckingham 
2001). Somites arise at an early stage of development by segmentation 
of the paraxial mesoderm, lateral to the neural groove and develop to 
form the myotome. Myotome cells, or presumptive myoblasts, are 
vigorously proliferating spindle-shaped cells, which have the capacity 
to differentiate into myoblasts. Myoblasts are capable of fusion to form 
syncytial myotubes, the precursors of myofibers.
Figure 6. Early events in 
myogenesis and 
synaptogenesis. (a)
Myogenic precursor cells 
arise from the somite, 
motor axons from somata 
in the neural tube, and 
Schwann cells from the 
neural crest. (b) Once 
these cells reach sites of 
muscles, myoblasts fuse to 
form myotubes that are 
innervated by motor axons, 
which are then surrounded 
by Schwann cells. (c) Initial 
contacts are unspecialized 
yet capable of rudimentary 
transmission. (d) As 
development proceeds, 
growth cones differentiate 
into nerve terminals, and 
AChRs accumulate in the 
postsynaptic membrane.
(e) By birth, the NMJ is fully functional. (From Sanes 
and Lichtman, 1999 (with permission)).
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Myogenesis
During embryogenesis in mouse (Mus musculus) and rat (Rattus 
norvégiens), somites develop from approximately embryonic day 8 (E8; 
Hogan, 1994). Organogenesis takes place from E10 until E14, followed 
by fetal growth and development until birth at approximately E20. At 
E12, muscle primordia already contain some multinucleate primary 
myotubes surrounded by myoblasts. Primary myotubes are elongated 
by myoblast fusion during two days, after which secondary myotubes 
are formed on the scaffold of primary myotubes between E14 and E16 
(Kelly and Zacks, 1969; Rubinstein and Kelly, 1981). Extracellular material 
is deposited on the myotube surface, beginning on E14, to form a 
continuous layer by E19 (Nakajima et al, 1980; Chiu and Sanes, 1984). 
The systems that specify myogenic identity are only beginning to be 
unraveled (Buckingham, 2001). Spatiotemporal expression of myogenic 
determination factors such as myogenin, Myf5, and MRF5 and family 
members of the MyoD, Wnt, and Pax families, together with the presence 
of signaling molecules such as growth factors (e.g. IGF, FGF-2, FGF-4, 
and TGF-ß), coordinate the proliferation and differentiation of myogenic 
cells (Rudnicki and Jaenisch, 1995; Buckingham, 2001).
Synaptogenesis
Motor nerves reach muscle primordia during the formation of primary 
myotubes, and innervate most of them, at about E12. Spontaneous 
quantal release of ACh precedes synaptic differentiation and the resulting 
electrical activity is shown to be important in differentiation and 
mononeuronal innervation of the myofiber and NMJ morphology 
(Grinnell, 1995; Busetto et al., 2000; Bezakova and L0mo, 2001). The nerve 
and the muscle each contribute to the synaptic differentiation on both 
the presynaptic and the postsynaptic side (Sanes et al., 1998b; Lin et al., 
2001). Specializations of the synaptic region include: 1) the clustering of 
AChRs in the motor endplate, which can be detected from E14, and 
replacement of the embryonic y-subunit of the AChR by the mature e- 
subunit 2) the enlargement of the nerve-muscle contact area, 3) the 
coverage of the nerve terminal by Schwann cells, 4) the widening of the 
synaptic cleft and the formation of a sBL, 5) the formation of dense zo­
nes, 6) the accumulation of AChE in the sBL, soon after the onset of 
AChR clustering and upon synaptic activity, and 7) the development of 
1 |j.m deep junctional folds in the postsynaptic membrane. Together these 
changes culminate in functional neuromuscular junctions with all pre- 
and postsynaptic specializations a few days postnatal. (Chiu and Sanes, 
1984; Hall and Sanes, 1993; Grinnell, 1995; Burden, 1998; Meier and 
Wallace, 1998; Sanes and Lichtman, 1999; 2001).
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Satellite cells
Of special interest is the regenerative capacity of muscle satellite cells 
that are present between the BL and the sarcolemma of myofibers. These 
undifferentiated multipotent muscle precursor cells mediate the postnatal 
growth and regeneration of muscle and are also activated in response to 
muscle exercise or trauma. Upon activation, satellite cells undergo multi­
ple rounds of division prior to fusing with existing myofibers or 
regeneration of injured muscle. Although the molecular mechanisms that 
regulate the activation and function of satellite cells are elusive, it is clear 
that factors, which are also involved in myogenesis, play important roles 
(Bischoff, 1994; Seale and Rudnicki, 2000; Hawke and Garry, 2001).
Extracellular matrix
The extracellular connective tissue of muscle is organized into three dis­
crete but mutually continuous sheets: the epimysium, the perimysium, 
and the endomysium. Muscle spindles, blood vessels, nerves, and fat 
cells are located within the perimysium. Here, blood vessels and nerves 
divide into a rich network of capillaries and nerve branches extending 
into the endomysium, which also contains fibroblasts, mast cells, and 
macrophages. The BL (see below) is a specialized sub-structure of the 
ECM, which lies close to the cell membrane. A sheet-like 50-100 nm thick 
BL, into which the extracellular domains of cell surface proteins may 
extend, completely encompasses muscle fibers.
The BL is a macromolecular network, which provides a structural 
and regulatory environment for cells. The BL is composed of several 
collagenous glycoproteins, noncollagenous glycoproteins, and 
proteoglycans (Table 1; Wight, 1991; Hall and Sanes, 1993; Kannus et al., 
1998; Meier and Wallace, 1998; Sanes and Lichtman, 1999). Whereas 
collagens are the major structural components of BL, noncollagenous 
glycoproteins, e.g. laminins, fibronectin, and tenascin mediate the 
adhesion of several cell types to collagenous substrates. Proteoglycans 
are major structural and regulatory components of the BL but also of the 
cell surface. These components will be elaborated upon further in this 
text.
Basal lamina
The BL of skeletal muscle contains significant amounts of collagen and 
laminin, that self-assemble to form supramolecular networks. These 
networks are interconnected by a large number of interactions with BL- 
resident proteins, notably entactin (nidogen) and proteoglycans. Cells
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Table 1. Components of the basal lamina and cell 
surface of muscle cells and their location
M olecu le Location Reference
Acetylcholinesterase s, BL McMahan et al., 1978
Acetylcholine receptor s, Cell S Salpeter and Loring, 1985
Carbohydrates (Lectin specific) s, Cell S Sanes and Cheny, 1982
Chondroitin sulfate proteoglycan c, BL Carrino and Caplan, 1982
Collagen IV (a1 and a2) e, BL Sanes et al., 1990
Collagen IV (a3, a4, and a5) s, BL Miner and Sanes, 1994
Collagen V e, BL Sanes and Cheny, 1982
Collagen XIII c, BL Sund et al., 2001
Collagen XVIII* c, BL Halfter et al., 1998
Decorin c, BL Andrade and Brandan, 1991
Dermatan sulfate proteoglycan c, BL Eggen et al., 1994
Dystrophin-glycoprotein complex c/s, Cell S Grady et al., 2000
ErbB2, 3, and 4 s, Cell S Zhu et al., 1995
Fibronectin c, BL Sanes and Cheny, 1982
Glypicans* c, Cell S Brandan et al., 1996
Heparin-binding growth associated molecule s, BL Szabat and Rauvala, 1996
Heparan sulfate epitopes c/s, BL Jenniskens et al., 2000
Heparan sulfate proteoglycan s, BL Anderson and Fambrough, 1983
Integrin-a3b1 s, Cell S Cohen et al., 2000
Integrin-a7(A/ B)ß1 s, Cell S von der Mark et al., 1991
Laminin-2 (merosin) e,n, BL Patton et al., 1997
Laminin-3 (s-laminin) s, BL Hunter et al., 1989
Laminins-4, -9, and -11 s, BL Patton et al., 1997
Laminin-8 n, BL Patton et al., 1997
M-cadherin c/s, Cell S Cifuentes-Diaz et al., 1996
Muscle-specific kinase (MuSK) s, Cell S Valenzuela et al., 1995
N-acetylgalactosaminyl-terminated carbohydrate s, BL Scott et al., 1988
N-acetylgalactosaminyl-terminated transferase s, Cell S Scott et al., 1990
Neural agrin* s, BL McMahan, 1990
Neural cell adhesion molecule (N-CAM) s, Cell S Rieger et al., 1985
Neuregulin-ß3 s, BL Rimer et al., 1998
Neuregulin-a s, Cell S Rimer et al., 1998
Nexin I s, BL Festoff et al., 1991
Nidogen c, BL Lerner and Torchia, 1986
Perlecan* c, BL Iozzo, 1994
S-nidogen s, BL Chiu and Ko, 1994
Syndecan-2* s, Cell S Hsueh et al., 1998
Syndecans* c, Cell S Bernfield et al., 1992
Tenascin-C c, BL Matsumoto et al., 1994
Tenascin-X c, BL Matsumoto et al., 1994
Tenascin-Y c, BL Hagios et al., 1996
Voltage gated sodium channels c, Cell S Lupa and Caldwell, 1991
Due to limitations of space, only a single reference has been cited for each entry 
* Heparan sulfate proteoglycan
Abbreviations: BL, basal lamina; Cell S, cell surface; c, common; c/s, common but concentrated (or 
different constitution) in synaptic; e, extrasynaptic; n, neural; s, synaptic
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are firmly anchored to adjacent BL by many receptor-ligand interactions, 
like the binding of collagen IV and laminins to integrins, laminin 
interactions with the dystrophin-glycoprotein complex, and the binding 
of laminins to cell surface proteoglycans (Fig. 7; Timpl and Brown, 1995; 
Erickson and Coughman, 2000).
The BL shows structural and functional specializations at sites of 
interaction with other cells. In the NMJ a sBL, which is continuous with 
the myofiber BL and with the Schwann cell BL, traverses the synaptic 
cleft and extends into the junctional folds (Hall and Sanes, 1993). 
Although morphologically indistinguishable from the extrasynaptic BL 
to which it is fused, the sBL is biochemically specialized to a high degree. 
Despite the fact that it only encompasses 0.1% of the myofiber surface, 
several BL-resident proteins or protein isoforms are concentrated in or 
are specific for the sBL. These include: neural agrin (McMahan, 1990), 
specific collagen IV isoforms (Sanes et al., 1990), several laminin isoforms 
(Hunter et al., 1989; Patton et al., 1997), AChE (McMahan et al., 1978), 
heparan sulfate proteoglycan (HSPG; Anderson and Fambrough, 1983), 
a N-acetylgalactosaminyl-terminated carbohydrate (Scott et al., 1988), 
nexin I (Festoff et al., 1991), and entactin (Chiu and Ko, 1994). Other 
proteins, like some collagen types, are totally absent from the sBL (Sanes 
and Cheney, 1982a). Only fibronectin and some other isoforms of col­
lagen and laminin are shared (Sanes, 1982; Sanes and Chiu, 1983; Sanes 
et al., 1990; Miner and Sanes, 1994; Patton et al., 1997). Staining with 
lectins or with monoclonal antibodies identified several carbohydrates 
specifically located on the myofiber surface (Sanes and Cheney, 1982b; 
Iglesias et al., 1992; Martin et al., 1999). Using phage display-derived 
antibodies against BL-resident heparan sulfate (HS) epitopes, it was 
shown that HS epitopes are also differentially distributed between 
synaptic and extrasynaptic BL (Jenniskens et al., 2000).
In recent years, it has become apparent that the BL plays many 
developm ental and physiological roles. The highly regulated 
spatiotemporal distribution of specific BL-components, contributed by 
muscle or by the innervating nerve, is thought to create a specific micro­
environment. The focal sequestering of biologically active proteins that 
bind to BL components, like e.g. growth factors, may be causal for 
processes such as myogenesis (Ontell and Kozeka, 1984; Kardami et al., 
1988; Jansen and Fladby, 1990), synaptogenesis (Anderson and 
Fambrough, 1983; Burden, 1998), and regeneration (Gulati et al., 1983; 
Caldwell et al., 1990; Husmann et al., 1996; Grounds et al., 1998). More­
over, during regeneration of the NMJ, pre- and postsynaptic 
specializations re-occur at the site of the original sBL even in absence of 
the muscle or nerve cell, respectively (Sanes, 1986). The structural 
integrity of the NMJ is lost when the BL is degraded (Salpeter et al.,
1992).
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N idogen
I Laminin-2 or -8
Figure 7. Complex interactions between the cell 
surface and the basal lamina. (a) At the neuromuscular 
junction, the nerve terminal of a motor neuron lies in a 
shallow gutter formed by the postsynaptic (muscle) 
membrane. The BL of the muscle and the nerve are 
continuous, though different in composition. The 
postsynaptic membrane contains clusters of AChRs on 
top of the junctional folds (adapted from Hall and 
Sanes, 1993 (with permission)). (b) In extrasynaptic 
areas the dystrophin glycoprotein complex (composed 
of dystrophin, a-dystroglycan (a), ß-dystroglycan (ß), 
sarcospan, sarcoglycans, and MuSK (M)) interacts with 
laminin(-2 or -8), which in turn interact with e.g. 
nidogen and collagens. (c) In synaptic areas the 
dystrophin glycoprotein complex contains utrophin 
instead of dystrophin and connects with AChRs 
through rapsyn (R). Agrin (A), a HSPG, interacts with 
a-dystroglycan, MuSK, and laminin(-3, -4, -9, or -11), 
which in turn interact with e.g. nidogen, collagens, and 
the HSPG perlecan, to which AChE is bound (Adapted 
from Jacobson et al., 2001 (with permission)).
Collagens
Collagens form a family of closely related proteins that distinguish 
themselves from other glycoproteins by a triple-helical segment. In 
skeletal muscle ECM, several collagen types and isoforms are 
demonstrated in situ (Mayne and Sanderson, 1985; Sanes, 1986; Sund et 
al., 2001) as well as in cultured myocytes (Beach et al., 1985). Of these 
proteins, collagen XVIII bares HS chains (Halfter et al., 1998), whereas
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collagen types IX and XII are part-time proteoglycans, sometimes having 
GAG side chains (Erickson and Couchman, 2000). Collagens I and III 
are major components of the epimysium and the perimysium, whereas 
collagen V is present in lesser amounts (Mayne and Sanderson, 1985). In 
the BL, collagens I, III, IV, and V are detected, of which collagen IV is 
most prominent. Collagen IV isoforms show a differential BL- 
distribution: a1 and a2 chains are less abundant in the sBL (Sanes et al.,
1990), whereas a3 and a4 are unique for, and a5 is strongly enriched in 
the sBL (Miner and Sanes, 1994). Some proteins, like AChE, contain a 
collagenous subunit that is responsible for the anchoring of this enzyme 
in the BL as well as for is synaptic localization (Hall, 1973; Vigny et al., 
1983; Inestrosa and Perelman, 1989), and which interacts with heparin 
(Rossi and Rotundo, 1996; Deprez et al., 2000). Mice that lack perlecan 
do not cluster AChE in the sBL (Arikawa-Hirasawa et al., 2002). Collagens 
are indispensable for cell adhesion and play important roles in 
developmental processes (Lai and Chu, 1996; Velleman, 1999; Sumiyoshi 
et al., 2001).
Down regulation of collagen isoforms or genetic mutations leading 
to defective proteins may be causal for muscular dystrophies and 
congenital myopathies as shown for collagen types I, III, IV, VI, and XIII 
(Hantai et al., 1985; Lamandé et al., 1998; Kvist et al., 2001).
Laminins
Laminins are a major class of BL proteins, composed of three disulfide- 
linked subunits, a, ß, and y Several laminin isoforms, composed of dif­
ferent subunits, show a restricted distribution in BL, especially with 
regard to the NMJ. Whereas laminin-2 (merosin) is located in the 
extrasynaptic neural BL, the isoforms -3 (s-laminin), -4, -9, and -11 are 
specific for the synaptic portion of the BL (Hunter et al., 1989; Patton et 
al., 1997). During myogenesis and synaptogenesis as well as after 
denervation, the expression of laminin isoforms is tightly regulated 
(Bayne et al., 1984; Olwin and Hall, 1985; Sanes et al., 1986; Gullberg et 
al., 1999). Laminins have been experimentally implicated in myofiber 
formation (Blanco-Bose and Blau, 2001) and are involved in the adhesion 
of collagenous substrates to cells through integrins (Gu et al., 1994; 
Crawley et al., 1997) and through a-dystroglycan (Pall et al., 1996).
Decreased expression of, deficiency for, mutations in, and blocking 
of laminin isoforms induce several muscular dystrophies and congenital 
myopathies (Angoli et al., 1997; Miyagoe et al., 1997; Brown et al., 1999; 
Cohn et al., 1999; Merlini et al., 1999). Moreover, aberrant distribution of 
several BL-proteins, notably laminin isoforms, is indicative for the dia­
gnosis of several congenital muscular dystrophies in mice and men 
(Hantai et al., 1985; Tome et al., 1994; Herrmann et al., 1996; Li et al., 1997; 
Ringelmann et al., 1999; Patton et al., 2001).
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Tenascins
Another component of BL is the class of tenascins, hexameric proteins 
that are involved in cell adhesion (Yokosaki et al., 1994) and are present 
in NMJ regions (Pedrosa-Domellöf et al., 1995). The isoforms tenascin-C 
and tenascin-X are reciprocally distributed in skeletal muscle (Matsumoto 
et al., 1994). Whereas tenascin-X and tenascin-Y are shown to be involved 
in myogenesis (Burch et al., 1995; Hagios et al., 1996; 1999), tenascin-C 
expression is modulated during muscle healing (Jarvinen et al., 2000) 
and in muscular dystrophy and inflammatory and congenital myopathies 
(Settles et al., 1996; Muller-Felber et al., 1998; Ringelmann et al., 1999).
The expression of tenascin-C is correlated with macrophage invasion 
in Duchenne muscular dystrophy (Gullberg et al., 1997), and its deficiency 
results in abnormal NMJ formation and reinnervation (Cifuentes-Diaz 
et a l, 1998; 2002).
Proteoglycans
Proteoglycans are complex macromolecules consisting of a protein core 
to which one or more glycosaminoglycan (GAG) moieties are covalently 
attached. GAGs are linear polymers of repeating disaccharides that 
contain a hexosamine and either a hexuronic acid or a galactose unit. 
Different types of GAGs exist, depending on the composition of the ba­
sic disaccharide unit (Table 2; Kjellén and Lindahl, 1991; Wright et al., 
1991): Hyaluronic acid (HA) is the simplest GAG structure, consisting 
of N-acetyl-D-glucosamine (GlcNAc) and glucuronic acid (GlcA) linked 
by ß1,3 and ß1,4 bonds, which can have up to 25,000 disaccharides. HA 
is the only GAG that is not linked to a protein core.
The galactosaminoglycans consist of two types: Chondroitin sulfates 
(CS) have a backbone consisting of N-acetyl-D-galactosamine (GalNAc) 
and GlcA, linked by ß1,3 and ßb1,4 bonds, of up to 250 disaccharides. 
Depending on the positions of sulfation of particular GalNAc residues, 
CS is referred to as chondroitin-4-sulfate or chondroitin-6-sulfate. 
Dermatan sulfates (DS) have a backbone similar to CS, in which 
individual D-GlcA residues are epimerized to L-iduronic acid (IduA), 
which in turn may be sulfated at position 2. By convention, the 
designation of the ß1,3 glycoside bond changes to a1,3 upon 
epimerization.
The glucosaminoglycans consist of three types: Keratan sulfates (KS) 
consist of a backbone of alternating GlcNAc and galactose (gal), bound 
by ß1,3 and ß1,4 bonds, of up to 80 disaccharides. Sulfation can occur on 
the 6 position of either sugar residues. Heparan sulfates (HS) have a 
backbone structure that consists of GlcNAc and GlcA, bound by a1,4 
and ß1,4 linkage, which can be up to 150 disaccharides in length. Upon 
chain elongation, a large number of modifications occur in the backbone, 
including N-deacetylation and N-sulfation, C-5 epimerization, 2-O-
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sulfation, 3-O-sulfation, and 6-O-sulfation. Due to these modifications, 
highly sulfated domains alternate with poorly sulfated domains within 
one HS chain. Heparin (Hep) is structurally similar to HS and has a 
degree of N-sulfation of usually more than 70% as compared to less than 
50% in HS. The term 'heparin' is reserved for the GAG component of the 
small proteoglycan serglycin, which is synthesized by mast cells; all other 
structurally related GAGs are called 'heparan sulfate' (Kjellén and Lindahl, 
1991).
Several GAGs are present in skeletal muscle, of which CS, DS, and 
HS are the most common. The CS/ DS proteoglycan decorin, a large DS 
proteoglycan, and a CS proteoglycan are present throughout the 
perimysium and endomysium (Carrino and Caplan, 1982; Andrade and 
Brandan, 1991; Eggen et al., 1994), whereas a specific CS proteoglycan is 
located within the T-tubular network (Davis and Carlson, 1994). Chan­
ges in quantity and intra-muscular distribution of all types of GAGs, 
most notably of CS, have been reported during myogenesis, regeneration, 
and in pathological conditions (Watanabe et al., 1986; Bertolotto et al., 
1987; Miller et al., 1987; Parthasarathy and Tanzer, 1987; Miller et al., 
1991).
Table 2. Various types of glycosaminoglycans
GAG D isaccharide  com position # Units Poss ib le  m odifications
CS GlcA(ß1,3)GalNAc(ß1,4) 250 4- or 6-O-sulfation
DS IduA(a1,3)GalNAc(ß1,4) 250 2-, 4-, and 6-O-sulfation
GlcA(ß1,3)GalNAc(ß1,4) 250 2-, 4-, and 6-O-sulfation
HA GlcA(ß1,3)GlcNAc(ß1,4) 25,000 -
HS/Hep GlcA(ß1,4)GlcNAc(a1,4)
or
150 N-deacetylation/ N-sulfation (<50%/>70%), 
C5-epimerization, 2-, 3-, and 6-O-sulfation
IduA(a1,4)GlcNAc(a1,4) 150 N-deacetylation/ N-sulfation (<50%/>70%), 
C5-epimerization, 2-, 3-, and 6-O-sulfation
KS gal(ß1,4)GlcNAc(ß1,3) 80 6-O-sulfation
Gal, D-galactose; GalNAc, N-acetyl-D-galactosamine; GlcA, glucuronic acid: GlcNAc, N-acetyl-D- 
glucosamine; IduA, L-iduronic acid.
Heparan sulfate proteoglycans
Heparan sulfate proteoglycans (HSPGs) constitute the major portion of 
PGs in the BL and on the cellular surface of skeletal muscle (Sanes, 1986; 
Brandan and Inestrosa, 1987) and of cultured myotubes (Noonan et al., 
1986; van Kuppevelt et al., 1992). A variety of core proteins exist, to which 
one or more HS moieties are attached (Fig. 8). Both the protein core and 
the HS moiety define the structure and function of HSPGs. Binding of 
various extracellular matrix components or of growth factors can be 
effectuated by mechanisms depending on the protein core, the HS 
sequence, or both. Based on the protein core, muscle BL proteoglycans 
include collagen XVIII (Halfter et al., 1998), perlecan (Iozzo, 1994), and
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Figure 8. Schematic 
representation of the 
HSPGs present in muscle. A 
total of thirteen genes 
encode agrin, perlecan, 
collagen type XVIII, six 
isoforms of glypican, and 
four isoforms of syndecan 
core proteins. Splice 
variants have been 
reported for agrin, 
perlecan, and type XVIII 
collagen. The bottom panel 
provides the keys to the 
protein modules and HS 
chain attachment sites 
(Modified from Iozzo, 2001 
(with permission)).
agrin (McMahan, 1990). Cell surface proteoglycans include the families 
of syndecans (Bernfield et al., 1992) and glypicans (Campos et al., 1993). 
The identification of agrin, a protein indispensable for AChR clustering, 
as a HSPG (Tsen et al., 1995), the role for perlecan in AChE clustering 
(Torres and Inestrosa, 1983; Brandan et al., 1985; Arikawa-Hirasawa et 
al., 2002), and their involvement in muscular diseases showed HSPGs to 
be major players in developmental and regulatory processes in muscle.
Agrin
The BL-resident HSPG agrin encompasses a core protein of 220-250 kDa, 
containing two GAG attachment sites (Tsen et al., 1995). Neural agrin is 
a key factor in the clustering and expression of AChRs in the postsynaptic 
membrane (Fallon et al., 1985; Lupa and Caldwell, 1991; Ferns et al., 1993; 
Hoch et al., 1994a; 1994b; Gesemann et al., 1995; Denzer et al., 1997b; Pun 
et al., 1997; Meier et al., 1998a; 1998b). Agrin is also involved in AChE 
clustering (Wallace et al., 1985; Ruegg and Bixby, 1998) and in the 
clustering of vgNa+Chs (Lupa and Cadwell, 1991; Sharp and Cadwell,
1996). Several alternatively spliced isoforms of the protein are described 
(Ferns et al., 1992, 1993; McMahan et al., 1992; Ruegg et al., 1992). The 
expression of these isoforms is developmentally regulated (Hoch et al.,
1993) and their distribution is highly specific, especially with respect to
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the synaptic site (Groffen et al, 1998; Sanes et al., 1998a; Burgess et al, 
1999; Hagiwara and Fallon, 2001). Certain domains in neural agrin 
isoforms are capable of inducing postsynaptic differentiation (Reist et 
al., 1992; Cohen et al., 1997; Meier et al., 1997; 1998a; Godfrey et al., 2000). 
Neural agrin also controls the stability of postsynaptic specializations 
(Bezakova et al., 2001), whereas muscle-derived agrin regulates the 
organization of cytoskeletal proteins and AChR aggregates (Wallace, 
1995; Bezakova and L0mo, 2001).
Agrin interacts with growth factors and with several BL and cell 
surface proteins, among which collagen type IV, laminin isoforms, 
tenascin, and the dystrophin-glycoprotein complex (Campanelli et al., 
1994; Gee et al., 1994; O'Toole et al., 1996; Cotman et al., 1999). AChRs are 
bound to this complex through rapsyn (Apel et al., 1995; Cartaud et al., 
1998; Fuhrer et al., 1999; Ramarao et al., 2001), a protein that inhibits 
agrin-induced AChR clustering when it is over expressed (Han et al., 
1999). At the NMJ, the interaction of agrin with the MuSK receptor 
tyrosine kinase complex is necessary for its functioning (Glass et al., 1996; 
Glass and Yancopoulos, 1997; Herbst and Burden, 2000). The importance 
of these interactions is shown in mice knock out for agrin, MuSK, or 
rapsyn, which all have severely disrupted NMJs (Gautam et al., 1996; 
1999). Laminin and integrin are also involved in the regulation of AChR 
clustering by agrin (Denzer et al., 1997a; Martin and Sanes, 1997; Burkin 
et al., 2000), whereas heparin and HS inhibit agrin-induced AChR 
clustering (Wallace, 1990; Hopf and Hoch, 1997; Sanes et al., 1998a).
Perlecan
Perlecan was the first BL-HSPG identified (Hassell et al., 1980). Its 270­
467 kDa core protein carries three HS chains at its N-terminal domain 
that may contribute up to approximately 50% of the total molecular mass 
(Costell et al., 1997; Noonan et al., 1991). Perlecan is present in virtually 
all BLs, and its interactions with several BL-resident proteins such as 
type IV collagen (Laurie et al., 1986; Villar et al., 1999), fibronectin (Here- 
mans et al., 1990), and laminins (Battaglia et al., 1992; Henry et al., 2001) 
play an important role in the assembly and integrity of the BL (Costell et 
al., 1999). During myogenesis, the expression of perlecan is down 
regulated (Larram et al., 1997a). At the NMJ, perlecan is involved in the 
anchorage of AChE in the sBL via its collagen tail (Torres and Inestrosa, 
1983; Brandan et al., 1985; von Bernhardi and Inestrosa, 1990; Peng et al., 
1999; Arikawa-Hirasawa et al., 2002), in association with dystroglycan 
(Peng et al., 1998; 1999). Splice variants, in which multiple modules may 
be absent, have been detected in human, mouse, and in the nematode 
Caenorhabditis elegans (Iozzo, 1994).
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Collagen XVIII
Collagen XVIII is the only collagen type shown to be a HSPG (Halfter et 
al., 1998). The 180 kDa protein contains ten triple-helical domains, which 
are variable in length. A C-terminal endostatin domain, which may have 
anti-angiogenic and tumour-suppressor activity, interacts with several 
BL proteins among which laminin-1 and perlecan (Sasaki et al., 1998). 
Three variant forms of collagen XVIII are described in mice and two in 
human, all of which are expressed in a tissue specific manner (Muragaki 
et al., 1995; Rehn and Pihlajaniemi, 1995; Saarela et al., 1998).
Glypicans
Glypicans are cell surface HSPGs that are anchored to the extracellular 
face of the plasma membrane via glycosylphosphatidylinositol. The core 
proteins have a largely globular structure with HS chains attached 
proximal to the plasma membrane (Filmus and Selleck, 2001). Originally 
found in intestine and lung, glypican was shown to be present at the 
surface of skeletal muscle cells (Campos et al., 1993). Changes in the 
expression of various glypican isoforms during development were 
reported in various organs among which skeletal muscle (Brandan et al., 
1996; Saunders et al., 1997; Litwack et al., 1998). Although a role in 
myogenesis is not yet reported, it is well established that glypicans can 
regulate the activity of growth and survival factors (Lander and Selleck, 
2000; Filmus and Selleck, 2001). Six isoforms of glypican are reported in 
mammals, whereas only one ortholog (dally) has been described in 
Drosophila melanogaster (Bernfield et al., 1999; Tumova et al., 2000).
Syndecans
Syndecans are transmembrane proteins with three HS chains attached 
to the N-terminus, distal from the plasma membrane. Whereas some 
syndecans also contain CS chains, the optimal biological activity of 
syndecan-1 is dependent on the presence of all three HS chains (Langford 
et al., 1998). The four members of this family (syndecan 1-4) have highly 
related cytoplasmic and transmembrane domains, but differ significantly 
in their extracellular domains, except for the location and number of HS 
attachment sites (Bernfield et a l ., 1992). Syndecan isoforms are 
differentially expressed during development and in mature tissues (Bern­
field et al., 1993; Larram et al., 1997b; Sogos et al., 1998; Olguin and 
Brandan, 2001). By binding of components of the cellular micro­
environment to their GAG chains, and because of their attachment to 
the cytoskeleton, syndecans are major players in the control of cell 
morphology, adhesion and migration (Chernousov and Carey 1993; Liu 
et al., 1998; Woods et al., 1998). The regulatory roles of syndecans, by 
binding of growth factors, are well documented (Carey, 1997). In skeletal
GENERAL INTRODUCTION I' 29
muscle, roles of syndecans include the inhibition of myoblast 
differentiation by syndecan-1 through a basic fibroblast growth factor- 
dependent mechanism (Larram et al., 1998), the involvement of syndecan 
-3 and -4 in satellite cell maintenance and muscle regeneration 
(Cornelison et al., 2001), the involvement of syndecan-2 in neural 
synaptogenesis (Hsueh et al., 1998), and the acceleration of myogenesis 
after syndecan-3 inhibition (Fuentealba et al., 1999).
Figure 9. Biosynthesis of heparosan and modification 
to HS. (a) The biosynthesis of heparosan occurs on a 
GAG linker tetrasaccharide
(GlcA(ß1,3)Gal(ß1,3)Gal(ß1,4)Xylß1-O-), which is 
attached to specific serine residues in the protein. The 
linker tetrasaccharide is synthesized by the stepwise 
addition by the respective glycosyltransferases of 
xylose, two galactose molecules, and glucuronic acid, 
followed by the addition of the first N- 
acetylglucosamine residue by GlcNAc transferase I. 
Next, HS co-polymerase, which has both GlcA 
transferase and GlcNAc transferase activity, synthesizes
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the repeating disaccharides ([-4GlcNAc(a1-4)GlcAß1-]n) 
by alternative addition of ß-GlcA and a-GlcNAc 
molecules. XylT, xylosyltransferase; GalT-1, 
galactosyltransferase I; GalT-2, galactosyltransferase 
II; GlcAT-1, glucuronyltransferase I; GlcNAcT-1, GlcNAc 
transferase I (adapted from Sugahara and Kitagawa, 
2000 (with permission)). (b) The bare HS-backbone 
can subsequently be modified by a series of enzymes. 
N-deacetylation and N-sulfation is performed by 
glucosaminyl N-deacetylase/N-sulfotransferase, C5- 
epimerization by D-glucuronyl C5-epimerase, 2-O- 
sulfation by heparan sulfate 2-sulfotransferase, 3-O- 
sulfation by 3-O-sulfotransferase, and 6-O-sulfation by 
heparan sulfate 6-O-sulfotransferase (adapted from 
Lindahl et al., 1994 (with permission)).
Biosynthesis of HS
The proposed pathway of HS biosynthesis consists of a series of reactions 
catalyzed by various enzymes, each responsible for a single step (Fig. 9; 
Lindahl et al., 1998; Selleck, 2000; Sugahara and Kitagawa, 2000).
Biosynthesis of the HS backbone (heparosan)
First, a linker tetrasaccharide is O-linked to the serine residue of a con­
sensus linkage region, consisting of Ser-Gly-X-Gly (X represents any 
amino acid; Bourdon et al., 1987; Dolan et al., 1997) or Ser-Gly-Asp (Dolan 
et al., 1997; Costell et al., 1997). It was shown that the proximal occurrence 
of Ser-Gly repeats (Zhang et al., 1995) as well as clusters of acidic amino 
acids (Zhang and Esko, 1994) favors glycosylation of a core protein with 
HS. The linker tetrasaccharide (GlcA(ß1,3)Gal(ß1,3)Gal(ß1,4)Xylß1-O- 
Ser) is formed through the stepwise addition of each monosaccharide 
residue by the respective specific glycosyltransferase, and is followed 
by the addition of the first GlcNAc residue by GlcNAc transferase I 
(Sugahara and Kitagawa, 2000; Selleck, 2000). Next, the repeating 
disaccharides ([-4G lcA ß1-4G lcN A ca1-]n) are added by HS co­
polymerase, an enzyme with both a-GlcNAc transferase and ß-GlcA 
transferase activity, which alternatively adds GlcNAc and GlcA.
Modification of heparosan to HS
The bare HS backbone (heparosan) is subsequently modified by a series 
of enzymes that convert it into an active HS molecule with functional 
domains, containing unique sequences of GlcA and IduA, and of N- 
acetyl, N-sulfate, and O-sulfate groups at various positions in various 
combinations (Habuchi, 2000; Selleck, 2000; Esko and Lindahl, 2001).
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1) The first modifications of the polysaccharide are catalysed by the 
bifunctional enzyme glucosaminyl N-deacetylase/N-sulfotransferase 
(NDST). NDST functions by N-deacetylation and N-sulfation of selected 
GlcNAc residues, which is a prerequisite for all other modifications. 
Four isoforms of NDST have been cloned (Hashimoto et al, 1992; Eriksson 
et al., 1994; Orellana et al., 1994; Aikawa and Esko, 1999). NDST-1 and 
NDST-2 have a wide tissue distribution (Humphries et al., 1997; 1998; 
Kusche-Gullberg et al., 1998; Aikawa et al., 2001), whereas NDST-3 and 
NDST-4 display a more restricted expression. Disruption (Fan et al., 2000; 
Ringvall et al., 2000) or decreased expression (Aikawa and Esko, 1999) 
of the gene encoding NDST-1 results in significantly lower N-sulfation 
levels of HS. Mice defective for NDST-1 die neonatally because of 
respiratory distress. NDST-2-deficient mice show no obvious HS defects, 
but instead are unable to synthesize fully sulfated heparin (Humphries 
et al., 1999; Forsberg et al., 1999). These results indicate the importance of 
NDST-1 and NDST-2 in HS and heparin synthesis, respectively.
2) C-5 epimerization of D-GlcA to L-IduA, performed by the enzyme 
D-glucuronyl C5-epimerase, is the second modification of the HS 
backbone (Crawford et al., 2001; Li et al., 2001a). No isoforms are known 
for this enzyme.
3) 2-O-sulfation of uronic acid residues (IduA or GlcA) is conducted 
by heparan sulfate 2-sulfotransferase (HS2ST), as was shown by studies 
of the purified (Kobayashi et al., 1996) and cloned (Kobayashi et al., 1997) 
enzyme, as well as in a CHO cell mutant, pgsF-17, defective in 2-O- 
sulfation (Bai and Esko, 1996). Only one gene encoding HS2ST has been 
identified in mammals. Mice defective for this enzyme show renal 
agenesis and die neonatally (Bullock et al., 1998).
4) 3-O-sulfation of glucosamine residues is catalyzed by heparan 
sulfate glucosaminyl 3-O-sulfotransferase (3-OST), as can be concluded 
from experiments with the purified enzyme (Liu et al., 1996) and the 
cloned 3-OST-1 (Schworak et al., 1997). Four additionally cloned isoforms 
(3-OST-2, -3A, -3B, and -4; Schworak et al., 1999) are shown to be 
differentially expressed in various tissues.
5) 6-O-sulfation of glucosamine residues is performed by heparan 
sulfate 6-O-sulfotransferase (HS6ST), an enzyme that has been purified 
(Habuchi et al., 1995) and cloned (Habuchi et al., 1998), and of which 
three isoforms are reported (HS6ST-1, -2, and -3; Habuchi et al., 2000). 
The expression of these isoforms is tissue-specific and each isoform has 
different substrate specificity, suggesting an important role for this 
enzyme in the synthesis of tissue-specific HS epitopes.
The large number of modifications in its backbone potentially makes 
HS a very information-dense biopolymer, to which several proteins may 
bind in a monosaccharide sequence-specific way (Salmivirta et al., 1996; 
Lindahl et al., 1998; Bernfield et al., 1999; Tumova et al., 2000; Turnbull et 
al., 2001; Gallagher, 2001).
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Physiological roles of HS
A large number of unique HS sequences are formed due to the variety in 
tissue-expression profile and substrate specificity of the various 
glycosyltransferase and sulfotransferase isoforms. The inter- and intra­
organ distribution of HS epitopes has been shown to differ in various 
organs in different stages of development (David et al., 1992; van den 
Born et al., 1992; van Kuppevelt et al., 1998; Jenniskens et al., 2000; Den­
nissen et al., 2002; Jenniskens et al., 2002a; van de Westerlo et al., 2002). 
Consensus sequences of some of these HS epitopes, as well as HS 
sequences involved in the binding of growth factors and antithrombin 
III have thus far been elucidated (Kjellén and Lindahl, 1991; Habuchi et 
al., 1992; Turnbull et al., 1992; Guimond et al., 1993; Lyon et al., 1994; 
Ashikari et al., 1995; Kreuger et al., 2001). Critical roles of HS in 
developmental processes and specific signaling pathways have recently 
been demonstrated by the identification of various mutations in 
biosynthetic enzymes of HS in Drosophila and Caenorhabditis, and in CHO 
cell lines (Sugahara and Kitagawa, 2000; Filmus and Selleck, 2001; Lander 
and Selleck, 2001). Indeed, HSPGs and especially the sulfation patterns 
of the HS moiety are considered to be regulators of developmental 
signaling (Lander, 1998; Selleck, 2000; Dhoot et al., 2001). Moreover, the 
generation of knock out mice for various proteoglycan core proteins or 
proteins involved in HS biosynthesis have significantly added to our 
understanding of the physiological roles of HS (Forsberg and Kjellén, 
2001). Due to their binding capacities for a large number of proteins 
(Table 3), HS or heparin present in the ECM or on cellular surfaces have 
been implicated in many cellular processes such as cell proliferation, 
cell differentiation, angiogenesis, metastasis, tumor growth, tissue rep­
air, tissue modeling, cell adhesion, microbial invasion, viral infection, 
endocytosis, lipoprotein metabolism, and protein expression (Jackson et 
al., 1991; Williams and Fuki, 1997; Iozzo, 1998; Lyon and Gallagher, 1998; 
Bernfield et al., 1999; Park et al., 2000; Perrimon and Bernfield, 2000; 
Tumova et al., 2000).
HS in myogenesis
Prior to the attribution of specific functions to individual proteoglycans 
present in the ECM, several reports recognized the involvement of ECM 
components in skeletal muscle development (Ontell and Kozeka, 1984; 
Jansen and Fladby, 1990). Especially for HSPGs, roles in development 
are envisaged (Perrimon and Bernfield, 2000). The developmental 
regulation of proteoglycan and HS synthesis during myogenesis in vitro 
is suggestive for possible roles in underlying processes (Noonan et al., 
1986; Miller et al., 1987, Larram et al., 1997a; 1997b; Jenniskens et al., 2000).
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Similar regulation of expression patterns in vivo strengthens the 
involvement of individual HSPGs or HS epitopes in myogenesis 
(Velleman, 1999; Velleman et al., 1999; Charbonnier et al., 2000; Cifuentes- 
Diaz et al., 2000; Gallagher, 2001; Olguin and Brandan, 2001; Jenniskens 
et al., 2002a). Heparin was shown to inhibit skeletal muscle growth 
(Kardami et al., 1988), whereas the addition of heparin, HS, or HS mime­
tics to satellite cell cultures increases differentiation (Rapraeger et al., 
1991; Olwin and Rapraeger, 1992; Stockholm et al., 1999). Satellite cells 
from mdx mice display elevated levels of HSPG receptors for FGF 
(Crisona et al., 1998). Moreover, Unc-52, the C. elegans ortholog of perlecan 
(Rogalski et al., 1993), is shown to be involved in body wall muscle 
integrity (Rogalski et al, 1995). The current view is that the concert of 
regulatory proteins and HS epitopes, present in highly specific 
spatiotemporal distribution patterns, provides an extracellular micro­
environment that is causal for the events of myogenesis.
Table 3. Various groups of glycosaminoglycan-binding 
proteins
Enzym es Extrace llu la r m atrix  prote ins
Lipolytic enzymes Collagens
Kinases Fibronectin
Phosphatases Laminin
Carbohydrate hydrolases, eliminases, transferases Thrombospondin
Proteases and esterases Vitronectin
Nucleases, polymerases, topoisomerases Fibrillin
Other enzymes, oxidases, synthetases, dismutases Receptor prote ins
Enzym e inh ib itors Steroid receptors
Serine protease inhibitors (serpins) Growth factor receptors
L ipoprote ins Channel proteins
Low and very low density lipoproteins V ira l coa t prote ins
Apolipoproteins HIV
Grow th factors HSV
Fibroblast growth factors Dengue
Epidermal growth factors Nuclear prote ins
Hepatocyte growth factors Histones
Platelet-derived growth factors Transcription factors
Transforming growth factors Others
Vasicular endothelial growth factors O ther prote ins
Chem okines Prion proteins
CXC chemokines Amyloid proteins
CC chemokines Fibrin
Se lectins Ion channels
Modified from Gunay and Linhardt, 1999
HS in synaptogenesis
Parallel to the recognition of the importance of HSPGs in muscle 
proliferation and differentiation, roles emerged for this class of 
proteoglycans in neural differentiation (Nurcombe et al., 1993; Brickman 
et al., 1998) and in the genesis of specialized cellular structures, such as
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the NMJ (Sanes and Lichtman, 2001). Axonal pathfinding towards and 
through muscle primordia is very accurate and thought to be guided by 
molecules of the interstitium (Letourneau et al., 1994; Burden, 1998). BL- 
HSPGs or associated proteins have been implicated in the induction of 
postsynaptic differentiation (Anderson and Fambrough, 1983; Chiu and 
Sanes, 1984; Bayne et al., 1984; Peng et al., 1995; 1998). A good example is 
the well-described role of agrin in AChR clustering (Gordon and Hall, 
1989; Ferns et al., 1993; Gordon et al, 1993; Bowen et al., 1996; Mook-Jung 
and Gordon, 1996; Li and Loeb, 2001). The sequestering of AChE and 
certain laminin isoforms in the sBL is also attributed to HS (Vigny et al., 
1983; Brandan et al., 1985; San Antonio et al., 1993; Rossi and Rotundo 
1996; Patton et al., 1997; Peng et al., 1999). Moreover, HSPGs were shown 
to be necessary for sBL formation and stabilization of AChR clusters 
(Grady et al., 2000; Jacobson et al., 2001). In vitro studies confirmed the 
direct involvement of HS and heparin in synaptogenesis by the 
demonstration of their ability to block AChR accumulation (Hirano and 
Kidokoro, 1989; Wallace, 1990; Hopf and Hoch, 1997; Hoch, 1999) and 
myotube innervation (Mars et al., 2000).
HS in excitation-contraction coupling
Little information is available about possible roles of HSPGs or their HS 
moieties in muscle physiology and e-c coupling, let alone about their 
mechanism of action. Extracellular heparin was shown to affect the kinetic 
properties of the DHPR (Knaus et al., 1990; 1992; Lacinova et al., 1993; 
Martinez et al., 1996). Whereas the RyR is activated by heparin in vitro 
(Ritov et al., 1985; Bezprozvanny et al., 1993; Ehrlich et al., 1994), the 
structurally similar inositol trisphosphate receptor is inhibited (Gosh et 
al., 1988; Kobayashi et al., 1988). Intracellular application of heparin blocks 
e-c coupling in an activation-dependent manner in toad, but not in rat 
muscle fibers, an effect most likely caused by a direct action of heparin 
on the DHPR voltage sensor (Lamb et al., 1994). The loss of anion- 
buffering capacity of the strongly negatively charged HS polymers near 
ion channels has been proposed as a mechanism with regard to ion 
channel modulation by HS or heparin (Bezprozvanny et al., 1993).
Direct evidence for the involvement of extracellular HS in muscle 
calcium kinetics has recently been obtained by our group in C2C12 
myoblast cultures in which HS epitopes were physiologically knocked 
out (Jenniskens et al., 2002b) and in primary myoblast cultures from mice 
carrying targeted disruptions in the gene encoding NDST-1 (Jenniskens 
et al., 2002c). Moreover, a unique GAG was discovered in the terminal 
cisternae of skeletal m uscle SR, which is involved in calcium  
housekeeping (Jenniskens et al., 2002d).
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HSPGs and HS in muscle pathology
In recent years, there has been an increasing number of reports on 
inherited of artificially induced defects in proteins of the skeletal muscle 
ECM, and on HSPGs present on the cell surface or in the BL, that are 
involved in (interstitial) myopathies (Table 4). In mdx mice, an animal 
model for Duchenne muscular dystrophy, an overdeposition of various 
ECM molecules was reported (Quirico-Santos et al., 1995).
The perlecan gene is mutated in chondrodystrophic myotonia 
(Schwartz-Jampel syndrome; Nicole et al., 2000) and in dyssegmental 
dysplasia (Silverman-Handmaker type; Arikawa-Hirasawa et al., 2001). 
In Schwartz-Jampel syndrome a significantly reduced number of 
truncated perlecan molecules is present in the skeletal muscle BL. The 
resulting partial impairment of perlecan function causes myotonic 
myopathy, which is consistent with the finding that perlecan is crucial 
for clustering of AChE at the NMJ (Arikawa-Hirasawa et al., 2002). More­
over, mutations in the Unc-52 gene of C. elegans are reported to be lethal 
or lead to paralysis (Rogalski et al., 1993). Mice knock out for agrin show 
aberrant synaptogenesis (Gautam et al., 1996; 1999), whereas the 
expression of agrin from an artificial minigene can rescue congenital 
muscular dystrophy in a mouse model (Moll et al., 2001). The Simpson- 
Golabi-Behmel syndrome has been attributed to defects in glypican-3 
(Pilia et al., 1996; Cano-Gauci et al., 1999).
Table 4. Inherited or artificially induced defects in cell 
surface and BL components and the resulting interstitial 
myopathy
Affected Causea In te rstitia l m yopathy Reference
Agrin* A Congenital muscular dystrophy Moll et al., 2001
A Defective neuromuscular synaptogenesis Gautam et al., 1999
Collagen VI I Bethlehem myopathy Lamandé et al., 1998
Collagen XIII A Progressive myopathy Kvist et al., 2001
Glypican-3* I Simpson-Golabi-Behmel syndrome Pilia et al., 1996
Laminin-2 I Merosin-negative congenital muscular dystrophy Tome et al., 1994
Laminin-a2 I Congenital muscular dystrophy Herrmann et al., 1996
Laminin-ß1 I Limb-girdle muscular dystrophy Li et al., 1997
MuSK A Defective neuromuscular synaptogenesis Gautam et al., 1999
Perlecan* I Schwartz-Jampel syndrome Nicole et al., 2000
I Silverman-Handmaker dyssegmental dysplasia Arikawa-Hirasawa et al., 
2001
A AChE clustering defects Arikawa-Hirasawa et al., 
2002
Rapsyn A Defective neuromuscular synaptogenesis Gautam et al., 1999
Sarcoglycans I Limb-girdle muscular dystrophy Sewry et al., 1996
Tenascin-C A Neuromuscular junction defects Cifuentes-Diaz et al., 1998
Unc-52** A Body wall muscle integrity and paralysis Rogalski et al, 1995
Due to limitations of space, only a single reference has been cited for each entry 
a A, artificially induced; I, inherited 
* Heparan sulfate proteoglycan 
** Perlecan ortholog in C. elegans.
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Thus, recent data indicate the involvement of several HSPGs in 
myopathies and muscular dystrophies. Mice knock out for NDST-1 die 
neonatally due to respiratory distress, whereas NDST-2 deficient mice 
show no defects. Therefore, the exact functions of the HS moieties, and 
possibly of individual HS epitopes, in muscle remain to be investigated.
Aim of the study and scope of this thesis
A growing number of physiological functions are attributed to the BL 
surrounding skeletal muscle fibers. Biochemical evidence is available 
for active roles of BL-resident HSPGs in myogenesis and muscle 
physiology. However, most research has focused on their protein cores, 
thus ignoring the HS moiety. The scope of this project was to investigate 
the distribution of HS and possible HS subspecies in skeletal muscle 
and to elucidate their role in muscle development and in e-c coupling. 
In 1997, when the research described in this thesis was initiated, only 
few antibodies that recognize HS had been described, but the recent 
demonstration that antibodies against specific HS epitopes could be 
raised by means of phage display included a promise for progress.
First, antibodies were selected by means of phage display against HS 
isolated from skeletal muscle (chapter 2). These antibodies present new 
tools in the study on the structure and role of HS. Several different 
antibodies were shown to define distinct HS epitopes that have a 
mutually different distribution in skeletal muscle. The unique distribution 
pattern of distinct HS epitopes, especially with regard to the NMJ, raises 
important issues as to their roles in muscle physiology.
In chapter 3 the HS epitopes that are selectively recognized by anti- 
HS antibodies are characterized. It is shown that all ten antibodies 
studied, have a different inter- and intra-tissue distribution and that they 
recognize different structural modifications of HS.
Chapter 4 describes studies on the spatiotemporal distribution of HS 
epitopes during myogenesis and synaptogenesis in situ in the mouse. 
Differences in their location and in the onset of their expression were 
noticed. These results may indicate an active role for specific HS epitopes 
in muscle development.
As described in chapter 5, the participation of HS in muscle calcium 
kinetics was investigated in primary myotube cultures of mice carrying 
a targeted disruption of genes involved in HS biosynthesis. Mice knocked 
out for NDST-1 are severely affected in their HS composition, and a sig­
nificant change in the kinetics of electrically induced calcium spikes was 
observed.
In chapter 6 various newly deviced eukaryotic expression systems 
are presented, in which anti-HS antibodies are expressed as intrabodies 
in a myoblast cell line (C2C12). The expression of these intrabodies results
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in the phenotypic knock out of HS at the cellular surface. Myotubes 
devoid of HS were studied with regard to their excitation-induced cal­
cium spiking, thus for the first time uncovering a role for HS epitopes in 
muscle calcium housekeeping.
A rare HS-like GAG epitope with a unique distribution in the termi­
nal cisternae of the SR is described in chapter 7. Calcium kinetics were 
studied in C2C12 myotubes in which this epitope was knocked out by 
expression of its antibody. The singular location and the novel action of 
this unique GAG epitope further strengthen the involvement of GAGs 
in muscle e-c coupling.
Chapter 8 concludes this thesis with a survey and indications for 
future research.
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The basal lamina enveloping skeletal muscle fibers contains 
different glycoproteins, including proteoglycans. To obtain more 
information on the glycosaminoglycan moiety of proteoglycans, 
we have selected a panel of anti-heparan sulfate antibodies 
from a semisynthetic antibody phage display library by panning 
against glycosaminoglycan preparations derived from skeletal 
muscle. Epitope recognition by the antibodies is strongly dep­
endent on O - and N-sulfation of the heparan sulfate. 
Immunostaining with these antibodies showed a distinct 
distribution of heparan sulfate epitopes in muscle basal lamina 
of various species. Clear differences in staining intensity were 
observed between neural, synaptic, and extrasynaptic basal 
laminae. Moreover, temporal and regional changes in abundancy 
of heparan sulfate epitopes were observed during muscle 
development both in vitro and in vivo. Taken together, these 
data suggest a role for specific heparan sulfate domains/ spe­
cies in myogenesis and synaptogenesis. Detailed analysis of 
the functions of heparan sulfate epitopes in muscle 
morphogenesis has now become feasible with the isolation of 
antibodies specific for distinct heparan sulfate epitopes.
Introduction
The basal lamina (BL) enveloping skeletal muscle fibers plays various 
roles in muscle development and regeneration (Sanes, 1986; Wright et 
al., 1991). Several BL molecules have been identified as specifically 
synaptic, extrasynaptic, or common (Sanes, 1982; Hall and Sanes, 1993). 
On the protein level, these include isoforms of laminin, collagen, and 
entactin (Sanes et al., 1990; Chiu and Ko, 1994; Patton et al., 1997). Lectin 
staining (Sanes and Cheney, 1982; Iglesias et al., 1992) and a recent re­
port on synapse-specific carbohydrates (Martin et al. 1999) indicate a 
spatial heterogeneity for carbohydrates as well.
Heparan sulfate proteoglycans (HSPGs), consisting of a core protein 
and a carbohydrate moiety (heparan sulfate (HS)), are main components 
of muscle BLs. So far, three BL HSPGs have been identified: perlecan, 
agrin, and type XVIII collagen (Noonan et al., 1991; Tsen et al., 1995; 
Halfter et al., 1998). HSPGs are implicated in developmental processes 
underlying myogenesis and synaptogenesis (Anderson and Fambrough, 
1983; Anderson et al., 1984; Bayne et al., 1984; Dmytrenko et al., 1990). 
Perlecan may effect neuromuscular junction (NMJ) formation by bin­
ding growth factors (Peng et al., 1998). Agrin, a major HSPG of the 
synaptic BL (sBL), orchestrates acetylcholine receptor (AChR) clustering 
(Campanelli et al., 1994; Ruegg and Bixby, 1998). Heparin and HS are 
involved in AChR clustering induced by nerve (Hirano and Kidokoro,
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1989) and agrin (Wallace, 1990). In muscle cell lines defective in 
glycosaminoglycan (GAG) synthesis, a causal relationship between GAGs 
and AChR clustering is demonstrated (Ferns et al., 1993; Gordon et al., 
1993; Mook-Jung and Gordon, 1996). HS binding may also mediate the 
synapse-specific anchoring of BL-resident proteins such as acetylcholine 
esterase and possibly certain laminin isoforms (Brandan et al., 1985; San 
Antonio et al., 1993; Patton et al., 1997).
Another major characteristic of HS is the binding of growth factors 
such as neuregulin (Fischbach and Rosen, 1997), midkine (Zhou et al.,
1997), heparin-binding growth-associated molecule (Peng et al., 1995; 
Szabat and Rauvala, 1996), heparin-binding epidermal growth factor­
like growth factor (Chen et al., 1995), and basic fibroblast growth factor. 
The latter protein is involved in postsynaptic differentiation (Peng et al.,
1991) and maintenance of the proliferative state of satellite cells 
(Rapraeger et al., 1991; Olwin and Rapraeger, 1992; Olwin et al., 1994; 
Crisona et al., 1998). Considering the diversity of proteins that bind HS, 
HS molecules may contain unique domains (epitopes) that are specific 
for these interactions.
Studies of HSPGs have mainly been focussed on the protein core. 
The structure and the role of the HS moiety are difficult to investigate 
because of a lack of appropriate tools. Only a few antibodies that 
recognize HS epitopes have been described (David et al., 1992; van den 
Born et al., 1992). Recently, we adapted phage display technology to 
obtain epitope-specific antibodies against HS (van Kuppevelt et al., 1998). 
Here we report on the isolation, characterization, and application of 
antibodies selected against HS-containing GAG preparations from 
skeletal muscle. We provide evidence for the existence of several specific, 
differentially distributed HS epitopes in (synaptic and extrasynaptic) 
muscle and nerve BLs. Moreover, we found a shift in abundancy of these 
epitopes in BLs of developing muscle both in vitro and in vivo. These 
data suggest an involvement of specific HS epitopes in myogenesis and 
synaptogenesis.
Materials and Methods
Materials
Synthetic single-chain variable fragment (scFv) library #1 (Nissim et al.,
1994) was generously provided by Dr. G. Winter (Cambridge University, 
Cambridge, United Kingdom). Human skeletal muscle samples were 
generously provided by Prof. Dr. D. Ruiter (Department of Pathology, 
University of Nijmegen, Nijmegen, The Netherlands). Torpedo marmarota 
electric organ was generously provided by Dr. M.H. De Baets (Depart­
ment of Immunology, University of Maastricht, Maastricht, The
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Netherlands). Mice (C3H, male, 70 days), rats (Wistar, male, six weeks), 
and rat embryos (Wistar, 10, 13, 16, and 19 d after conception) were 
obtained from the University of Nijmegen Central Animal Laboratory. 
C3H mouse-derived skeletal muscle (C2C12) cell line was purchased from 
American Type Culture Collection (Rockville, MD). Glycosaminoglycan- 
deficient myoblast (S27) cell line was a generous gift of Dr. Z. Hall (Dep­
artment of Physiology, University of California, San Francisco, CA); 
mutant Cinese hamster ovary (CHO) cell lines were kindly provided by 
Dr. J. Esko (Department of Biochemistry, University of Alabama, 
Birmingham, AL).
For phage display, two Escherichia coli strains were used: suppressor 
strain TG1 [K12, supE, hsdA5, thi A(lac-proAB), F'(traD36, proAB+, lacIq, 
lac ZAM15)] and non-suppressor strain HB2151 [K12, ara, thi A(lac-pro), 
F'(proAB+, lacIq, ZAM15)]. Helper phage VCS-M13 was from Stratagene 
(La Jolla, CA).
All chemicals used were purchased from Merck (Darmstadt, 
Germany), unless stated otherwise. Bacterial media (2xTY and LB) and 
cell culture media were from Life Technologies (Paisley, Scotland). 
Chondroitinase ABC (from Proteus vulgaris, EC 4.2.2.4), chemically 
modified heparin kit, anti-chondroitin sulfate (CS) "stub" antibody (2B6), 
and anti-heparan sulfate stub antibody (3G10) were from Seikagaku 
Kogyo Co. (Tokyo, Japan). Heparinase III (from Flavobacterium heparinum, 
EC 4.2.2.8), heparan sulfate from bovine kidney and from porcine 
intestinal mucosa, heparin from porcine intestinal mucosa, chondroitin 
4-sulfate and chondroitin 6-sulfate from bovine trachea, dermatan sulfate 
(DS) from porcine intestinal mucosa, keratan sulfate from bovine cornea, 
hyaluronic acid from human umbilical cord, DNA from calf thymus, 
phenylmethylsulfonyl fluoride (PMSF), N-ethylmaleimide, aprotinin, 
sodium azide, pepstatin A, and bovine serum albumin (fraction V) were 
from Sigma (St. Louis, MO). Microlon 96-wells microtiter plates and 
immunotubes were from Greiner (Frickenhausen, Germany). Anti-c-Myc 
tag mouse monoclonal IgG (clone 9E10) was from Boehringer Mannheim 
(Mannheim, Germany), Anti-c-Myc tag rabbit polyclonal IgG (A-14) was 
from Santa Cruz Biotechnology (Santa Cruz, CA). Alkaline phosphatase- 
conjugated rabbit anti-mouse IgG was from Dakopatts (Glostrup, Den­
m ark). Alexa 488-conjugated goat anti-rabbit IgG and 
tetram ethylrhodam ine isothiocyanate (TRITC)-conjugated a- 
bungarotoxin were from Molecular Probes (Eugene, OR). Mowiol (4-88) 
was from Calbiochem (La Jolla, CA). PCR chemicals and Taq polymerase 
(DNA polymerase from Thermus aquaticus) were from Promega (Madison, 
WI), PCR primers were from Biolegio (Malden, The Netherlands), and 
restriction enzyme BstNI was from New England Biolabs (Beverly, MA). 
ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit 
was from PE Applied Biosystems (Norwalk, CT).
All experiments were performed at ambient temperature (21OC), 
unless stated otherwise.
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Isolation of glycosaminoglycans from skeletal muscle
Mouse and human skeletal muscle specimens were homogenized, 
defatted in 20 vol of acetone at -20OC for 16 h, and dried in a desiccator. 
Per gram of muscle tissue, 4 ml 50 mM sodium phosphate buffer, pH 
6.5, containing 2 mM EDTA, 2 mM cysteine, and 10 units papain were 
added. Papain digestion was performed for 16 h at 65OC and the 
remaining debris was pelletted. Residual protein fragments were 
removed from the glycosaminoglycans by mild alkaline borohydride 
digestion in 0.5 M NaOH/ 0.05 M NaBH4 at 4OC. After overnight 
digestion, the mixture was neutralized by addition of 6 M HCl. Residual 
protein fragments were precipitated by addition of 100% (w /v) 
trichloroacetic acid to a final concentration of 6% and precipitation at 
0OC for 1 h. Precipitated proteins were removed by centrifugation (10,000 
xg for 20 min at 4OC) and glycosaminoglycans were isolated by addition 
of 5 vol. of 100% ethanol to the supernatant and overnight precipitation 
at -20OC. After centrifugation (10,000 xg for 30 min at 4OC), the pelletted 
glycosaminoglycans were washed with 70% ethanol, dried, and dissolved 
in 10 mM Tris-HCl, pH 6.8. This crude glycosaminoglycan preparation 
was further deprived of protein contamination by DEAE Sepharose co­
lumn chromatography, eluting glycosaminoglycans at 0.5 M and 1.0 M 
NaCl in 10 mM Tris-HCl, pH 6.8. GAG-containing eluates were pooled, 
and after ethanol precipitation the residual salt was removed by a 70% 
(v/v) ethanol wash. The resulting glycosaminoglycan preparations were 
dissolved in MilliQ water and stored at 4OC.
Phage display
Phage display was essentially performed as described (Van Kuppevelt 
et al., 1998). Synthetic scFv library #1 was subjected to four rounds of 
panning against mouse or human skeletal muscle glycosaminoglycan 
preparations. The library contains approximately 108 different scFv anti­
body clones, composed of 50 different heavy (VH) chain V segments with 
synthetic (randomly synthesized) complementarity-determining region 
3 (CDR3) fragments and one light (VL) segment. This library was in vitro- 
synthesized from V gene segments, derived from human lymphocytes, 
using PCR (Tomlinson et al., 1992; Nissim et al., 1994). After the last round 
of selection, single colonies were picked and the antibodies expressed 
by these clones were evaluated for reactivity by ELISA. Clones displaying 
reactive antibodies were further analyzed by colony-PCR amplification 
of the antibody coding region and restriction digestion of the full-length 
PCR products with BstNI (CC*A/ TGG). Unique clones were grown at a 
larger scale and individual plasmid DNAs were sequenced using PelB- 
seq (5'-CCGCTGGATTGTTATTACTC-3') as a primer (located within 
the PelB leader sequence).
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Large scale preparation of antibodies
To produce large quantities of scFv antibodies, plasmid DNA from 
selected clones was used to transform non-suppressor E. coli strain 
HB2151. Five hundred milliliters of prewarmed 2xTY medium containing 
0.1% (w/v) glucose and 100 m g/m l ampicillin were inoculated with an 
overnight culture of transformed HB2151 and grown with vigorous 
shaking at 37OC until an OD600 of 0.3 was reached. Induction was 
effectuated by addition of isopropyl-ß-D-thiogalactopyranoside (IPTG) 
to a final concentration of 1 mM. After 3 h incubation at 30OC the culture 
was cooled on ice for 20 min and cells were pelleted (3000 xg for 10 min 
at 4OC). One-tenth volume of 10x protease inhibitor mix (0.1 M EDTA, 
250 mM iodoacetamine, 1 M N-ethylmaleimide, 1% (w/v) NaN3, 1.5 
mTIU/ml aprotinin, 0.1% (w/v) pepstatin A, 1 mM pMsF) was ad ded 
to the supernatant, which was subsequently divided into aliquots and 
stored at 4OC. The cells were resuspended by vigorous vortexing in 5 ml 
ice-cold 200 mM sodium-borate buffer, pH 8.0, containing 160 mM NaCl, 
1 mM EDTA and protease inhibitors. After centrifugation (5000 xg for 
30 min at 4OC) the supernatant (the periplasmic fraction containing the 
scFv antibodies) was filtered through a 0.45 |J.m filter, dialyzed overnight 
at 4OC against PBS, divided into aliquots, and stored at -20OC.
Evaluation of antibody specificity by ELISA
Unless stated otherwise, supernatants of IPTG-induced HB2151 cultu­
res were used for ELISA. Affinity of the antibodies to various molecules 
was evaluated by ELISA in two ways: scFv antibodies were applied to 
wells of Microlon microtiter plates, coated with the molecule concerned 
(10 m g/m l coating solution), and allowed to bind for 90 min. 
Alternatively, scFv antibodies were pre-incubated overnight with the 
test molecule (10 mg/ml) in PBS/ 0.1% (w/v) Marvel, followed by trans­
fer to and 90 min incubation in wells previously coated with heparin. 
Test molecules included glycosaminoglycan preparations from mouse 
and human skeletal muscle, HS preparations from bovine kidney and 
human lung, prepared as described above, commercially available 
heparan sulfate from bovine kidney and from porcine intestinal mucosa, 
heparin, chemically and enzymatically modified heparin, chondroitin 
4-sulfate, chondroitin 6-sulfate, dermatan sulfate, keratan sulfate, 
hyaluronic acid, DNA, Marvel and bovine serum albumin (fraction V). 
Bound scFv antibodies were detected using anti-c-M yc mouse 
monoclonal antibody 9E10, followed by alkaline phosphatase-conjugated 
rabbit anti-mouse IgG (60 min each). Plates were washed three times 
with PBS containing 0.1% (v/v) Tween-20 (PBST) after each incubation. 
Enzyme activity was detected using 1 m g/m l p-nitrophenyl phosphate 
in 1 M diethanolamine/ 0.5 mM MgCl2, pH 9.8, and absorbance was 
read at 405 nm.
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Immunohistochemistry
Periplasmic fractions of IPTG-induced HB2151 cultures were used for 
immunohistochemistry, unless stated otherwise. Location of the epitopes 
recognized by the antibodies in several tissues was assessed both on 
cryosections of tissue specimens and on monolayers of cultured cell lines. 
Tissues included human skeletal muscle and diaphragm, rat and C3H 
mouse skeletal muscle, rat denervated skeletal muscle, rat embryos, and 
T. marmarota electric organ. Tissue specimens were snap-frozen in liquid 
nitrogen-cooled isopentane and stored at -8 0 OC. W ild-type and 
glycosylation-deficient CHO cell lines were studied at confluency, 
whereas myoblast (C2C12 and S27) cell lines were analyzed at various sta­
ges of differentiation. Cells were grown as previously described (Portiér 
et al., 1999), differentiated in Ultroser brain extract medium, washed three 
times with PBS, dried overnight, and stored at -80OC. Cryosections (3 or 
5 |J.m) or tissue cultures were rehydrated for 10 min in PBS, blocked with 
PBS containing 0.1% (w/v) BSA for 20 min, and incubated with scFv 
antibodies for 90 min. Bound antibodies were detected using anti-c-Myc 
rabbit polyclonal antibody A-14 and Alexa 488-conjugated goat anti­
rabbit IgG (60 min each). For visualization of AChR clusters, TRITC- 
conjugated alpha-bungarotoxin was included in the final incubation. 
Cryosections or tissue cultures were washed three times with PBS after 
each incubation. Finally, the cryosections or tissue cultures were fixed 
in 100% methanol, dried and embedded in Mowiol (10% (w/v) in 0.1 M 
Tris-HCl, pH 8.5/ 25% (v/v) glycerol/ 2.5% (w/v) NaN3). As a control, 
primary, secondary, or conjugated antibodies were omitted.
Evaluation of antibody specificity by immunohistochemistry
To assess the heparan sulfate specificity of the scFv antibodies, 
cryosections or tissue cultures were pre-incubated with heparinase III 
to digest heparan sulfate (0.02 U /m l in 50 mM NaAc/ 50 mM Ca(Ac)2, 
pH 7.0) overnight at 37OC, or with chondroitinase ABC, which digests 
chondroitin and dermatan sulfate (1 U /m l in 25 mM Tris-HCl, pH 8.0) 
for 30 min at 37OC. As a control, cryosections or tissue cultures were 
incubated in the reaction buffer without enzyme. After washing three 
times with PBS and blocking with PBS/ 0.1% (w/v) BSA, cryosections 
and tissue cultures were incubated with antibodies and processed for 
immunofluorescence as described above. The efficiency of chondroitinase 
ABC treatment was evaluated by incubation of cryosections with an 
antibody (2B6) against chondroitin sulfate "stubs", generated by 
chondroitinase. Heparan sulfate stubs were visualized using anti-A- 
heparan sulfate antibody (3G10).
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Denervation of rat skeletal muscle
The musculus gastrocnemius and the musculus soleus of the left legs of 
young adult rats were denervated by cutting the efferent motor nerves 
innervating these muscles. The ends of these nerves were fastened to 
the musculus biceps femoris to prevent reinnervation (Degens et al., 1992). 
After 11 d, rats were killed, and the calves of both the left (denervated) 
and right (control) legs were isolated and processed as described in 
immunohistochemistry.
Results
Selection of antibodies against skeletal muscle GAGs
To select scFv antibodies against skeletal muscle GAG epitopes, GAGs 
were isolated from human and from C3H mouse skeletal muscle. 
Typically, 10 |J.g GAG could be purified from 1 g muscle tissue (wet 
weight). All GAG preparations contained approximately equal amounts 
of CS and HS and were approximately 4-fold richer in DS (Fig. 1).
Four rounds of panning were performed against mouse skeletal 
muscle-derived GAG preparations, resulting in antibodies that bear the 
prefix AO. Antibodies with the prefix RB were obtained after panning 
against human skeletal muscle-derived GAGs. This approach yielded a 
set of unique anti-HS antibodies, based on the amino acid sequence of 
their heavy chain CDR3, a major determinant in antigen specificity (Table 
1).
Figure 1. Silver-stained 1% 
agarose gel of a muscle 
glycosaminoglycan 
preparation. Lane 1, sample 
buffer (control); lane 2, 5 
ng GAG standard; lane 3,
20 ng GAG standard; lane 
4, Typical glycosamino­
glycan preparation of mouse 
skeletal muscle. Dermatan 
sulfate (DS) is present at 
approximately 4-fold higher 
concentration compared 
with chondroitin sulfate (CS) 
and heparan sulfate (HS).
!
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Table 1. CDR3 sequences and germline VH gene 
segments of anti-HS scFv antibodies
Clone CDR3 sequence VH family DP segment
AO4B05 LKQQGIS 3 53
AO4B08 SLRMNGWRAHQ 3 47
AO4F12 AMTQKKPRKLSL 1 7
RB4CB9 HAPLRNTRTNT 3 38
RB4CD12 GMRPRL 3 38
RB4EA12 RRYALDY 3 32
RB4EG12 SGRKYFRARDMN 1 4
Antibodies with the prefix AO were obtained after panning against GAGs from mouse skeletal muscle, 
whereas antibodies with the prefix RB were selected by panning against GAGs isolated from human 
skeletal muscle. CDR3 sequences are shown in single-letter amino acid code. VH families and DP 
segments were deduced from the Sanger Centre Germline Quiry (http://www.sanger.ac.uk/ 
DataSearch/gq_search.shtml) by applying the full length Vh sequences of the anti-HS scFv antibody 
clones (nomenclature according to Tomlinson et al., 1992).
Table 2. Evaluation o f anti-HS antibody specificity by 
ELISA
GAG preparation AO4B05 AO4B08 AO4F12 RB4CB9 21
Û
C4BR 21AE4BR RB4EG12
K5 capsular polysaccharide (E. coli)a - - - - - - -
HS (bovine kidney) + + + + + + +/- + + +/- +/-
HS (porcine intestinal mucosa) + + + + +/- + + + +/-
HS (human lung, 0.5 M NaCl fraction)b + +/- - - - + +/-
HS (human lung, 1.0 M NaCl fraction)b + + + + + + + + + + + + + +
Heparin (porcine intestinal mucosa) + + + + + + + + + + + + + + + + +
Heparin, desulfated and N-acetylatedc - - - - - - -
Heparin, desulfated and N-sulfatedc - - - - - - -
Heparin, N-desulfated and N-acetylatedc - - +/- - - - -
Antibody-containing supernatants of IPTG-induced E. coli HB2151 cultures were applied to various GAG 
preparations immobilized on microtiter plates. Bound antibodies were detected using anti-c-Myc mouse 
monoclonal antibody 9E10, followed by alkaline phosphatase-conjugated rabbit anti-mouse IgG, after 
which enzymatic activity was measured using p-nitrophenyl phosphate as a substrate.
Substrate affinity: + + + , very strong; + + , strong; +, moderate; +/-, weak; -, absent (n=5). 
aSimilar to the HS precursor polysaccharide.
bHS fraction eluting from anion exchange column at the NaCl concentration indicated. 
cInhibition-ELISA.
Characterization of antibodies
All antibodies showed a high reactivity in ELISA for the GAG preparation 
against which they were selected, whereas the reactivity for various GAG 
species derived from other tissues varied significantly. Despite the fact 
that the antibodies were selected against a GAG mixture that consisted 
predominantly of DS, antibodies showed affinity only for HS and heparin. 
No reactivity was observed with chondroitin 4-sulfate, chondroitin 6- 
sulfate, dermatan sulfate, keratan sulfate, hyaluronic acid, DNA, Marvel 
(blocking agent) and Microlon (data not shown). Antibodies reacted to 
various extents with a highly sulfated HS fraction (eluting at 1.0 M NaCl 
in ion exchange chromatography) and with a low-sulfated fraction 
(eluting at 0.5 M NaCl) of human lung (Table 2). All antibodies showed 
a major cross-reactivity with heparin, which is highly sulfated. Antibodies
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Figure 2. Staining of 
heparinase Ill-treated 
skeletal muscle 
cryosections with anti-HS 
scFv and anti-HS stub 
antibodies. Non-treated (a) 
and heparinase Ill-treated 
(b, c) cryosections of 
mouse skeletal muscle 
tissue were incubated with 
periplasmic fraction of anti- 
HS antibody AO4F12 (a, b) 
or anti-heparan sulfate stub 
antibody (3G10) (c). Bound 
scFv antibodies were 
visualized by incubation 
with rabbit polyclonal anti- 
c-Myc IgG (al, b1), 
followed by Alexa 488- 
conjugated goat anti-rabbit 
or anti -mouse IgG (a and 
b, or c, respectively). AChR 
clusters present in the 
neuromuscular junction 
were visualized using 
TRITC-conjugated alpha- 
bungarotoxin (a2-c2). 
Although in untreated 
tissue, the AO4F12 epitope 
is clearly present in the 
muscle BL (al), staining 
disappeared during 
heparinase treatment (bl), 
indicating the HS nature of 
the epitope. Staining of heparan sulfate stubs in 
heparinase-treated tissue showed HS to be present 
throughout the muscle BL (cl). Note the higher 
staining intensity of AO4F12 at NMJs (al, a2, arrows), 
regardless of the overall quantity of HS in the NMJ (cl, 
c2, arrows). Scale bar, 50 jim.
AO4B05, AO4B08, and (to a somewhat lesser extent) RB4CD12 showed 
a high reactivity for HS from bovine kidney and porcine intestinal 
mucosa, whereas all other antibodies interacted only moderately or 
weakly. K5 capsular polysaccharide from E. coli, which is similar to the 
HS precursor, was not bound by any of the antibodies.
To investigate which chemical groups are recognized by the diffe­
rent antibodies, we determined the reactivity of the antibodies towards 
modified heparin preparations (Table 2). Completely desulfated and N- 
acetylated heparin as well as completely desulfated and N-sulfated 
heparin were not recognized by any of the antibodies. Heparin that was 
N-desulfated and N-acetylated also was not recognized by the antibodies, 
except for AO4F12, which showed a weak binding.
HEPARAN SULFATE HETEROGENEITY IN SKELETAL MUSCLE 63
To ascertain the HS specificity of the antibodies, immunofluorescence 
studies were performed on cryosections of skeletal muscle tissue that 
were treated with heparinase III before incubation. Heparinase treatment 
of cryosections resulted in a total loss of staining for all antibodies (Fig. 
2), whereas treatment with chondroitinase ABC did not (data not shown). 
Staining of heparinase-treated cryosections with anti-HS stub antibody 
3G10 (which reveals all HS that is present) showed HS to be equally 
distributed in synaptic and extrasynaptic BL (Fig. 2c).
Table 3. Immunostaining patterns of anti-HS 
antibodies
Tissue AO4B05 AO4B08 AO4F12 RB4CB9 21AE4BR21DC4BR 21GE4BR
Mature hu ma n,  rat,  and mo us e skeleta l muscle
Extrasynapt ic  basal lamina +  + + + + + + + + + + / - -
Sy na pt i c  basal lamina +  +  + + + + + + + + + + + + + + +
Endo-  and per ineurium +  + + + + + + + + + + + + +
Capillary basal  lamina +  + + + + + + + + + - -
Arterial basal lamina + + + + + + + + + - -
Electric organ (Torpedo marmarota)
Electrocyte,  non- innervated face +  + + + + / - + + + / - +
Electrocyte,  innervated face +  + + + + + + + + / - +
Endoneurium +  + + + - + + / - +
Per ineurium + / - + + + + + + - + / -
Rat  em bry o skeleta l muscle  ( 1 9  days  in utero)
Extrasynapt ic basal lamina +  + + + + + + + + + - + / -
Sy napt ic  basal  lamina +  + + + + + + + + + + - + +
Nerve basal  lamina +  + +  + + + + + + + + + + / - +
S m o o th  muscle  basal  lamina (ar tery) +  + + + + + + + + + - -
C,C. ,  skeleta l muscle cell line
Cell surfa ce  (on co nt a ct  places) + + + + + + + + + + + + - d) - d)
Basal lamina (during di fferent iation) + + a) +  +  a) + + a) + +  +  +  b) - d) - d)
AChR c lusters + + a) + + + a) + + + + + - -
S 27 cell line (defect ive  in proteoglycan syn thesis )
Cell surfa ce  (on co nt a ct  places) - - d) - d) - d) - C) - d) - d)
Basal lamina (during di fferent iation) - - d) - d) - d) - C) - d) -
CHO cell line (wi ld- type)
Cell surface + + + + + + + + - d)
CHO cell line ( 6 7 7  mutant)
Cell surface - - - d) - c) -  C) - d)
CHO cell line (F 1 7  mu tant)
Cell surface - - d) - d) - c) - - d) - d)
CHO cell line ( 7 4 5  mutant)
Cell surface - - - -C)
-  C) - d) - d)
Cryosections of human, rat, and mouse skeletal muscle, T. marmarota electric organ, and rat embryo, as 
well as fixed monolayers of CHO (wild-type and glycosylation-deficient mutants, grown to confluency), 
and C2Ci2 and S27 cells (differentiated for 0-15 d) were incubated with periplasmic fractions containing 
anti-HS scFv antibodies. Bound antibodies were visualized by incubation with rabbit polyclonal anti-c-Myc 
IgG followed by Alexa 488-conjugated goat anti-rabbit IgG. AChR clusters present in muscle 
neuromuscular junction, T. marmarota electrocytes, and C2Ci2 myotubes were visualized using TRITC- 
conjugated a-bungarotoxin.
Staining intensity: + + + , very strong; + + , strong; + , moderate; +/-, weak; -, absent (n=3 (cryosections), 
n = 2 (tissue cultures)).
a) Staining intensity decreased with differentiation level.
b) Staining intensity increased with differentiation level.
c) Small granules within the cytosol: + + .
d) Small granules around the nucleus: + + .
Cell lines that are defective in GAG synthesis are not surface- 
stained by anti-HS antibodies
To further establish the anti-HS nature of the scFv antibodies, we 
investigated cell lines that are defective in GAG synthesis. Developmental 
stages from half-confluent to 8 d of differentiation of the S27 cell line
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(Gordon and Hall, 1989) and confluent cultures of different CHO cell 
lines (wild type, N-acetylglucosaminyl- and glucuronosyltransferase- 
deficient; pgsD-677 (Lidholt et al., 1992), heparan sulfate uronic acid 2- 
O-sulfotransferase deficient; pgsF-17 (Dr. J. Esko, personal 
communication), and xylosyl transferase deficient; pgsA-745 (Esko et 
al., 1985)) were analyzed by immunofluorescence.
In contrast to wild-type myoblast cell line C2C12 (see below), the surface 
of S27 myoblasts was not immunoreactive for any of the antibodies, nor 
were places of cell-cell contact. On alignment and fusion, and at day 8 of 
differentiation, myotubes were not stained either, indicating that the BL 
of this mutant cell line does not contain any of the HS epitopes recognized 
by any of the antibodies (Table 3, Fig. 3). A noteworthy observation was 
the distinct staining of perinuclear and cytosolic granules by some 
antibodies (Table 3).
A04B05 RB4CD12 RB4EA12 Figure 3. Staining of S27
muscle cell line with anti-HS 
scFv antibodies. S27 cultures 
were grown to confluency 
and subsequently 
differentiated up to 8 days. 
Cultures of different 
developmental stages (half 
confluent (a l-c l), 1 day 
(a2-c2), and 8 days (a3-c3) 
of differentiation) were fixed 
and subsequently incubated 
with the periplasmic fraction 
of scFv antibodies AO4B05 
(a), RB4CD12 (b), and 
RB4EA12 (c), respectively. 
Bound antibodies were 
visualized by incubation with 
rabbit polyclonal anti-c-Myc 
IgG followed by Alexa 488- 
conjugated goat anti-rabbit 
IgG. None of the epitopes 
recognized by any of the 
antibodies can be visualized 
at the surface of myoblasts (a1-c1). For AO4B05, 
staining is not visible in aligning myoblasts (a2), or 
during myotube formation (a3). The epitope recognized 
by RB4CD12 is present in perinuclear granules in 
myoblasts (b l, arrows). During the alignment of 
myoblasts, the granular staining around the nucleus 
persists (b2, arrows), to change into a predominant 
cytosolic granular staining during myotube formation 
(b3). ScFv antibody RB4EA12 strongly stains peri­
nuclear granules in myoblasts (cl, arrows). In aligning 
myoblasts and during myotube formation, the granular 
staining around the nucleus persists (c2, c3, arrows). 
Scale bar, 25 jim.
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Figure 4. Staining of wild­
type and glycosylation- 
deficient CHO cell lines with 
anti-HS scFv antibodies.
CHO cultures (wild type (al 
to c l), N-acetyl­
glucosaminyl- and 
glucunorosyltransferase- 
deficient pgsD-677 (a2-c2), 
heparan sulfate uronic acid 
2-O-sulfotransferase- 
deficient pgsF-17 (a3-c3), 
and xylosyl transferase- 
deficient pgsA-745 (a4-c4)) 
were grown to confluency 
and subsequently fixed and 
incubated with the 
periplasmic fraction of scFv 
antibodies AO4B05 (a),
RB4CD12 (b), and RB4EA12
(c), respectively. Bound 
antibodies were visualized 
as in figure 3. The AO4B05 
epitope is present to a high 
degree at the surface of 
wild-type CHO cells where 
cell-cell contacts are made 
(al, arrowhead). Staining is 
not visible in any of the CHO 
mutant cell lines (a2-a4).
Wild-type CHO cells are 
moderately stained at the
surface by antibody RB4CDl2 at places of cell-cell 
contact (b l, arrowhead). In CHO mutant cell line pgsD- 
677 a faint granular perinuclear staining is visible (b2, 
arrow), whereas cell lines pgsF-l7 and pgsA-745 show 
a slightly elevated background staining (b3 and b4, 
respectively). The epitope recognized by RB4EAl2 does 
not appear at the surface in any of the CHO cell lines 
but shows a distinct, perinuclear, and granular staining 
in all CHO cell lines used. In wild-type, pgsD-677, and 
pgsF-l7 cells, these granules are predominantly 
located at the perinuclear region on one side of the cell 
(cl-c3, arrows). In pgsA-745 cells, the granular 
staining is present around the entire nucleus (c4).
Scale bar, 25 jim.
Wild-type CHO cells showed a clear surface staining at sites of cell­
cell contact when incubated with antibodies AO4B05, AO4B08, AO4F12, 
RB4CB9, and RB4CD12 (Table 3, Fig. 4a,b), whereas incubation with 
RB4EA12 and RB4EG12 did not (Table 3, Fig. 4c). None of the 
glycosylation-defective CHO mutant cell lines showed any surface 
staining (Fig. 4). As in the S27 cell line, some antibodies showed a distinct 
staining of perinuclear and cytosolic granules (Table 3, Fig. 4).
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Anti-HS antibodies bind distinct HS epitopes in skeletal muscle 
basal lamina
Incubation of cryosections of human, rat, and mouse skeletal muscle 
with each of the anti-HS antibodies yielded a clear staining of the muscle 
BL, which was similar in the species examined (Table 3, Fig. 5). Staining 
patterns of the antibodies on muscle BL were mutually distinct, ranging 
from a strong staining of the entire BL (AO4B05, AO4B08, AO4F12, 
RB4CB9, and RB4CD12), to a staining concentrated in (RB4EA12), or 
almost exclusive for (RB4EG12) the sBL. Antibodies AO4B05, AO4F12, 
RB4CD12, RB4EA12, and RB4EG12 stained the sBL more intensely than 
the extrasynaptic BL. The BL of neural tissues showed very strong 
(AO4F12, RB4CD12, and RB4EA12), strong (AO4B05), or moderate 
(AO4B08, RB4CB9, and RB4EG12) staining. BLs of blood vessels showed 
strong to moderate (AO4B05, AO4B08, AO4F12, RB4CB9, and RB4CD12) 
or no (RB4EA12 and RB4EG12) staining. The latter two antibodies hardly 
stain muscle BL extrasynaptically and appear to be neuron- and synapse- 
specific. Most antibodies that stain bloodvessels showed differences in 
staining intensity between arteries, large blood vessels, and capillaries.
The staining patterns of anti-HS antibodies provided convincing 
evidence for the existence and unique distribution of multiple HS 
epitopes within the skeletal muscle BL. To investigate the distribution 
of these HS epitopes with regard to the sBL, cryosections containing 
NMJs were incubated both with the antibodies and with TRITC- 
conjugated a-bungarotoxin. a-Bungarotoxin exclusively binds AChRs, 
thus allowing identification of NMJs. The AO4F12 epitope does not fully 
colocalize with AChR clusters, yet there is considerable overlap between 
the distribution of the AO4F12 epitope in the sBL and the presence of 
dense patches of AChR on the postsynaptic membrane (Fig. 5a1-a3). 
RB4CD12, on the other hand, showed an almost complete colocalization 
with AChR clusters (Fig. 5b1-b3). RB4EA12 showed a strong preference 
for neural and synaptic BL, thus completely colocalizing with AChR clus­
ters in NMJs (Fig. 5c1-c3). Finally, the RB4EG12 epitope showed a 
moderate staining that was limited to neural and synaptic BLs only (Fig. 
5d1-d3).
HS epitopes recognized by anti-HS antibodies abound in T. 
marmarota electric organ
Because the anti-HS antibodies showed differential staining patterns with 
regard to nerve- and muscle-derived (extrasynaptic and synaptic) BLs, 
and to investigate whether the HS epitopes are present in non­
mammalian species as well, we tested the antibodies for BL staining in 
the electric organ of the electric ray (T. marmarota). The electric organ is 
evolutionary derived from muscle tissue and shows dense patches of 
AChR clustering on the innervated face of the electrocytes. The various 
anti-HS antibodies showed a distinct staining of the electric organ (Table
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Figure 5. Staining of mouse skeletal muscle basal lamina 
with anti-HS scFv antibodies. Cryosections of C3H skeletal 
muscle were incubated with periplasmic fractions of anti- 
HS antibodies AO4F12 (a), RB4CD12 (b), RB4EA12 (c), 
and RB4EG12 (d), respectively. Bound antibodies were 
visualized by incubation with rabbit polyclonal anti-c-Myc 
IgG followed by Alexa 488-conjugated goat anti-rabbit IgG 
(a1-d1). AChR clusters present in the neuromuscular 
junction were visualized using TRITC-conjugated alpha- 
bungarotoxin (a2-d2). Double-label micrographs (a3-d3) 
show in yellow the colocalization of the HS epitopes bound 
by the scFvs and AChR clusters. The epitope recognized by 
AO4F12 is present in endoneural and perineural, as well as 
in endomysial BLs, but is clearly more abundant in 
synaptic versus extrasynaptic BL (a1). Note that this 
epitope does not fully colocalize with AChR clusters; there 
is a clear overlap from the BL epitope recognition (green) 
via a zone in which both epitopes are present (yellow) to 
the dense patches of AChR (red) (a3). The RB4CD12 
epitope is also present throughout neural and endomysial 
BLs and is slightly more abundant at NMJs (b1), but covers 
the entire region of AChR clustering (b3). Antibody 
RB4EA12 stains epitopes present in neural BL to a larger 
extent than those present in endomysial BL (c1, c3, 
arrows), shows a high abundancy in sBL (c1), and covers 
areas of AChR clustering entirely (c3). The epitope 
recognized by RB4EG12 hardly stains endomysial BL but 
resides in neural BL and at nMjs (d1), where it does not 
completely cover areas of AChR clustering (d3). Scale bar, 
50 |im.
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A04B05 A04F12 RB4CB9 Figure 6 . Starnrng of
Torpedo electric organ with 
anti-HS scFv antibodies. 
Cryosections of Torpedo 
electric organ were 
incubated with periplasmic 
fractions of anti-HS scFv 
antibodies AO4B05 (a), 
AO4F12 (b), and RB4CB9
(c), respectively. Bound 
antibodies (a1-c1 and a2- 
c2) and AChR clusters (a3- 
c3) were visualized as in 
figure 5. Double-label 
micrographs (a4 to c4) 
show in yellow the 
colocalization of AChR 
clusters and the HS 
epitopes bound by the 
scFvs. The AO4B05 epitope 
is present in large 
quantities in the 
endoneurium (a1, 
asterisks) and in 
electrocyte BLs (a2) but 
hardly at all in the 
perineurium (a1, arrows). 
Double staining of 
electrocytes reveals that 
this epitope is present not 
only on the innervated face 
but throughout the 
electrocyte BL (a4, arrows). 
The epitope recognized by AO4F12 is present in the 
endoneurium (b1, asterisk), but is more abundant in 
the perineural BLs (b1, arrows). In electrocytes, the 
presence of this epitope on the innervated face is less 
pronounced, whereas specific regions of the non­
innervated membrane accommodate the epitope in 
large amounts (b2). Double staining shows this epitope 
to be partially colocalized with AChR clusters on the 
electrocyte-innervated membrane (b4). The 
endoneurium is not stained by antibody RB4CB9 (c1, 
asterisk), whereas this epitope is very abundant in the 
perineurium (c1, arrows). In electrocytes, its presence 
is restricted to the innervated membrane (c2-c4). Scale 
bar, 50 |im.
3, Fig. 6), ranging from a strong staining of both electrocyte and 
endoneural BLs (AO4B05 (Fig. 6a1-a4), AO4B08, AO4F12 (Fig. 6b1-b4), 
and RB4CD12)), to a predominantly strong (RB4CB9 (Fig. 6c2-c4)), 
moderate (RB4EG12), or weak (RB4EA12) staining of the electrocyte BL. 
AO4B08, AO4F12 (Fig. 6b2-b4), and RB4CD12 stained specific regions 
of the electrocyte with a higher intensity. AO4F12 (Fig. 6b1), RB4CB9
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(Fig. 6c1), and, to a lesser extent, AO4B08 and RB4CD12 stained the 
perineural BL. The endoneural BL was strongly stained by AO4B05 (Fig. 
6a1) and to a lesser extent by AO4B08, AO4F12 (Fig. 6b1), RB4CD12, 
and RB4EG12.
Double-label micrographs of the epitope recognized by AO4B05 with 
alpha-bungarotoxin showed that the AO4B05 epitope partially 
colocalizes with the dense patches of AChR clusters on the innervated 
face of the electrocytes (Fig. 6a4). Double labeling of the AO4F12 epitope 
showed a slightly lower staining intensity of the non-innervated 
membrane, as compared with the innervated membrane, except for some 
brightly stained regions (Fig. 6b4). The RB4CB9 epitope was almost 
exclusively located at the electrocyte-innervated face, virtually 
completely colocalizing with the AChR clusters (Fig. 6c4).
Anti-HS antibodies show a developmental occurrence of HS 
epitopes in skeletal muscle basal lamina
The diversity of staining patterns obtained with the antibodies in mat­
ure skeletal muscle prompted us to investigate the occurrence of HS 
epitopes during muscle development. Special attention was paid to chan­
ges in the occurrence of specific HS epitopes within the endomysial, 
neural, and synaptic BL. This study was performed in three ways. First, 
cryosections of rat embryos at various developmental stages (days 10, 
13, 16, and 19 in utero) were studied. In this way, the occurrence of and 
possible changes in BL-HS epitopes during muscular development and 
synaptogenesis could be studied in the presence of both muscular and 
neural tissue. Second, cultures of the mouse skeletal muscle cell line C2C12 
at developmental stages ranging from half-confluent to 15 d of 
differentiation were analyzed. In doing so, we could monitor the presence 
of and changes in HS epitopes during myogenesis, as well as during the 
clustering of AChRs in the presence of muscular tissue only. Third, 
cryosections of denervated skeletal muscle of rat were studied. In 
denervated muscle cells, we looked at a possible upregulation or 
downregulation of HS epitopes as a result of the regeneration process.
In early embryonic stages of the rat (days 10-16), strong staining of 
the endomysial as well as a distinct interaction with neural BL was 
observed on immunostaining with AO4B05, AO4B08, AO4F12, RB4CB9, 
and RB4CD12. Antibody RB4EA12 predominantly stained neural tissue, 
whereas RB4EG12 showed an amorphous staining in developing muscle 
regions (data not shown). Rat embryos at day 19 in utero showed a more 
defined organ texture in cryosections, which enabled us to examine the 
presence of the HS epitopes in greater detail (Table 3, Fig. 7). Although 
RB4CD12 showed a strong staining of the entire neural and endomysial 
BL, the staining intensity was markedly lower in the sBL (Fig. 7a). 
RB4CB9, on the other hand, stained the sBL considerably stronger than 
the extrasynaptic BL (Fig. 7b). RB4EG12, binding HS epitopes present in
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Figure 7. Staining of rat 
embryo skeletal muscle 
with anti-HS scFv 
antibodies. Cryosections of 
rat embryos (day 19 in 
utero) were incubated with 
periplasmic fractions of 
anti-HS scFv antibodies 
RB4CD12 (a), RB4CB9 (b), 
RB4EG12 (c), and RB4EA12 
(d), respectively. Bound 
antibodies (a1-d1) and 
AChR clusters (a2-d2) were 
visualized as in figure 5.
The epitope recognized by 
antibody RB4CD12 is 
present throughout neural 
(asterisk) and endomysial 
BLs (a1) and is slightly less 
abundant in the sBL of 
developing NMJs (a1, a2, 
arrow). The epitope 
recognized by RB4CB9 is 
present in smooth muscle 
BL (arrowheads point at an 
artery) throughout the 
endomysial BL (b1) but is 
more abundant at NMJs 
(arrows in b1 and b2). 
RB4EG12 stains, at a low 
level, throughout the 
endomysial BL (granular 
staining in c1), but the 
epitope involved is more 
abundant at developing 
NMJs (c1, c2, arrows). The 
epitope recognized by 
RB4EA12 is only slightly 
present in the endomysial 
BL (d1) and absent in sBL 
(d1, d2, arrows). Scale bar, 
25 jim.
c2
neural and synaptic BL in fully developed skeletal muscle, strongly 
interacted with HS epitopes within the sBL and showed a faint, although 
definite staining of the extrasynaptic BL (Fig. 7c). The epitope recognized 
by RB4EA12, preferentially staining neural tissue and sBL in mature 
muscle, could hardly be visualized in BL of skeletal muscle tissue at day
19 of rat embryogenesis. However, this antibody did stain large cytosolic 
granules (Fig. 7d). Staining of BL in tissues other than skeletal muscle 
was also observed (data not shown).
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Figure 8. Staining of C2C12 
muscle cell line with scFv 
antibody AO4B05 during 
differentiation. C2C12 
cultures were grown to 
confluency and 
subsequently differentiated 
up to 15 days. Cultures of 
different developmental 
stages (half confluent (a), 1 
d (b), 8 d (c1, c2), and 15 d 
(d1, d2) of differentiation) 
were fixed and subsequently 
incubated with the 
periplasmic fraction of scFv 
antibody AO4B05. Bound 
scFv antibodies (a, b, c1, 
d1) and AChR clusters 
present on the surface of 
multinucleated myotubes 
(c2, d2) were visualized as 
in figure 5. The epitope 
recognized by AO4B05 is 
present to a high degree at 
the surface of myoblasts in 
regions where cell-cell 
contacts are made (a). In 
aligning myoblasts (b), a 
clear surface staining is 
visible that becomes more 
pronounced after myotube 
formation at sites where 
AChR clusters develop (c1, 
c2, arrows). As 
differentiation proceeds, 
both the staining of the BL
and the staining at AChR clusters decrease (d1, d2, 
arrows). Scale bar, 25 jim.
Cultures of mouse skeletal muscle cell line C2C12 were incubated with 
antibodies at stages ranging from half-confluent to 15 d of differentiation 
(Table 3, Fig. 8-10). Immunostaining with AO4B05, AO4B08, AO4F12, 
Rb4CB9, and RB4CD12 resulted in a strong staining of the myoblast 
surface. An intense staining was observed at places where myoblasts 
made contact. However, upon alignment and fusion (processes that 
trigger BL formation), the entire myotube surface was stained. AChR 
clusters, which develop on the surface of multi-nucleated myotubes at 
approximately day 3 of differentiation, were also stained by these 
antibodies. AO4B05 (Fig. 8), RB4CB9, and RB4CD12 (Fig. 9), especially, 
showed an enhanced staining of the myotube BL at sites of AChR
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Figure 9. Staining of C2C12 
muscle cell line with scFv 
antibody RB4CD12 during 
differentiation. C2C12 
cultures were grown to 
confluency and 
subsequently differentiated 
up to 15 days. Cultures of 
different developmental 
stages (half confluent (a), 1 
d (b), 8 d (c1, c2), and 15 d 
(d1, d2) of differentiation) 
were fixed and subsequently 
incubated with the 
periplasmic fraction of scFv 
antibody RB4CD12. Bound 
scFv antibodies (a, b, c1, 
d1) and AChR clusters 
present on the surface of 
multinucleated myotubes 
(c2, d2) were visualized as 
in figure 5. The RB4CD12 
epitope can be visualized at 
the myoblast surface at 
sites where cells have made 
mutual contacts (a). Note 
the perinuclear staining of 
the myoblasts at half­
confluent stage (a, 
arrowheads). After 
alignment, a strong surface 
staining is visible (b).
During myotube formation, 
this staining intensifies, 
especially at sites of AChR 
clustering (c1, c2, arrows). 
Ongoing differentiation does not lead to reduced AChR 
cluster staining, whereas the overall staining of the BL 
decreases slightly (d1, d2, arrows). Scale bar, 25 jim.
clustering. A striking feature was that the overall staining intensity 
decreased strongly during differentiation for antibodies AO4B05 (Fig. 
8), AO4B08, and AO4F12. Antibodies RB4EA12 and RB4EG12 were not 
able to stain the surface of C2C12 cells at any stage of differentiation. Both 
antibodies stained small cytosolic granules which were predominantly 
present near the nuclei (Fig. 10).
Incubation of cryosections of rat skeletal muscle 11 days after 
denervation with various anti-HS antibodies did not result in staining 
patterns that were any different from control muscle. After heparinase 
treatment, no differences in staining intensity with anti-HS stub anti­
body 3G10 could be seen in BLs of denervated, versus control muscle 
(data not shown).
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Figure 10. Staining of C2C12 
muscle cell line with scFv 
antibody RB4EA12 during 
differentiation. C2C12 
cultures were grown to 
confluency and 
subsequently differentiated 
up to 15 days. Cultures of 
different developmental 
stages (half confluent (a), 1 
d (b), 8 d (c1, c2), and 15 d 
(d1, d2) of differentiation) 
were fixed and 
subsequently incubated with 
the periplasmic fraction of 
scFv antibody RB4EA12.
Bound scFv antibodies (a, b, 
c1, d1) and AChR clusters 
present on the surface of 
multinucleated myotubes 
(c2, d2) were visualized as 
in figure 5. The epitope 
recognized by RB4EA12 is 
not present at the surface 
of myoblasts in regions 
where cell-cell contacts 
have been made (a). Note 
the faint staining in the 
perinuclear region of 
myoblasts at the half­
confluent stage (a, 
arrowheads). A granular 
staining within the cytosol is 
visible in early stages of 
alignment (b) but 
disappears during myotube
formation (c1). During further differentiation, no BL 
staining is seen at AChR clusters (d1, d2, arrows). 
Nevertheless, a faint perinuclear staining occurs in 
some myotubes displaying AChR clusters (d1, d2, 
arrows). Scale bar, 25 jim.
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Discussion
In this paper, we report the selection of a set of unique anti-HS scFv 
antibodies. The HS epitopes recognized by these antibodies are shown 
to be differentially distributed in BLs of both developing and mature 
skeletal muscle. GAG preparations isolated from mouse and human 
skeletal muscle specimens were used to select a series of anti-HS 
antibodies by phage display. Despite the enrichment of the muscle GAG 
preparations for DS, only anti-HS antibodies were selected. To our 
knowledge, no anti-DS antibodies have been described so far.
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In ELISA, all anti-HS scFv antibodies showed a differential reactivity 
with several HS preparations and with heparin, reflecting the epitope 
specificity of each antibody. The requirement of both N- and O-sulfate 
groups for proper epitope recognition was shown by desulfation of 
heparin, which is known for its high number of disaccharide units and 
high levels of N-sulfation. Desulfation completely abolished recognition 
by all antibodies, and N-resulfation could not restore the heparin-anti- 
body interaction. Because CS and DS are not bound by any of the 
antibodies, sulfation patterns specific for HS are likely to be important 
in the structure of the epitopes involved.
In our experiments, CHO cells showed a distinct HS staining for most 
antibodies, which was less intense than the staining of C2C12 cells. This is 
probably because HS from CHO cells is relatively poorly sulfated (40­
45% N-sulfation and ~0.8 sulfate/ disaccharide (Bame et al., 1991)). None 
of the cell-surface HS epitopes recognized by any of the antibodies 
described here could be detected in cell lines that are defective in GAG 
synthesis. This was the case with the S27 cell line, a genetic variant of the 
C2 mouse skeletal muscle cell line, which is severely hampered in GAG 
synthesis but does align and fuse to form myotubes during differentiation 
(Gordon and Hall, 1989). Several CHO mutants defective in GAG 
synthesis caused by the loss or impaired functioning of enzymes involved 
in glycosylation (Esko et al., 1985; Lidholt et al., 1992) failed to show any 
cell surface staining, which indicates their inability to properly synthesize 
the HS epitopes involved. The granular staining seen with some 
antibodies in many cells may reflect the staining of certain cellular 
compartments like the Golgi apparatus or lysosomes. Because of the 
defective cellular machinery for the correct synthesis of GAGs, immature 
HS epitopes or degradation products of HS molecules may be confined 
to these organelles.
All anti-HS scFv antibodies showed distinct reactivity in 
immunofluorescence with the BL of mature skeletal muscle. Staining 
patterns of the antibodies on human and rat muscle were consistent with 
those obtained on mice, reflecting an interspecies conservation of the 
epitopes involved. Most antibodies stained the entire muscular BL, but 
some antibodies showed a more intense staining in synaptic regions. 
Because of the presence of junctional folds in the postsynaptic membrane, 
BL is two- to threefold more abundant at NMJs than extrasynaptically 
(Sanes and Chiu, 1983). This local concentration of BL might explain the 
higher staining intensity of some antibodies at the NMJ, but we did not 
observe a higher abundance of HS in the synaptic cleft by heparitinase 
III digestion and anti-stub staining. A more appealing explanation is the 
possibility that certain HS epitopes are specifically concentrated in the 
sBL. The incomplete overlap of the AO4F12 epitope with AChR clus­
ters, in contrast with e.g. RB4CD12 and RB4EA12 (Fig. 5), suggests 
differences in location of these epitopes within the sBL. Antibodies that 
predominantly recognize epitopes present in neural and synaptic BL,
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such as RB4EA12 and RB4EG12, may indicate the neural origin of the 
epitopes involved. Results obtained on aneurally cultured skeletal muscle 
cells support this view, because these antibodies did not stain BLs at 
sites of AChR clustering (see further). The synapse-specific occurrence 
of distinct HS epitopes may prove to be causal for the restricted location 
of NMJ-resident, HS-binding proteins such as agrin, acetylcholine 
esterase, growth factors, and certain laminin isoforms.
Most HS epitopes recognized by the antibodies proved to be located 
close to AChR clusters, present on the innervated face of electrocytes, in 
the electric organ of the electric ray (T. marmarota). Anti-HS antibodies 
recognized their epitopes, which were embedded in mutually distinct 
patterns and quantities within neural BLs and in BLs on both the 
innervated and non-innervated side of the electrocytes. Despite the 
conserved distribution of the epitopes with regard to neural, synaptic, 
and extrasynaptic BL among the mammals tested, the distribution within 
the elasmobranch electric organ appeared to differ. Extracellular matrix 
isolated from Torpedo electric organ can induce AChR clustering in 
fibroblasts (Hartman et al., 1991). The heavily glycosylated HSPG agrin 
appears to be involved in the clustering of AChR in Torpedo electrocytes 
(Cartaud et al. 1996). The staining patterns of our anti-HS antibodies on 
cryosections of the electric organ add proof to the mutually distinct HS 
epitopes involved and raise curiosity about their function in organ 
morphogenesis.
During myogenesis in developing rat embryos, some of the HS 
epitopes were present in endomysial and synaptic BL in a pattern diffe­
rent from that seen in mature muscular tissue. Because NMJs appear 
between day 14 and 16 of embryonic life (Engel, 1994), the occurrence of 
HS epitopes during synaptogenesis was investigated on cryosections of 
embryos at days 10-19 in utero. Most antibodies stained endomysial as 
well as neural BLs during embryonic muscular development, as may be 
expected on the basis of their staining patterns in mature skeletal muscle 
tissue. However, clear differences in developmental appearance could 
be distinguished for epitopes recognized by some antibodies (RB4CB9, 
RB4CD12, RB4EA12, and RB4EG12) especially at sites of synaptogenesis. 
Local binding of growth factors and cytokines to specific HS sequences, 
as reviewed recently by Lyon and Gallagher (1998), may prove to be 
elemental in tissue morphogenesis. The distinct distribution in both time 
and space of these HS epitopes argues for such a regulatory mechanism.
The HS epitopes recognized by our antibodies were present in C2C12 
skeletal muscle cells at various stages of differentiation. Aneurally grown 
C2C12 myoblasts start aligning when they reach confluency. When cul­
ture medium is changed to differentiation medium containing 10% rat 
brain extract, AChR clusters appear at approximately day 3 of 
differentiation (Portiér et al., 1999). On mutual contact, C2C12 myoblasts 
expressed most of the HS epitopes described in this paper in large 
quantities on their surface. Alignment and fusion resulted in a complete
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staining of the newly formed BL by corresponding antibodies. These 
observations are in accordance with the 3-fold increase in HS synthesis 
in myotube cultures, compared with proliferating or aligning cultures 
(Noonan et al., 1986). Some antibodies showed steady levels or even a 
marked increase in overall staining intensity of the BL during further 
differentiation, consistent with the upregulation of the HSPG glypican 
during C2C12 differentiation (Brandan et al., 1996). Overall BL staining 
intensity of other antibodies decreased during later stages of 
differentiation. These results may be related to observations of Larram 
et al. (1997a,b) on downregulation of the HSPGs perlecan and syndecan-
1 during C2C12 cell differentiation. AChR cluster formation was 
accompanied by a strong local increase of certain HS epitopes, arguing 
for a possible role of these epitopes in the clustering of this ion channel. 
Antibodies RB4EA12 and RB4EG12 were not capable of BL staining at 
any stage of C2C12 cell differentiation, in accordance with their supposed 
neural origin.
Attempts to detect possible changes in the abundance of HS epitopes 
in denervated skeletal muscle proved to be elusive. Endomysial and 
neural BLs persist after damage or degeneration of either muscle or nerve 
cells, or both (Hall and Sanes, 1993). Synaptic and extrasynaptic 
proteoglycan deposits are conserved in both size and morphology in 
denervated skeletal muscle (Anderson et al., 1984), serving as scaffolds 
for the regeneration of both muscle and nerve tissue, thus causing NMJs 
to develop at sites where they were present before the degeneration. 
Moreover, Fadic and co-workers (1990) reported proteoglycan synthesis 
to be upregulated after denervation. Recently, GAGs were shown to be 
potent stimulants of insulin-like growth factor-1-mediated muscle 
reinnervation (Gorio et al., 1998). Because HS binds several growth factors 
involved in tissue morphogenesis and because of the unique distribution 
of certain HS epitopes, we suspect certain roles for HS epitopes in this 
regeneration process.
In conclusion, we show that it is possible to select for highly specific 
anti-HS antibodies against GAG preparations from skeletal muscle. The 
antibody-defined HS epitopes have distinct distribution characteristics 
in skeletal muscle BL and are similarly distributed in humans, rats, and 
mice. Obvious differences in extrasynaptic and synaptic BL staining were 
observed in mature versus developing skeletal muscle. The unique 
distribution patterns in skeletal muscle of the HS epitopes recognized 
by the scFv antibodies described in this article, both in time and in space, 
raise questions as to the biological roles of these HS epitopes. Of special 
interest are their roles in myogenesis, more specifically in synaptogenesis 
and the accompanying postsynaptic specializations such as the clustering 
of AChRs and other ion channels. The occurrence of these HS epitopes 
in HSPGs that have already been implicated in developmental processes 
awaits further investigation. Tools are now available to study more 
accurately the role of HS epitopes separate from their core protein.
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Heparan sulfates (HS) are long, linear polysaccharides with a 
high degree of variability. They bind to a vast number of proteins 
such as growth factors and cytokines, and these interactions 
are likely to be mediated by specific HS domains. To investigate 
the structural diversity and topological distribution of HS 
domains in tissues, we selected a panel of 10 unique anti-HS 
antibodies using phage display technology. All 10 antibodies 
recognize a specific HS epitope as demonstrated by ELISA using 
defined synthetic HS oligosaccharides, modified HS/heparin 
molecules, and HS isolated from a variety of organs. The 
chemical groups involved in the epitopes could be indicated, 
the position of sulfate groups being of major importance. All 
HS epitopes have a defined tissue distribution as shown by 
immunohistochemistry using rat organs.
Taken together, data show that in vivo a large number of 
defined HS epitopes exists, which do not occur randomly, but 
are tightly, topologically, regulated.
Introduction
Heparan sulfates (HS), a class of glycosaminoglycans, are long linear 
complex polysaccharides covalently bound to a protein core. They have 
an ubiquitous distribution in the extracellular matrix and on cell surfaces 
and have been implicated in many basic biological phenomena such as 
cell migration, adhesion and differentiation. They play a role in such 
diverse processes as growth factor/cytokine handling, enzyme 
regulation, lipid metabolism, blood coagulation, and viral entry (Kjellén 
and Lindahl, 1991; Ruoslahti and Yamaguchi, 1991; Salmivirta et al., 1996; 
Iozzo, 1998). This involvement is mediated by interactions of HS with a 
vast number of proteins such as growth factors/ cytokines, enzymes, 
protease inhibitors, extracellular matrix molecules and viral coat proteins 
(Conrad, 1998; David, 1993). The large number of interactions suggests 
an extensive structural variation within HS. Chemical analysis of HS- 
derived disaccharides indeed indicates a large structural diversity (Lyon 
et al., 1994; Sanderson et al., 1994; Maccarana et al., 1996), which is brought 
about by specific chain modifications during HS biosynthesis. The 
importance of defined monosaccharide sequences for specific interactions 
with proteins has been demonstrated for the binding and activation of 
anti-thrombin III by HS/heparin (Atha et al., 1984; Lindahl et al., 1984). 
In addition, specific structural requirements for binding to basic fibroblast 
growth factor and hepatocyte growth factor have been defined (Ashikari 
et al., 1995; Faham et al., 1996). These observations indicate that HS 
modifications do not occur randomly, but that a controlled expression
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of specific domains/sequences in HS exists. To investigate if indeed a 
large number of different HS domains in tissues occurs, we selected a 
panel of epitope-specific anti-HS antibodies using phage display 
technology. Using these antibodies we chemically and topologically 
characterized the HS epitopes involved. We chose antibody phage 
display because it allows for the generation of antibodies against poorly 
immunogenic molecules such as HS.
Materials and Methods
Materials
A human semi-synthetic antibody phage display library (Nissim et al., 
1994, now officially named synthetic scFv Library #1) was generously 
provided by Dr. G. Winter, Cambridge University, Cambridge, U.K. This 
library contains 50 different VH genes with synthetic random 
complementarity determining region 3 segments, which are 4-12 amino 
acid residues in length. The heavy chains are combined with a single 
light chain gene (DPL 16). The library contains > 108 different clones. All 
antibodies contain a c-Myc tag.
Heparan sulfate from bovine kidney, chondroitinase ABC (Proteus 
vulgaris, EC 4.2.2.4), chemically modified heparan sulfate and heparin 
kits, anti-chondroitin sulfate "stub" antibody (2B6), and anti-heparan 
sulfate "stub" antibody (3G10) were from Seikagaku Kogyo Co., Tokyo, 
Japan. Heparin from porcine intestinal mucosa, chondroitin 4-sulfate 
from whale cartilage, chondroitin 6-sulfate from shark cartilage, 
dermatan sulfate from porcine skin, keratan sulfate from bovine cornea, 
hyaluronate from human umbilical cord, DNA from calf thymus, dextran 
sulfate, bovine serum albumin (fraction V), heparinase I (from 
Flavobacterium heparinum, EC 4.2.2.7), heparinase II (from Flavobacterium 
heparinum), and heparinase III (heparitinase, from Flavobacterium 
heparinum, EC 4.2.2.8), were from Sigma (St Louis, MO). Alkaline 
phosphatase-conjugated rabbit anti-mouse IgG was from Dakopatts 
(Glostrup, Denmark). Mouse anti-c-Myc tag IgG (clone 9E10) was from 
Boehringer Mannheim (Mannheim, Germany). Alexa 488-conjugated 
goat anti-mouse IgG was from Molecular Probes (Eugene, OR). PCR kit 
was from Promega (Madison, WI). ABI Prism Big Dye Terminator Cycle 
Sequencing Ready Reaction Kit was from PE Applied Biosystems (Nor­
walk, CT). Mowiol (4-88) was from Calbiochem (La Jolla, CA). Restriction 
enzyme BstNI was from New England Biolabs (Beverly, MA). Polystyrene 
Maxisorp Immunotubes were from Nunc (Roskilde, Denmark). Various 
HS preparations were a generous gift from Dr. Keiichi Yoshida, 
Seikagaku Corp. (Japan). Synthetic HS oligosaccharides were all from
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Sanofi-Synthélabo Recherche (Toulouse, France).
Selection of antibodies against heparan sulfate by library 
panning
Phage display-derived antibodies were obtained as described (van 
Kuppevelt et al., 1998), using 4 rounds of panning against bovine kidney 
HS, human lung HS (HS isolated using papaine/ alkaline borohydride 
digestion followed by anion exchange chromatography), and mouse and 
human skeletal muscle HS (Jenniskens et al., 2000). Briefly, antibody- 
expressing phages were added to HS-coated tubes and bound phages 
were eluted at high pH in order to allow for infection of E. coli TG1 cells. 
After overnight amplification, phage were rescued by addition of hel­
per phage and used for further rounds of selections. After the last two 
rounds, single bacterial colonies were picked and the antibodies 
expressed were evaluated.
Screening for bacteria expressing antibodies against heparan 
sulfate
Screening for bacteria expressing anti-HS antibodies was performed as 
described (van Kuppevelt et al., 1998). Briefly, single colonies picked 
from the last 2 rounds of selection were grown in 96-well polystyrene 
round bottom plates until bacterial growth was visible. Antibody 
production was induced by adding isopropyl-ß-D-thiogalacto- 
pyranoside. Plates were centrifuged and the supernatant containing 
soluble antibodies was applied to wells of polystyrene microtiter plates 
previously coated with HS. Bound antibodies were detected using a 
mouse monoclonal antibody (9E10) directed against the c-Myc tag, 
followed by incubation with alkaline phosphatase-conjugated rabbit anti­
mouse IgG. Alkaline phosphatase activity was detected using p- 
nitrophenyl phosphate as a substrate. Absorbance was measured at 405 
nm.
Screening bacterial clones for unique antibody inserts using 
PCR, fingerprinting, and sequencing
Bacteria expressing anti-HS antibodies were analyzed for the presence 
of full length inserts by 25 cycles of PCR using plasmid DNA as temp­
late (van Kuppevelt et al., 1998). Fingerprinting was performed using 
BstNI (CC*a/ tGG) as the restriction enzyme. PCR and fingerprinting 
analysis were performed using 1% (w/v) and 4% (w/v) agarose gels 
respectively. To establish the complementarity determining region 3, and 
the germ line VH gene DNA segments, unique clones were sequenced 
using FOR LINK SEQ RIC (5'-GCCACCTCCGCCTGAACC-3') as the
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primer (located in the linker region between the VH and the VL gene). 
For this purpose, dsDNA was isolated using standard procedures.
Source of antibodies
To obtain optimal amounts of soluble anti-HS antibodies, phages were 
allowed to infect the non-suppressor E. coli strain HB2151. The 
periplasmic fraction of bacteria was used as the source of antibodies 
(van Kuppevelt et al., 1998). Briefly, bacteria were grown at 37OC until 
an optical density of 0.5-0.8 was reached. Induction was obtained by 
addition of isopropyl-ß-D-thiogalactopyranoside. After incubation at 
30OC for 3h, the culture was harvested, and the pellet resuspended in 
200 mM Na-borate buffer (pH 8.0) containing 160 mM NaCl and 1 mM 
EDTA. After centrifugation the supernatant was filtered and dialyzed 
versus PBS. The preparation thus obtained is the periplasmic fraction.
Characterization of antibodies by ELISA
Reactivity of the anti-HS antibodies with various molecules was 
evaluated in ELISA in two ways: a) by application of antibodies to wells 
of polystyrene plates coated with the test molecules, and b) by an 
inhibition assay in which the antibodies were incubated with the test 
molecule for 16 h at 22OC, followed by transfer to wells previously coated 
with HS (bovine kidney, (van Kuppevelt et al., 1998)). Test molecules 
included HS from bovine kidney, aorta, lung, intestine, human aorta, 
pig intestine and whale lung, heparin, dermatan sulfate, chondroitin 4- 
and 6-sulfate, keratan sulfate, dextran sulfate, hyaluronate, K5 
polysaccharide from E. coli, bovine serum albumin (BSA), marvel (the 
non-fat milk preparation using as a blocking reagent during panning) 
and DNA. To analyse which chemical groups in HS are involved in anti­
body-binding, a large number of modified HS preparations and synthetic 
HS-oligosaccharides were evaluated. They included HS from bovine 
kidney which was digested with heparinase I, II or III, or with HNO2 at 
pH 1.5, and chemically modified HS (bovine kidney) and heparins 
(porcine intestine). The latter included preparations that were completely 
desulfated and N-acetylated, preparations that were completely O- 
desulfated and N-sulfated, and preparations that were N-desulfated and 
N-acetylated. The antibodies were also analyzed using a panel of 12 
defined synthetic HS oligosaccharides.
Bound antibodies were detected using anti c-Myc tag mouse 
monoclonal antibody 9E10 and alkaline phosphatase-conjugated rabbit 
anti-mouse IgG antibody. Enzyme activity was detected using p- 
nitrophenyl phosphate as the substrate and absorbance was read at 405 
nm.
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Characterization of antibodies and localization of HS epitopes 
by immuno-histochemistry
Various rat tissue specimens (Wistar, male, 3 months old) were snap- 
frozen in liquid isopentane cooled with liquid nitrogen, and stored at - 
70OC. Cryosections (5 |J.m) were rehydrated for 10 min in PBS, blocked 
with PBS containing 1% (w/v) BSA, and incubated with anti-HS 
antibodies for 90 min at 22OC. As a control, antibodies from non-related 
clones were used. These antibodies did not stain rat tissue sections. 
Antibodies were detected by incubation with mouse anti-c-Myc tag 
antibodies (9E10, culture supernatant), followed by alexa 488-conjugated 
goat anti-mouse IgG (1:200 in PBS containing 1% BSA), both for 90 min 
at 22OC. After each incubation, sections were washed in PBS (3 x 10 min). 
Additional controls were the omission of primary or conjugated anti­
body.
To evaluate the specificity of the antibodies, cryosections were 
pretreated with heparinase III (digests HS), and with chondroitinase 
ABC (digests dermatan and chondroitin sulfates). As control, sections 
were incubated in the reaction buffer without enzyme. After rinsing and 
blocking, the sections were incubated with antibodies and processed for 
immunofluorescence as described. The efficacy of heparinase III 
treatment was analyzed using antibodies (3G10) against HS "stubs" 
generated by heparinase III. The efficacy of chondroitinase ABC 
treatment was evaluated by incubation of sections with antibodies (2B6) 
against chondroitin sulfate "stubs" generated by chondroitinase ABC. 
Specificity of the anti-HS antibodies was further tested by overnight 
preincubation of the antibodies with various molecules, viz. HS (bovine 
kidney), heparin, dermatan sulfate, chondroitin 4- and 6- sulfate, keratan 
sulfate, dextran sulfate, hyaluronate and DNA as described (van 
Kuppevelt et al., 1998), followed by processing for immunofluorescence.
Results
Selection of anti-heparan sulfate antibodies
Ten antibodies were selected on basis of amino acid sequence of the 
complementarity determining region 3 and/or VH-gene (table 1; 
Tomlinson et al., 1992). Five antibodies were obtained against bovine 
kidney HS (antibodies HS3A8, HS3B7, HS4A5, HS4D4 and HS4E4), and 
three antibodies against human lung HS (antibodies EV3B2, EV3D1 and 
EV3C3). The antibodies against mouse and human skeletal muscle HS 
(antibodies AO4B08 and RB4EA12, respectively) have been described 
previously (Jenniskens et al., 2000).
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Table 1. Some characteristics of the anti-HS antibodies
Antibody DP- gene VH - family VH -  CDR3 sequence
HS3A8 DP - 38 VH - 3 GMRPRL
HS3B7 DP - 3 VH - 1 SRKTRKPFMRK
HS4A5 DP - 65 VH - 4 WVTEP
HS4D4 DP - 58 VH - 3 GMRPRL
HS4E4 DP - 38 VH - 3 HAPLRNTRTNT
EV3B2 DP - 38 VH - 3 GKMKLNR
EV3C3 DP - 42 VH - 3 GYRPRF
EV3D1 DP - 47 VH - 3 SISMNGVGVRIQ
AO4B08 DP - 47 VH - 3 SLRMNGWRAHQ
RB4EA12 DP - 32 VH - 3 RRYALDY
Given are the DP-gene number (according to Tomlinson et al., 1992), VH-germ line gene family, and 
amino acid sequence of the VH complementarity determining region 3 (CDR3).
Table 2. Reactivity of anti-HS antibodies with various 
HS preparations (ELISA)
Preparation
Antibody
HS3A8 HS3B7 HS4A5 HS4D4 HS4E4 EV3B2 EV3C3 EV3D1 AO4B08 RB4EA12
1 1 0 0 1 0 0 1 0 0 10 0 1 0 0 10 0 1 0 0 1 0 0 1 0 0 1 0 0
2 (0) 0  ±  0 4  ±  8 0  ±  0 0  ±  0 0  ±  0 0  ±  0 0  ±  1 3  ±  3 1 ±  0 2 ±  2
3 ( 0 . 5 6 ) 5  ±  1 7  ±  1 0  ±  0 0  ±  2 26  ±  15 20  ±  1 0  ±  0 15  ±  1 3 2  ±  1 0  ±  0
4  ( 0 . 6 0 ) 8  ±  5 1 8  ±  4 0  ±  0 0  ±  0 2 2 2  ±  45 0  ±  0 10  ±  6 32  ±  1 5 6  ±  2 7  ±  10
5 ( 0 . 8 4 ) 23  ±  2 4 4  ±  4 2 4  ±  3 3 ±  0 9  ±  10 2 4 8  ±  16 1 4 3  ±  4 0 15 7  ±  6 11 4  ±  15 3 6 6  ±  51
6  ( 0 . 9 1 ) 14  ±  1 5 2  ±  3 2 8  ±  3 0  ±  1 0  ±  0 4 2  ±  9 4 2  ±  3 2 1 3  ±  4 2 9  ±  1 10 1  ±  21
7  ( 0 . 9 8 ) 4 0  ±  2 2 9  ±  3 5 8  ±  8 2 2  ±  7 33  ±  7 2 0 8  ±  11 17 9  ±  18 3 0  ±  8 3 9  ±  6 3 8 3  ±  8
8  ( 1 . 0 1 ) 4 6  ±  5 7 1  ±  7 3 9  ±  3 2 2  ±  5 3 5  ±  3 2 4 8  ±  2 0 2 4 1  ±  14 2 0 7  ±  8 1 5 0  ±  8 2 3 7  ±  33
9  ( > 1 ) 8 6  ±  3 8 2  ±  2 30  ±  2 6 3  ±  2 3 1 0 9  ±  10 3 4  ±  12 4 4  ±  3 28  ±  6 37  ±  1 31  ±  18
1 0  ( 1 . 6 4 ) 51  ±  1 6 8  ±  3 4 2  ±  3 2 0  ±  6 1 3 5  ±  18 33  ±  14 1 1 4  ±  8 6 31  ±  1 4 2  ±  2 13  ±  22
The ratio of sulfate groups to disaccharide is indicated in parentheses. Values (in % of reactivity with 
HS from bovine kidney) represent mean ± SD (n = 3).
1, HS from bovine kidney; 2, K5 capsular polysaccharide (E. coli, Similar to the HS precursor); 3, HS 
from bovine aorta; 4, hS from human aorta; 5, HS from bovine kidney (fraction A: elutes from an 
anion exchange column between 0.7 and 1.1 M NaCl); 6, HS from bovine lung; 7, HS from bovine 
intestine; 8, HS from bovine kidney (fraction B: elutes from an anion exchange column between 1.1 
and 1.25 M NaCl); 9, HS from whale lung; 10, HS from porcine intestinal mucosa.
Specificity of anti-heparan sulfate antibodies
Using ELISA, antibodies were shown to be specific for HS and heparin, 
and not to be reactive with other glycosaminoglycans like dermatan 
sulfate, chondroitin sulfates, hyaluronate and keratan sulfate, nor with 
other polyanionic molecules like dextran sulfate and DNA. Antibodies 
show a characteristic reactivity with HS preparations isolated from 
various sources like bovine kidney, aorta, lung and intestine, human 
aorta, and whale lung (table 2). None of the antibodies is reactive with 
the bacterial capsular polysaccharide K5 which is similar to the HS 
precursor polysaccharide. Therefore, all 10 antibodies recognise specific 
structural modifications.
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Table 3. Reactivity of anti-HS antibodies with modified 
HS and heparin molecules (inhibition ELISA)
GAG
Antibody
HS3A8 HS3B7 HS4A5 HS4D4 HS4E4 EV3B2 EV3C3 EV3D1 AO4B08 RB4EA12
1 6 2 3 2 2 0 6 13 3 2 0 13
2 1 6 2 1 1 1 1 6 7 1
3 - - - - - - - - - -
4 - - - - 2 5 - - - - -
5 - 13 - 2 5 - - - - - 12
6 - - - - - - - - - -
7 - - - - 3 7 - - - - -
8 - - - 2 5 - - - - - -
9 - - - - - - - - - -
10 - - - 13 - - 2 0 - - -
11 - - - - - - - - - -
12 6 - - 5 22 10 5 - 6 -
Numbers (IC5J  represent the amount of test substance (starting with 100 ^g/ml) which results in a 
50% inhibition of the binding of the antibody to HS (n=3).See text for explanation.
-, no inhibition; 1, HS (bovine kidney); 2, heparin (porcine intestinal mucosa); 3, completely 
desulfated/N-acetylated heparin; 4, completely desulfated/N-sulfated heparin; 5, N-desulfated/N- 
acetylated heparin; 6, completely desulfated/N-acetylated HS; 7, completely desulfated/N-sulfated 
HS; 8, N-desulfated/N-acetylated HS; 9, HNO2 (pH 1.5)-treated HS; 10, Heparinase I-digested HS;
11, Heparinase II-digested HS; 12, Heparinase Ill-digested HS.
HNO2 cleaves glycosidic linkages involving glucosamine with the amino group either N-sulfated or 
unsubstituted. Heparinase I cleaves the linkages GlcNS±6S-IdoUA2S , heparinase II the linkages 
GlcNAc/S±6S-GlcUA/IdoUA±2S, and heparinase III the linkages GlcNAc-IdoUA and GlcNAc/S±6S- 
GlcUA. IC50 values in ^g/ml.
Table 4. Reactivity of anti-HS antibodies with synthetic 
HS oligosaccharides (inhibition ELISA)
GAG
Antibody
HS3A8 HS3B7 HS4A5 HS4D4 HS4E4 EV3B2 EV3C3 EV3D1 AO4B08 RB4EA12
1 - - - - -  2 0 - - - -
2 - - - - -  - - 13 - -
3 - - 3 5 - -  9 - 2 - -
4 - - - - -  - - - - -
5 25 - 6 2 5 -  3 - - 3 -
6 - - - - -  3 5 - 5 - -
7 - - - - -  13 8 - - -
8 - - 13 - -  2 5 13 - - -
9 1 - 6 3 -  0 . 4 6 13 5 20
10 1 - 3 5 -  0 . 3 2 6 6 -
11 6 - 4 - -  9 2 5 - - -
12 3 30 3 - -  5 6 - - 5
Numbers (IC50) represent the amount of oligosaccharide (starting with 100 ^g/ml) which results in a 
50% inhibition of the binding of the antibody to HS (n=2). See text for explanation.
-, no inhibition; 1, GlcNAc6S-GlcUAaMe; 2, IdoUA-GlcNAc-GlcUAßMe; 3, GlcNS6S-GlcUA- 
GlcNS6SaMe; 4, GlcN-GlcUA-GlcNaMe; 5, IdoUA2S-GlcNS6S-IdoUA2S-GlcNS6SaMe; 6, GlcUA-GlcNS- 
GlcUA-GlcNS-IdoUA2SaMe; 7, IdoUA-GlcNS-GlcUA-GlcNS-IdoUA2SaMe; 8, GlcUA-GlcNS-IdoUA-GlcNS- 
IdoUA2SaMe; 9, GlcNS6S-GlcUA-GlcNS36diS-IdoUA2S- GlcNS36diSaMe; 10, GlcNS6S-GlcUA- 
GlcNS36diS-IdoUA2S-GlcNS6SaMe; 11, GlcNS6S-GlcUA-GlcNS36diS-IdoUA-GlcNSaMe, 12, GlcNS6S- 
GlcUA-GlcNS36diS-IdoUA-GlcNS6SaMe; GlcNS, N-sulfated glucosamine; GlcNAc, N-acetylated 
glucosamine; GlcUA, glucuronic acid; IdoUA, iduronic acid; 6S, 6-O-sulfation; 2S, 2-O-sulfation. IC50 
values in ^g/ml.
Analysis of HS epitopes recognized by the antibodies
Antibodies were tested for reactivity with modified HS/heparin 
preparations (table 3), and with various synthetic HS oligosaccharides 
(table 4), to identify which modifications in HS are involved in binding. 
Results show that all antibodies recognize different structures in HS. In
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all cases, sulfate groups are essential. HS and heparin stripped from their
O- and N-sulfate groups are not reactive with the antibodies. Treatment 
of HS with HNO2 at pH 1.5 (cleavage at N-sulfated glucosamine residues 
(GlcNS) and the rare N-unsubstituted glucosamine residues) abolishes 
antibody binding. Treatment of HS with heparinase I (cleaves at sulfated 
domain structures) results in loss of binding activity of 8 out of 10 
antibodies. For a number of antibodies, structural modifications of HS 
important for binding could be identified (tables 3 and 4). HS3A8 
recognizes highly sulfated domains within HS, since it reacts only with 
highly sulfated oligosaccharides. The antibody strongly prefers 6-O-, N- 
sulfated glucosamine (GlcNS6S) and prefers sulfated iduronic acid 
(IdoUA2S) over non-sulfated iduronic acid (IdoUA). The preferred 
sequence (starting at the non-reducing end) is GlcNS6S-IdoUA2S- 
GlcN6S6. Antibodies HS3B7 and RB4EA12 recognize IdoUA-GlcNS6S 
containing domains, 2-O sulfation of IdoUA impeding binding (compare 
compound 10 and 12, and 11 and 12, table 4). Differences in topological 
distribution (see below), however, indicate that each antibody recognizes 
a different epitope. Antibody HS4A5 recognizes various sequences and 
the preferred sequence can best be described as GlcNS±6S - IdoU±2S - 
GlcNS±6S. N-sulfation alone is not sufficient for binding (table 3). This 
generic sequence may indicate the recognition of a wide variety of 
structures, but the restricted topological distribution (blood vessel- 
associated basement membranes only, see below) argues against this 
(Fig. 1). Antibodies HS4D4 and AO4B08 are reactive with domains 
containing GlcNS6S-IdoUA2S-GlcNS6S sequences. Non-sulfated IdoUA 
impedes binding (compare compound 10 and 12, table 4). For AO4B08 
an additional 3-O-sulfate group on GlcNS6S has no influence (compare 
compound 9 and 10, table 4). HS4D4, however, requires an additional 
modification possibly 3-O sulfation of GlcNS6S (compare reactivity of 
HS4D4 and A04B08 for compound 5, table 4). N-sulfation seems of mi­
nor importance (table 3). HS epitopes recognized by the two antibodies 
have a different topological distribution (see below). Antibody HS4E4 is 
not reactive with any of the synthetic HS oligosaccharides tested. It is 
the only antibody that reacts with completely desulfated/N-sulfated 
heparin/HS (table 3), suggesting that N-sulfation is of major importance. 
It reacts strongly with human aorta HS (table 2), which is largely devoid 
of 6-O- sulfation (Safaiyan et al., 2000), and which may indicate that this 
modification is inhibitory. Taken together, these data suggest that HS4E4 
recognizes GlcNS-IdoUA2S containing domains. EV3B2 recognizes 
domains containing GlcNS±6S - UA - GlcNS±6S, where UA represent 
GlcUA or IdoUA. 2-O-sulfation of IdoUA improves binding (compare 
compounds 10 and 12, table 4); 3-O-sulfation of GlcNS seems to be of no 
importance (compare compound 9 and 10, table 4). EV3D1 needs GlcUA 
in a certain chemical context, preferably flanked by a GlcNS (±6S), but 
not by a non-sulfated IdoUA (compare compounds 6 and 7, and 
compounds 10 and 12, table 4). The final antibody, EV3C3, recognizes
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HS structures which could not be clearly identified. All antibodies, except 
EV3C3, EV3D1, and EV3B2, bind to perlecan, a HS-proteoglycan isolated 
from the ECM of the Engelbreth-Holm-Swarm mouse sarcoma (Hassell 
et al, 1980) (data not shown).
Table 5. Distribution of HS-epitopes defined by 
antibodies in rat kidney
Basal Lamina
Antibody
HS3A8 HS3B7 HS4A5 HS4D4 HS4E4 EV3B2 EV3C3 EV3D1 AO4B08 RB4EA12
1 +  + + +  + +  + - +  + +  + +  + - -
2 + +  + - +  + + + +  + +  + +  + +  +  -
3 +  + +  + +  + +  + + +  + +  + +  + + -
4 +  + +  + - +  + + + +  + +  + + + +  +  +  +  *
5 + + - +  + + + + + + + -
6 + + + +  + + + + / - + / - + -
Cryosections were processed for immunofluorescence as described (van Kuppevelt et al., 1998).
1, Glomerulus; 2, Bowman's capsule; 3, Peritubular capillaries; 4, Cortical tubules; 5, Smooth muscle 
cells; 6, Large blood vessel endothelium. Staining: ++, strong; +, moderate; +/-, weak; -, absent.
* Only a subset of tubules is stained.
Localization of HS epitopes using immunohistochemistry
Each antibody showed that the HS structure it recognizes, has a defined 
topology. In the kidney, the anti-HS antibodies primarily stain basement 
membranes (Fig. 1, table 5). Antibodies HS4A5, RB4EA12, and HS4E4/ 
AO4B08 (both have a similar topology) recognize structures with a clear 
different topological distribution compared to structures recognised by 
the other antibodies. These antibodies show a more or less similar tissue 
distribution, be it with some difference in staining intensity. Some 
antibodies (HS3A8 and HS4D4) show a similar topological staining in 
renal tissue, but a differential distribution in testicular tissue (Fig. 1). 
Staining of all the antibodies was abolished by pretreatment of sections 
with heparinase III, but not with chondroitinase ABC. Preincubation of 
antibodies with HS and heparin precluded staining. Incubation with 
other glycosaminoglycans, with dextran sulfate, or with DNA has no 
effect.
Discussion
Next to proteins and nucleic acids, polysaccharides may form a third 
group of information-dense biopolymers. This especially holds for HS, 
a class of linear polysaccharides involved in many basic cellular 
phenomena. Theoretically, cells can generate a large potential of diffe­
rent monosaccharide sequences (domains) in HS (see below). To study
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Figure 1. Immunostaining 
of rat renal (a-f) and 
testicular tissue (g,h) with 
anti-HS antibodies. 
Cryosections were 
incubated with antibody 
HS4E4 (a), HS4A5 (b), 
RB4EA12 (c), a non-related 
phage display-derived 
antibody (d), HS3A8 (e, g) 
and HS4D4 (f, h). Note the 
similar staining of HS3A8 
and HS4D4 in renal tissue 
(e,f) and the differential 
staining of these antibodies 
in testicular tissue (g, h).
*: glomerulus. Arrow in g 
and h: smooth muscle 
cells. Scale bar: 25 |im (d, 
g, h) or 50 |im (a, b, c, e, 
f).
if such a potential indeed exists in vivo, we selected 10 anti-HS antibodies 
by phage display technology. This technology has proven to be very 
useful for obtaining antibodies against HS, which are almost non- 
immunogenic (van Kuppevelt et al., 1998; Jenniskens et al., 2000). All 10 
antibodies recognize an unique epitope structure, the position of sulfate 
groups being of major importance. Together with the 5 anti-HS antibodies 
already described (van Kuppevelt et al., 1998; David et al., 1992; Raats et 
al., 2000), and which are different with respect to the ones described 
here, it implies that at least 15 different HS epitopes are present in the 
kidney, the nature of the epitopes being highly complex. All epitope 
structures have a defined topological tissue distribution, indicating that 
in vivo a tightly controlled biosynthetic apparatus for HS exists. This 
may also be true for chondroitin sulfates, since a number of anti- 
chondroitin sulfate antibodies have been generated thatshow a specific 
distribution in tissues (Couchman et al., 1984; Sorrell et al., 1990).
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The biosynthesis of HS allows for a large number of different 
sequences. The HS precursor polysaccharide chain is made up of 
repeating disaccharide units which consist of a glucuronic acid and a N- 
acetylated glucosamine (GlcNAc) residue. These disaccharide units, of 
which there can be up to a 150 in HS, can undergo a number of 
modifications. Some GlcNAc residues are N-deacetylated and 
subsequently N-sulfated, and this step serves as a trigger for further 
modifications such as epimerization of GlcUA to IdoUA, 2-O sulfation 
of GlcUA and IdoUA, and 6-O- and/or 3-O-sulfation of GlcN. 
Modification occurs in specific regions of the polysaccharide chain 
leading to highly modified domains (N- and O- sulfate rich) interspaced 
by less modified domains (Kjellén and Lindahl, 1991; Salmivirta et al., 
1996). The number of disaccharides units and their possible modifications 
can (theoretically) give rise to a tremendous structural variation. An 
octasaccharide, for instance, already has over a million possible 
monosaccharide sequences. The importance of specific modifications in 
vivo have been demonstrated. Genetic studies in Drosophila, mice and 
men reveal the involvement of HS in cell differentiation and 
morphogenesis. In Drosophila, mutations in genes encoding enzymes 
involved in HS biosynthesis (sugarless, sulfateless and tout velu) lead 
to a loss of specific signalling pathways (FGF, Wingless and Hedgehog), 
resulting in severe alterations in phenotype. In mice, a mutation in the 
gene encoding 2-O-sulfotransferase, leads to multiple developmental 
abnormalities, whereas targeted gene disruption in the genes encoding 
glucosaminyl N-deacetylase/N-sulfotransferase-1 and -2 result in let­
hal respiratory distress and mast cell abnormalities respectively 
(Perrimon and Bernfield, 2000). In men, mutations in glycosyltransferases 
involved in HS biosynthesis (EXT1 and EXT2) lead to hereditary multi­
ple exostoses (McCormick et al., 1998). These findings indicate that 
specific HS modifications play a crucial role in developmental processes. 
Our data indicate that indeed a large number of HS epitopes exists in 
vivo and that these do not occur randomly, but are tightly, topologically, 
regulated. This indicates the existence of a tightly controlled pattern of 
modifications occurring during biosynthesis of HS.
Aberrations in HS fine structure have been implied in various 
pathological conditions including nephropathies, cancer, and bacterial 
and viral infections (Shieh et al., 1992; van Putten and Paul, 1995; Chen 
et al., 1997; Kleeff et al., 1998; Raats et al., 2000; Shukla et al., 2000). The 
antibodies described here, and which probably have a Kd of about 0.1 
|j.M (van Kuppevelt et al., 1998), can be used in ELISA, 
immunohistochemistry and FACS analysis. They can probably also be 
used for immunoblotting, although we did not test this.
With the emerging HS sequencing technology (Turnbull et al, 1999; 
Venkataraman et al., 1999), and new methods to prepare synthetic HS 
oligosaccharides (Petitou et al., 1999), the antibody-defined HS structures 
presented here may be characterised at the monosaccharide level. The
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epitope defined by anti-HS antibody 10E4 was recently partially 
characterized (Leteux et al., 2001). Well defined anti-HS antibodies will 
make it possible to pin-point defined structural modifications, and 
perhaps even monosaccaride sequences, to biological processes in health 
and disease.
References
Ashikari S, Habuchi H, and Kimata K (1995) Characterization of heparan sulfate oligosaccharides 
that bind to hepatocyte growth factor. J.Biol.Chem. 270:29586-29593.
Atha DH, Stephens AW, and Rosenberg RD (1984) Evaluation of critical groups required for the 
binding of heparin to antithrombin. Proc.Natl.Acad.Sci.USA. 81:1030-1034.
Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, and Marks RM (1997) 
Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate Nature 
Med. 3:866-871.
Conrad HE (1998) In: Heparin Binding Proteins. San Diego: Academic Press.
Couchman JR, Caterson B, Christner JE, and Baker JR (1984) Mapping by monoclonal antibody 
detection of glycosaminoglycans in connective tissues. Nature 307:650-652.
David G, Mei Bai X, Van Der Schueren B, Cassiman J-J, and Van Den Berghe H (1992) 
Developmental changes in heparan sulfate expression: in situ detection with mAbs. J.Cell Biol. 
119:961-975.
David G (1993) Integral membrane heparan sulfate proteoglycans. FASEB J. 7:1023-1030.
Faham S, Hileman RE, Fromm JR, Linhardt RJ, and Rees DC (1996) Heparin structure and 
interactions with basic fibroblast growth factor. Science 271:1116-1120.
Hassell JR, Robey P, Barrach H, Wilczek J, Rennard S, and Martin GR (1980) Isolation of a 
heparan sulfate-containing proteoglycan from basement membrane. Proc.Natl.Acad.Sci.USA. 
77:4494-4498.
Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function.
Annu.Rev.Biochem. 67:609-652.
Jenniskens GJ, Oosterhof A, Brandwijk R, Veerkamp JH, and van Kuppevelt TH (2000) 
Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display- 
derived antibodies. J.Neurosci. 20:4099-4111.
Kjellén L and Lindahl U (1991) Proteoglycans: structures and interactions. Annu.Rev.Biochem. 
60:443-475.
Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD, and Korc M (1998) The 
cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic 
carcinoma cells and is overexpressed in human pancreatic cancer. J.Clin.Invest. 102:1662-1673.
Leteux C, Chai W, Nagai K, Herbert CG, Lawson AM, and Feizi T (2001) 10E4 Antigen of scrapie 
lesions contains an unusual nonsulfated heparan motif. J.Biol.Chem. 276:12539-12545.
Lindahl U, Thunberg L, Backstrom G, Riesenfeld J, Nordling K, and Bjork I (1984) Extension 
and structural variability of the antithrombin-binding sequence in heparin. J.Biol.Chem . 259:12368­
12376.
Lyon M, Deakin JA, and Gallagher JT (1994) Liver heparan sulfate structure. A novel molecular 
design. J.Biol.Chem . 269:11208-11215.
Maccarana M, Sakura Y, Tawada A, Yoshida K, and Lindahl U (1996) Domain structure of 
heparan sulfates from bovine organs. J.Biol.Chem. 271:17804-17810.
McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP, and Tufaro F (1998) The 
putative tumor suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nature Genet. 
19:158-161.
9 4  I CHAPTER THREE
Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, Winter G (1994) 
Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J. 
13:692-698.
Perrimon N and Bernfield M (2000) Specificities of heparan sulphate proteoglycans in 
developmental processes. Nature 404:725-728.
Petitou M,Herault JP, Bernat A, Driguez PA, Duchaussoy P, Lormeau JC, and Herbert JM
(1999) Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 398:417-422.
Raats CJI, van den Born J, and Berden JHM (2000) Glomerular heparan sulfate alterations: 
mechanisms and relevance for proteinuria. Kidney Int. 57:385-400.
Ruoslahti E and Yamaguchi Y (1991) Proteoglycans as modulators of growth factor activities. Cell 
64:867-869.
Safaiyan F, Lindahl U, and Salmivirta M (2000) Structural diversity of N-sulfated heparan sulfate 
domains: distinct modes of glucuronyl C5 epimerization, iduronic acid 2-O-sulfation, and glucosamine 
6-O-sulfation. Biochemistry 39:10823-10830.
Salmivirta M, Lidholt K, and Lindahl U (1996) Heparan sulfate: a piece of information. FASEB J. 
10:1270-1279.
Sanderson RD, Turnbull JE, Gallagher JT, and Lander AD (1994) Fine structure of heparan 
sulfate regulates syndecan-1 function and cell behavior. J.Biol.Chem. 269:13100-13106.
Shieh M-T, Wudunn D, Montgomery R I, Esko JD, and Spear JG (1992) Cell surface receptors 
for herpes simplex virus are heparan sulfate proteoglycans. J.Cell Biol. 116:1273-1281.
Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosen­
berg RD, and Spear PG (1999) A novel role for 3-O-sulfated heparan sulfate in herpes simplex 
virus-1 entry. Cell 99:13-22.
Sorrell JM, Mahmoodian F, Schafer IA, Davis B, and Caterson B (1990) Identification of 
monoclonal antibodies that recognize novel epitopes in native chondroitin/ dermatan sulfate 
glycosaminoglycan chains: their use in mapping functionally distinct domains of human skin. 
J.Histochem.Cytochem. 38:393-402.
Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G (1992) The repertoire of human 
germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. 
J.Mol.Biol. 227:776-798.
Turnbull JE, Hopwood JJ, and Gallagher JT (1999) A strategy for rapid sequencing of heparan 
sulfate and heparin saccharides. Proc.Natl.Acad.Sci.USA. 96:2698-2730.
van Kuppevelt TH, Dennissen MABA, Van Venrooij WJ, Hoet RMA, Veerkamp JH (1998) 
Generation and application of type-specific anti-heparan sulfate antibodies using phage display 
technology. J.Biol.Chem. 273:12960-12966.
van Putten JPM and Paul SM (1995) Binding of syndecan-like cell surface proteoglycan receptors is 
required for Neisseria gonorroeae entry into human mucosal cells. EMBO J. 14:2144-2154.
Venkataraman G, Shriver Z, Raman R, and Sasisekharan R (1999) Sequencing complex 
polysaccharides. Science 286:537-542.
LARGE DOMAIN DIVERSITY OF HEPARAN SULFATES I' 95
96 CHAPTER THREE
Chapter 4
Spatiotemporal Distribution of 
Heparan Sulfate Epitopes 
During Myogenesis and 
Synaptogenesis: A Study in 
Developing Mouse Intercostal 
Muscle
Guido J. Jenniskens 
Theo Hafmans 
Jacques H. Veerkamp 
Toin H. van Kuppevelt
Department of Matrix Biochemistry, University 
Medical Center, NCMLS, Nijmegen, The 
Netherlands
Developmental Dynamics (2002) 
225:In Press.
DOI: 10.1002/dvdy.10138

Formation of a basal lamina (BL) ensheathing developing skeletal 
muscle cells is one of the earliest events in mammalian skeletal 
muscle myogenesis. BL-resident heparan sulfate proteoglycans 
(HSPGs) have been implicated in various processes during 
myogenesis, including synaptic differentiation. However, 
attention has focused on the proteoglycan protein core, ignoring 
the glycosaminoglycan moiety mainly because of a lack of 
appropriate tools. Recently, we selected a panel of anti-heparan 
sulfate (HS) antibodies that are applied here to study the 
spatiotemporal distribution of specific HS epitopes during 
myogenesis. In mouse intercostal muscle at E14, formation of 
acetylcholine receptor clusters at synaptic sites coincides with 
HS deposition. Whereas some HS epitopes show a general 
appearance throughout the BL, one epitope preferably clusters 
at synaptic sites, but does so only from E16 onwards. Signifi­
cant changes in the HS epitope-constitution of both synaptic 
and extrasynaptic BL were observed during elongation and 
maturation of primary myotubes, a process preceding secondary 
myotube development. As a whole, the data presented here 
strengthen previous observations on developmental regulation 
by BL components, and add to the putative roles of specific HS 
epitopes in myogenesis and synaptogenesis.
Introduction
The synaptic cleft of the neuromuscular junction (NMJ) is occupied by a 
layer of extracellular material, which escheats all vertebrate skeletal 
muscle fibers: the basal lamina (BL). Several BL components are 
distributed in distinct synaptic and extrasynaptic regions, whereas others 
are common (Hall and Sanes, 1993). For many years, it has been 
recognized that BL-resident proteins play a regulating role in the 
differentiation and maintenance of both pre- and postsynaptic 
membranes (Burden, 1998; Meier and Wallace, 1998). Thus far, only few 
reports on the composition of the BL during myogenesis and 
synaptogenesis mention proteoglycans.
Proteoglycans are proteins which have a glycosaminoglycan (GAG) 
chain covalently attached to a core protein. In the case of heparan sulfate 
proteoglycans (HSPGs), the GAG moiety consists of heparan sulfate (HS), 
an unbranched chain of 30 to 150 disaccharides. Each HS disaccharide 
unit, consisting of a glucosamine and an uronic acid residue, can be 
modified by N-deacetylation, N-sulfation, 2-O-, 3-O-, and/ or 6-O- 
sulfation and C-5 epimerization. The concert of these modifications 
potentially makes HS a very information-dense biopolymer, to which 
several proteins may bind in a monosaccharide sequence-specific way
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(Salmivirta et al., 1996; Bernfield et al., 1999; Tumova et al., 2000; Turnbull 
et al., 2001; Gallagher, 2001). In developmental processes however, the 
functions of HS have remained mostly under appreciated until recently 
(Perrimon and Bernfield, 2000).
In recent years, there have been a number of reports on the roles of 
BL-resident HSPGs in myogenesis and synaptogenesis. These include 
the roles of agrin in acetylcholine receptor (AChR) clustering (Ruegg 
and Bixby, 1998; Lin et al., 2001), the involvement of syndecan-2 in neural 
synaptogenesis (Hsueh et al., 1998), the binding of growth factors in NMJs 
by perlecan (Peng et al., 1998), the focal immobilization of BL-resident 
proteins like acetylcholine esterase (AChE) by perlecan (Peng et al., 1999), 
the involvement of perlecan in the assembly of laminin in the BL (Henry 
et al., 2001), and the maturation and maintenance of the NMJ and its 
synaptic BL by the dystrophin-glycoprotein complex and associated 
HSpGs (Grady et al., 2000; Jacobson et al., 2001).
As early as 1984, it was shown that synaptic and extrasynaptic parts 
of the muscle BL are subject to dynamic changes during synaptogenesis 
(Chiu and Sanes, 1984). More specific, expression of two HS-related 
epitopes (David et al., 1992), perlecan (Larram et al., 1997a), alternatively 
spliced isoforms of agrin (Hoch et al., 1993), the HSPG-families of the 
syndecans (Bernfield et al., 1993; Larram et al., 1997b; Sogos et al., 1998) 
and glypicans (Brandan et al., 1996; Litwack et al., 1998), the proteoglycans 
decorin (Velleman et al., 1999), and SPOCK (Charbonnier et al., 2000; 
Cifuentes-Diaz et al., 2000) have been shown to be developmentally 
regulated. Olguin and Brandan recently reported the temporal and spatial 
co-expression of HSPGs syndecan-3 and decorin with myogenin, a 
transcription factor responsible for the induction of terminal skeletal 
muscle differentiation (Olguin and Brandan, 2001). Moreover, Nurcombe 
and coworkers found evidence for differential glycosylation of a HSPG 
core protein during murine neural cell differentiation (Nurcombe et al., 
1993; Brickman et al., 1998). HS structure itself is also subject to regulation 
during development and aging in vivo (Feyzi et al., 1998; Guimond et al., 
2001). Taken together, HSPGs and especially the sulfation patterns of 
the HS moiety are considered candidate regulators of developmental 
signaling (Lander, 1998; Selleck, 2000; Dhoot et al., 2001). However, much 
has to be learned about the distribution of specific HS epitopes during 
myogenesis in vivo and the roles of this class of glycosaminoglycans in 
developmental processes.
Recently, we reported on the selection of a panel of phage display- 
derived antibodies that recognize specific HS epitopes (Jenniskens et al.,
2000). In the present study, we describe the spatiotemporal distribution 
of several HS epitopes during myogenesis in mouse intercostal muscle, 
and their distribution with regard to developing synapses. For the first 
time, specific HS epitopes of the cellular HS constitution are shown to 
be subject to a dynamic distribution during myogenesis and 
synaptogenesis in vivo.
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Materials and Methods
Materials
C3H mice were obtained from the University of Nijmegen Central Ani­
mal Laboratory. All chemicals used were from Merck (Darmstadt, 
Germany), unless stated otherwise. Bovine serum albumin (fraction V), 
and NaN3 were obtained from Sigma (St. Louis, MO). Target Unmasking 
Fluid was purchased from Boehringer Mannheim (Mannheim, Germany), 
anti-pan sodium channel rabbit polyclonal IgG (SP19) from Alomone 
labs (Jerusalem, Israel). Anti-c-Myc tag goat polyclonal IgG (A-14) was 
from Santa Cruz Biotechnology (Santa Cruz, CA). Alexa 488-conjugated 
donkey anti-goat IgG, goat anti-rabbit IgG, and Alexa 594-conjugated a- 
bungarotoxin were purchased from Molecular Probes (Eugene, OR). 
Mowiol (4-88) was obtained from Calbiochem (La Jolla, CA).
Anti-heparan sulfate antibodies
Preparation of anti-heparan sulfate antibodies (periplasmic fractions) 
AO4B05, AO4B08, RB4CD12, RB4EA12, and control antibody MPB01 
was performed as described (Jenniskens et al., 2000). Antibody MPB01 
was randomly selected from scFv library #1. This antibody is a member 
of VH family 3, has DP segment 38, bears the CDR3 sequence PKRTRN 
(single-letter amino acid code), and is not reactive with HS or heparin 
from any source tested, as analyzed by ELISA and IFA techniques.
Pre- and postnatal mouse tissue
C3H mice were bred under standard conditions and monitored for 
vaginal plugs twice a day. The first day of occurrence of a vaginal plug 
was taken as day 0 of gestation (E0). Pregnant mice were quarantinised 
and kept solitary until the litter had reached the indicated E-number 
(12, 13, 14, 15, 16, 17, 18, and 20 days in utero). Mice were anesthetized 
and killed by cervical dislocation, in accordance with the ethic regulations 
of the university. Embryos were isolated either with (E12 and 13) or 
without (E14-E20) the surrounding uteric tissue, rinsed in PBS, snap- 
frozen in liquid nitrogen-cooled isopentane, and stored at -80OC. Birth 
occurred on average at day E20 (P0). Mice of postnatal day 2 (P2) were 
anesthetized prior to freezing. For each developmental stage, at least 
three individual mice, derived from two separate litters, were studied. 
Adult intercostal muscles were difficult to isolate in a way appropriate 
for cryosectioning, because of the presence of osteofied ribs. We therefore 
used specimens of the m. soleus, isolated from the pregnant females 
that were killed, for studying adult NMJs.
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Immunohistochemistry
5 to 10 |J.m thick cryosections of whole embryos, newborns or adult tissue 
specimens were cut, mounted on slides, dried thoroughly, and stored at 
-80OC until use. Cryosections were rehydrated in PBS for 10 min. After 
20 min blocking in PBS containing 0.1% (w/v) BSA, cryosections were 
incubated with anti-heparan sulfate antibodies for 90 min. Bound 
antibodies were visualized using anti-c-Myc goat polyclonal antibody 
A-14 and Alexa 488-conjugated donkey anti-goat IgG (60 min each). 
AChR clusters were stained by Alexa 594-conjugated a-bungarotoxin, 
included in the final incubation. Primary antibodies against voltage gated 
ion channel were applied for 60 min, after which bound antibodies were 
visualized using Alexa 488-conjugated goat anti- rabbit IgG for 60 min. 
Following each incubation, cryosections were washed three times 10 min 
with PBS. Finally, cryosections were fixed in 100% methanol, dried, and 
embedded in Mowiol (10% (w/v) in 0.1 M Tris-HCl, pH 8.5/ 25% (v/v) 
glycerol/ 2.5% (w/v) NaN3). As a control, primary, secondary or 
conjugated antibodies were omitted. Also, a control phage display- 
derived scFv antibody that does not react with HS was used (MPB01). 
To investigate the possibility of epitope masking by tissue-resident HS- 
binding proteins, cryosections were incubated in high-salt buffer (PBS/
1 M NaCl) or in Target Unmasking Fluid prior to immunostaining. Since 
no apparent changes in staining patterns were observed, we assume that 
the procedure described here allows for the staining of all HS epitopes 
present in the tissue. All incubations were performed at ambient 
temperature (21OC). Photographs were taken, using a constant shutter 
time, on a Zeiss Axioskop immunofluorescence microscope (Göttingen, 
Germany). Confocal images were made on a Nikon Diaphot inverted 
microscope attached to a BioRad MRC1024 ES confocal laser scanning 
microscope (Hemel Hempstead, UK). Digital images were processed 
using Confocal Assistant 4.02 and Adobe Photoshop 6.0 software.
Results
Histogenesis of mouse intercostal muscle
Intercostal muscle was chosen for studying muscle development and 
synaptogenesis, since its muscle mass is relatively homogeneous, well 
innervated, and easy to monitor (Theiler, 1989; Hogan et al., 1994). To 
improve the comparability between intercostal muscles of different 
developmental stages, we focused our study on the m. intercostalis externus 
between ribs 5 and 6.
Intercostal muscles are divided in two main muscle-masses: m. inter- 
costalis internus and m. intercostalis externus (Fig. 1). The m. intercostalis 
internus is located at the internal side and has a function in drawing
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Figure 1. Overview of m. 
intercostalis internus and 
m. intercostalis externus at 
E20 (birth). The 
cryosection was stained 
with an anti-HS antibody 
(a), control antibody 
MPB01 (c), and a- 
bungarotoxin (b and d). HS 
epitopes are localized in 
both extrasynaptic and 
synaptic BL (arrows in a), 
as well as in perimysial 
structures including nerves 
(asterisk in a) and blood 
vessels. The curved line 
marks the border between 
the m. intercostalis 
internus (I), which consists 
of a relatively 
heterogeneous population 
of loosely dispersed small 
muscle fibers, and the m. 
intercostalis externus (E) 
comprising a more 
homogeneous set of muscle 
fibers with a larger diame­
ter. Note that 
neuromuscular junctions 
are positioned in the center 
of the intercostal muscle 
mass (b). Non-HS control 
antibody MPB01 does not 
stain any extracellular 
structure (c). The ribs 
(costa; C) in the upper left- 
hand (a and b) and lower 
right-hand corners (a-d) 
are visible because of high 
levels of autofluorescence. 
L, lung. Scale bar, 25 |im (a 
and b); 50 |im (c and d).
adjacent ribs together during forced expiration. The m. intercostalis 
externus is located at the external side and elevates adjacent ribs during 
inspiration. During late-embryogenesis, we observed an asynchronous 
development of these intercostal muscles. From cranial to caudal, the m. 
intercostalis externus showed a more pronounced differentiation, as 
compared to the m. intercostalis internus. Whereas the latter consisted of 
a relatively heterogeneous population of loosely dispersed small muscle 
fibers, the m. intercostalis externus showed a more organized homogeneous 
distribution of fibers with a larger diameter. Moreover, the m. intercosta-
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lis externus contained more nerve bundles and blood vessels in corridors 
of perimysial connective tissue. The observed differences got more 
pronounced during the course of embryogenesis.
Localization of HS epitopes
Information about the anti-HS antibodies and their corresponding 
epitopes is given in table 1. Localization of individual epitopes is depicted 
in figures 2-7 and is summarized in table 2.
Table 1. Complementarity determining region 3 
(CDR3) sequences and preferred HS sequences of the 
anti-HS antibodies used in this study.
Antibody CDR3 sequence preferred HS binding-sequence
AO4B05 LKQQGIS ND
AO4B08 SLRMNGWRAHQ GlcNS6S-IdoUA2S-GlcNS6Sa
RB4CB9 HAPLRNTRTNT b
RB4CD12 GMRPRL GlcNS6S-IdoUA2S-GlcNS6Sa
RB4EA12 RRYALDY GlcNS6S-IdoUA-GlcNS6S
MPB01 PKRTRN not reactive with HS
CDR3 sequences are shown in single-letter amino acid code. The preferred HS sequence was deduced 
as described in Dennissen et al., 2002. Antibodies RB4CB9 and RB4CD12 (previously selected against 
human skeletal muscle GAGs) are identical to HS4E4 and HS4D4 (selected against a kidney HS 
preparation), respectively.
a Antibodies AO4B08 and RB4CD12 recognize different HS epitopes, as deduced by their differential 
reactivity in ELISA assay and different staining patterns in muscle and kidney (Jenniskens et al., 
2000; Dennissen et al, 2002).
b Preferred sequence is not known, N-sulfation is indispensible, and 6-O sulfation is likely to be 
inhibitory.
ND: not determined.
Table 2. Immunostaining of the antibodies used in this 
study during myogenesis.
Antibody E12 -13 E14 E16 E18 E20 P2 adult
AO4B05 +/-, gr ++, c + + , c + + , c + + , c ++, c ++, c
AO4B08 +/-, gr ++, gr + + , c + + , c + + , c ++, c ++, c
RB4CB9 +/-, gr + + , gr ++, c ++, c ++, c + + , c ++, c
RB4CD12 +/-, gr +, gr + + , c + + , c + + , c ++, c ++, c
RB4EA12 - -a +/-a-b +b ++b ++b ++b
MPB01* - - - - - - -
Transversal sections of intercostal muscle at E12, E13, E14, E16, E18, E20, and P2, as well as adult m. 
soleus were stained for various HS epitopes and for AChR clusters. Immunostaining patterns of the 
antibodies presented in this study are summarized with regard to muscle BL reactivity. Staining intensity: 
++, strong; +, moderate; +/-, weak; -, absent (n = 5). 
gr: granular staining of the BL. 
c: continuous staining of the BL. 
a staining of small intracellular granules. 
b predominant staining of the synaptic BL.
* control antibody.
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Figure 2. Staining of 
developing skeletal muscle 
with antibody AO4B05. 
Transversal sections of 
intercostal muscle at E14 
(a), E16 (b), E18 (c), E20 
(d), and P2 (e) were 
stained for HS epitope 
AO4B05 (a1-e1) and AChRs 
(a2-e2). The AO4B05 HS- 
epitope is present in in 
newly formed BL, both in 
synaptic (arrows) and in 
extrasynaptic BL. Scale bar, 
25 im .
12 and 13 days in utero
At early developmental stages, intercostal muscle masses were scarcely 
detectable as such, when using immunohistochemical methods to stain 
for HS. Muscle primordia, at these stages, consist of fibroblasts and 
mononucleated myoblasts, the latter fusing to form primary myotubes. 
Upon myoblast fusion, patches of extracellular matrix material are 
formed on the myotube surface. Ongoing deposition of extracellular
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Figure 3. Staining of 
developing skeletal muscle 
with antibody AO4B08. 
Transversal sections of 
intercostal muscle at E14 
(a), E16 (b), E18 (c), E20 
(d), and P2 (e), stained for 
HS epitope AO4B08 (a1- 
e1) and AChRs (a2-e2). At 
E14, the AO4B08 HS- 
epitope is present in BL, in 
a granular distribution, in 
synaptic areas (a, arrows) 
as well as in extrasynaptic 
areas. From E16 onwards, 
the HS-epitope is 
homogenously distributed 
throughout the BL, 
irrespective of synapses (b­
e, arrows). Scale bar, 25 
|im.
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material results in the formation of a continuous BL in the following 
days. Except for RB4EA12, the antibodies used in this study showed a 
faint, granular staining of extracellular material in myogenic regions. 
Control antibody MPB01 showed no staining whatsoever in all 
developmental stages examined.
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Figure 4. Staining of 
developing skeletal muscle 
with antibody RB4CD12. 
Transversal sections of 
intercostal muscle at E14 
(a), E16 (b), E18 (c), E20
(d), and P2 (e), stained for 
HS epitope RB4CD12 (a1- 
e1) and AChRs (a2-e2). 
Although present in a 
granular distribution at E14 
(a), HS-epitope RB4CD12 is 
evenly distributed in 
muscle BL during 
development (b-e). 
Compared with synaptic 
(arrows) and extrasynaptic 
BL, a more intense staining 
was achieved for blood 
vessels and nerves present 
in perimysial connective 
tissue (arrowheads). Scale 
bar, 25 |im.
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14 days in utero
At 14 days in utero, the intercostal muscle appeared as a relatively loosely 
dispersed muscle mass. Nuclei were relatively large and located in the 
center of the myotubes. Blood vessels and nerve bundles were located 
in connective tissue surrounding myogenic areas.
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Figure 5. Staining of 
developing skeletal muscle 
with antibody RB4EA12. 
Transversal sections of 
intercostal muscle at E14 
(a), E16 (b), E18 (c), E20
(d), and P2 (e), stained for 
HS epitope RB4EA12 (a1- 
e1) and AChRs (a2-e2). At 
14 days in utero, HS- 
epitope RB4EA12 could be 
detected in small 
perinuclear granules, 
whereas it was not present 
in muscle BL at all (a). 
During myogenic 
differentiation, staining for 
this HS epitope was poor 
and granular in 
extrasynaptic BL, but 
abundant in the synaptic 
portion of the BL (b-e, 
arrows) and nerve BL. 
Scale bar, 25 |im.
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BL formation had progressed to a nearly continuous sheet, which 
could be stained with anti-HS antibodies AO4B05 (Fig. 2a), AO4B08 (Fig. 
3a), RB4CB9, and, to a lesser extent, RB4CD12 (Fig. 4a). The HS epitope 
recognized by AO4B05 was present throughout the newly formed BL. 
AO4B05 staining was slightly more intense at some sites of AChR 
aggregation. Antibodies AO4B08 and RB4CB9 showed a more granular 
staining of the BL. Antibody RB4EA12 (Fig. 5a) did not stain muscle BL,
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Figure 6. Staining of 
developing skeletal muscle 
with an antibody against 
vgNa+channels. Transversal 
sections of intercostal 
muscle at E14 (a), E16 (b), 
E18 (c), E20 (d), and P2 
(e), stained for 
vgNa+channel(a1-e1) and 
AChRs (a2-e2). 
VgNa+channels, which are 
located in the muscle 
plasma membrane, could 
be visualized as early as 
E14, the stage in which 
AChR clustering occurs (a, 
arrow). In all stages of 
muscle development, these 
ion channels were evenly 
distributed in the 
membrane, apart from a 
slight decrease in density in 
synapses (a-e, arrows). 
Scale bar, 25 |im.
e 2
but was present in small intracellular granules.
Consistent with reports in literature, AChR clustering was first visible 
at E14. The voltage-gated sodium channel (vgNa+channel), another post 
synaptic ion channel involved in excitation-contraction coupling (e-c 
coupling), showed a uniform distribution over the myotube membrane, 
with a decrease in density at AChR clusters (Fig. 6a).
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16 days in utero
The diameter of the myotubes had increased by E16. Also, muscle masses 
were more compact and clusters of myotubes were separated by septa 
of connective tissue containing nerve bundles and blood vessels. In 
general, nuclei were smaller and were located either centrally or 
eccentrically, forming a heterogeneous set of multi-nucleated myotubes. 
The m. intercostalis internus and m. intercostalis externus were 
distinguishable, which enabled us to focus on the latter from this 
developmental stage onwards.
Antibodies AO4B05 (Fig. 2b), AO4B08 (Fig. 3b), RB4CB9, and 
RB4CD12 (Fig. 4b) stained the entire muscle BL. AO4B08 and RB4CB9 
predominantly stained the muscle BL, whereas RB4CD12 epitopes were 
also present in blood vessels and in nerves located in the perimysium. 
RB4EA12 (Fig. 5b) continued to stain perinuclear granules but stained 
also, faintly, at sites of AChR clustering.
VgNa+channels (Fig. 6b) showed a modest, overall distribution over the 
myotube membrane at this stage.
18 days in utero
By 18 days in utero, myotube diameter had further increased. Myotubes 
had become more homogeneous, both in size and in shape, approaching 
the regular pattern of mature muscle. Myonuclei were predominantly 
located eccentrically, although central nuclei could be observed 
occasionally.
Antibodies AO4B05 (Fig. 2c), AO4B08 (Fig. 3c), RB4CB9, and 
RB4CD12 (Fig. 4c) stained the muscle BL in a way comparable to that 
seen in 16-day fetuses. RB4EA12 (Fig. 5c) failed to stain cytosolic granules 
as well as the extrasynaptic BL, but showed a distinct staining of the 
synaptic BL.
The vgNa+channel (Fig. 6c) continued to be evenly distributed over the 
sarcolemma.
20 days in utero/ birth
At birth, the m. intercostalis externus appeared more homogeneous and 
densely packed when compared to earlier developmental stages. This 
uniform maturation state is in line with the distribution of AO4B05 (Fig. 
2d), AO4B08 (Fig. 3d), RB4CB9, and RB4CD12 (Fig. 4d) epitopes that 
stained the entire muscle BL. RB4EA12 (Fig. 5d) stained the extrasynaptic 
BL only to a minor extent, whereas a strong signal was achieved for 
synaptic and nerve BL.
VgNa+channels (Fig. 6d) were homogeneously distributed over the 
myotube membrane.
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Figure 7. Comparison of 
the distribution of HS 
epitopes AO4B08 and 
RB4EA12 at synaptic sites. 
Confocal images of sections 
through neuromuscular 
junctions of adult m. soleus 
stained for AO4B08 (a1), 
RB4EA12 (b1), control 
antibody MPB01 (c1) and 
AChRs (a2, b2, and c2). 
Merged images are shown 
in color (a3, b3, and c3). 
HS-epitope AO4B08 is 
present throughout the 
endomysial BL, including 
synaptic regions (a1 and 
a3). In contrast, HS- 
epitope RB4EA12 is hardly 
present in the 
extrasynaptic BL, but 
enriched in synapses, 
where it colocalizes tightly 
with AChR clusters (b1 and 
b3). Control antibody 
MPB01 does not stain 
muscle BL at all (c1 and 
c3). Scale bar, 50 |im.
2 days postnatal
During early postnatal development, no major changes were observed 
in the distribution of HS epitopes: AO4B05 (Fig. 2e), AO4B08 (Fig. 3e), 
and RB4CB9 stained the entire BL. The RB4CD12 epitope (Fig. 4e) was 
evenly distributed over the muscle BL, but was more abundant in neural 
and capillary BL. RB4EA12 (Fig. 5e) was predominant in synaptic and 
neural BL. VgNa+channels (Fig. 6e) were homogeneously distributed over 
the cell membrane.
Adult
Following fetal development, staining patterns of the HS epitopes 
studied, did not undergo major changes with regard to BL location. 
Confocal imaging of the NMJs of m. soleus enabled us to visualize 
differences in the location of individual HS epitopes with regard to AChR 
clusters. Most antibodies stained the entire BL, and were located separate 
from AChR clusters, as exemplified by AO4B08 (Fig. 7a1-c1). RB4EA12 
(Fig. 7a2-c2), however, showed a tight colocalization with AChR clus­
ters.
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Discussion
Skeletal muscle tissue is derived from embryonic mesenchyme of the 
somites (Grinnel, 1995). During early mouse embryogenesis, organ 
primordia are established, followed by organogenesis from E10 until 
E14, and subsequent fetal growth and development (Hogan, 1994). In 
extensor digitorum longus muscle at embryonic day 12, motor nerves reach 
muscle primordia, which already contain some multinucleate primary 
myotubes surrounded by myoblasts. Primary myotubes are elongated 
by myoblast fusion during two days, after which myogenesis resumes 
with the generation of secondary myotubes. The second generation of 
myotubes is formed on the scaffold of primary myotubes between E14 
and E16. This biphasic character of myotube development is thought to 
be caused by the necessity of primary myotubes to first reach a certain 
stage of maturation, including sarcolemmal changes, before secondary 
myotube development can be supported (Ontell and Kozeka, 1984; Jan­
sen and Fladby, 1990). Extracellular material is deposited on the myotube 
surface, beginning on E14, to form a continuous BL by E19 (Chiu and 
Sanes, 1984).
One of the HS epitopes examined in this study (AO4B05) surrounds 
primary myotubes in a relatively continuous staining at the onset of BL 
formation, at E14. Other HS epitopes that are also present throughout 
the muscle BL (AO4B08, RB4CB9, and RB4CD12) show a less continuous, 
granular distribution. Thus, a specific HS epitope is present in a more or 
less continuous sheet surrounding primary myoblasts before BL 
completion, whereas other HS epitopes are deposited in the course of 
BL formation. Since BL formation during maturation of primary 
myotubes may be causal for the onset of generation of secondary 
myotubes, we suspect significant roles for individual HS epitopes in the 
formation and integrity of developmental stage-specific BL. Deposition 
and accumulation of certain HS epitopes, both qualitatively and 
quantitatively, may add to form a BL capable of directing developmental 
processes. Moreover, spatial differences in the density of specific HS 
epitope deposits may be causal for the induction of local adaptations, 
such as synaptic specializations.
AChR clustering at sites of neuromuscular contact first occurs 
approximately on day E14. At this time, the synaptic cleft already contains 
BL material (Nakajima et al, 1980), of which the HSPG agrin is involved 
in the clustering of AChR (Ruegg and Bixby, 1998). During fetal growth, 
a faint staining of AChRs in the extrasynaptic cell membrane is observed, 
as well as a stronger cytosolic staining of this protein in and around 
synaptic areas (see e.g. fig 2a2-e2). This elevated staining may be due to 
higher expression levels of AChR from synaptic nuclei. Newly formed 
AChRs are detected in the cytosol, most probably located within Golgi 
vesicles while being transported to the sarcolemma, and in the cell
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membrane before clustering at synaptic sites. Specializations of the 
synaptic regions take place during the days of myogenesis following 
E14. A few days postnatally, these alterations culminate in functional 
neuromuscular junctions containing a continuous sBL, a thickened 
postsynaptic membrane, and junctional folds. One of the prominent 
features of the developing NMJ, the accumulation of AChE, is detectable 
soon after AChR clustering; nearly all junctional areas are rich in AChE 
by E18 (Chiu and Sanes, 1984). This process is mediated by BL-resident 
dermatan sulfate proteoglycans and HSPGs (Brandan et al., 1985; von 
Bernhardi and Inestrosa, 1990), among which perlecan (Peng et al., 1999).
The most striking staining pattern was observed for HS epitope 
RB4EA12, which preferably clusters at synaptic sites by E16 and 
accumulates at these locations thru E20. AO4B05, AO4B08, and RB4CB9 
are present in the sBL as early as E14, during the onset of AChR clustering. 
Such regulated appearance of HS epitopes simultaneous with the 
aggregation of synapse-specific proteins is indicative for a possible 
involvement of these HS epitopes in the processes involved. The late 
appearance of RB4EA12 and its persisted synaptic location in adult tissue, 
occur parallel to the clustering and retention of AChE in sBL However, 
this HS epitope colocalizes tightly with AChR clusters that are located 
in the postsynaptic membrane. This may indicate that HS epitope 
RB4EA12 is possibly present in cell surface HSPGs like glypicans and 
syndecans, rather than in BL-resident HSPGs like agrin and perlecan. It 
should be noted however, that a single HS chain can be up to 100 nm in 
length and is therefore able to span the entire synaptic cleft regardless of 
the location of the protein core. Other HS epitopes show a distinct 
spatiotemporal distribution with regard to AChR clusters and 
vgNa+channels, but stain the entire BL surrounding the muscle fibers. 
At present, we have no information as to a possibly restricted occurrence 
of unique HS epitopes on specific proteoglycans. Defining the HS epitope- 
profiles of individual core proteins forms a major challenge for future 
studies.
Polypeptide growth factors, like epidermal growth factor, fibroblast 
growth factor-2, insulin-like growth factors and transforming growth 
factor-ß, play key roles in myogenesis (McCusker and Clemmons, 1994). 
Some of the growth factors are known to interact with HS or heparin. 
Fibroblast growth factors, for instance, regulate the growth and 
differentiation of embryonic primary myoblasts (Itoh et al., 1996; 
Flanagan-Steet et al., 2000) as well as secondary and adult myoblasts 
(Flanagan-Steet et al., 2000). Moreover, fibroblast growth factor-2 is 
involved in both presynaptic (Dai and Peng, 1995) and postsynaptic (Peng 
et al., 1991) differentiation. Therefore, we studied the spatiotemporal 
distribution of several growth factors (epidermal growth factor, fibroblast 
growth factor-2, insulin-like growth factor, and transforming growth 
factor-ß), with regard to the HS epitopes studied here. We were unable 
to detect correlations between the distribution of either of these growth
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factors with regard to the distribution patterns of the HS epitopes (data 
not shown). In future studies, it will be interesting to determine any 
potential interactions between HS-binding growth factors and the HS 
epitopes defined by the antibodies studied here. Such studies require a 
more biochemical approach and would significantly contribute to our 
understanding of the mechanisms underlaying growth factor mediated 
processes.
In recent years, it has become widely accepted that especially the 
sulfation pattern of HS domains regulates specific interactions with HS- 
binding proteins (Bernfield et al., 1999; Tumova et al., 2000). Binding of 
fibroblast growth factor-2 requires 2-O-sulfation of iduronic acid residues, 
whereas additional 6-O-sulfation of the glucosamine residue is required 
for the binding of fibroblast growth factor-1 (Kreuger et al., 2001). 
Previously, carbohydrates (e.g. N-acetylated galactosamine) were shown 
to be primarily located in the sBL, and differentially located within the 
synapse, on basis of lectin and antibody-binding profiles (Sanes and 
Cheney, 1982; Iglesias et al., 1992; Martin et al., 1999). By regulating the 
structure of HS and the spatiotemporal distribution of specific HS 
epitopes, the muscle and the innervating nerve may create a specific 
microenvironment, which attracts and sequesters HS binding proteins 
necessary for the correct development of the NMJ.
Synaptic development is lifelong process rather than an embryonic 
event. NMJs persist for a lifetime, but undergo structural and functional 
changes due to a dynamic equilibrium that permits remodeling in res­
ponse to alterations in activity (reviewed by Sanes and Lichtman, 1999). 
Following fetal development, HS is also shown to be subject to age-related 
changes (Feyzi et al., 1998).
In summary, considering the tight and dynamic regulation of HSPG 
expression during myogenesis, we looked in detail to the occurrence of 
specific HS epitopes. Our results indicate a highly regulated 
spatiotemporal expression of various HS epitopes during muscle 
development. The results presented in this study argue for roles of 
individual HS epitopes in developmental processes underlying 
myogenesis and synaptogenesis.
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The biosynthesis of heparan sulfate (HS), present on the cell 
surface and in the basal lamina surrounding cells, is a multi­
step process of which each step is mediated by a specific 
enzyme. The initial modification of the precursor polysaccharide, 
N-deacetylation followed by N-sulfation of selected N-acetyl- 
D-glucosam ine residues, is catalyzed by the enzyme 
glucosaminyl N-deacetylase/ N-sulfotransferase (NDST). This 
event is a key step that regulates the overall sulfate content of 
the polysaccharide. Here, we report on the effects of NDST 
deficiency on calcium kinetics in myotubes from NDST-1 and 
NDST-2-defective mice, indicating a novel role for HS in skeletal 
muscle physiology.
Immunostaining for specific HS epitopes shows major chan­
ges in HS composition in cultured myotubes and in skeletal 
muscle tissue derived from NDST-1-/- mice. No changes were 
observed for NDST-2-/- and heterozygous mice. Using high-speed 
UV confocal laser scanning microscopy, aberrant calcium kine­
tics were observed in NDST-1-/- myotubes, but not in NDST-2-/ 
- or heterozygous myotubes. Electrically-induced calcium spikes 
had significantly lower amplitudes, and a reduced removal rate 
of cytosolic calcium, indicating the importance of HS in muscle 
calcium kinetics.
Introduction
Heparan sulfate proteoglycans present on the cell surface and in the 
basal lamina (BL) surrounding cells are involved in various biological 
processes. The HS chains, which are covalently attached to a protein 
core, exert their biological functioning through the selective binding of 
proteins. These interactions depend on HS domains with specific patterns 
of sulfation (Kjellén and Lindahl, 1991; Salmivirta et al., 1996; Lindahl et 
al., 1998; Bernfield et al., 1999). The complex processes involved in the 
structural modification of the HS chain that lead to the generation of 
such domains are beginning to be unraveled. The proposed pathway of 
HS biosynthesis involves a cascade of enzymes, each responsible for a 
single modification step (recently reviewed in: Habuchi, 2000; Selleck, 
2000; Sugahara and Kitagawa, 2000; Gallagher, 2001).
After formation of a HS precursor polysaccharide, consisting of 
repeating D-glucuronic acid and N-acetyl-D-glucosamine residues, the 
bifunctional enzyme glucosaminyl N-deacetylase/ N-sulfotransferase 
(NDST) catalyzes the first modifications of the precursor polysaccharide, 
where the acetyl group of selected N-acetyl-D-glucosamine residues is 
replaced with a sulfate group. This reaction is a prerequisite for all other
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modifications such as C-5 epimerization, 2-O-sulfation, 3-O-sulfation, 
and 6-O-sulfation, which only occur in the vicinity of N-sulfate groups 
(Lindahl et al., 1998).
Four isoforms of NDST have been identified (Hashimoto et al., 1992; 
Eriksson et al., 1994; Orellana and Hirschberg, 1994; Aikawa and Esko,
1999). NDST-1 and NDST-2 are widely distributed (Humphries et al., 
1997; Humphries et al., 1998; Kusche-Gullberg et al., 1998; Aikawa et al.,
2001), while NDST-3 and NDST-4 have a more restricted expression. 
Disruption of the genes encoding NDST-1 (Fan et al., 2000; Ringvall et 
al., 2000) and NDST-2 (Forsberg et al., 1999; Humphries et al., 1999) gave 
insights in the roles of these enzymes in the biosynthesis and 
physiological roles of HS and heparin, a highly sulfated form of HS. 
NDST-1-deficient mice are capable of synthesizing N-sulfated HS, but 
the sulfate content is significantly lower than that of HS from wild type 
mice, indicating the importance of this enzyme in HS biosynthesis 
(Ringvall et al., 2000). So far, no obvious defects in HS have been found 
in NDST-2-deficient mice, which instead are unable to synthesize fully 
sulfated heparin (Humphries et al., 1999; Forsberg et al., 1999). However, 
the increased lethality of NDST-1 and NDST-2 double knock-out mice, 
compared to NDST-1-deficient mice, suggests that NDST-2 also plays a 
role in HS biosynthesis (Forsberg and Kjellén, 2001).
Different roles for HS or heparin in calcium kinetics have been 
suggested, such as the buffering of calcium (Bezprozvanny et al., 1993), 
influencing growth factor signaling (Patel et al., 1998), or regulating the 
activity of ion channels such as the dihydropyridine receptor (Knaus et 
al., 1990; Lacrinova et al., 1993; Martinez et al., 1996) and the ryanodine 
receptor (Bezprozvanny et al., 1993; Ritov et al., 1985). The availability of 
mice deficient in NDST-1 and NDST-2 provides a means to further 
investigate the role of HS in skeletal muscle calcium kinetics in a 
physiological setting.
In the present study, we report on the effects of the HS deficiency on 
electrically-induced calcium spikes. Immunostaining for specific HS 
epitopes is reduced in skeletal muscle and in cultured myotubes of NDST-
1-/-, but not in other genotypes. NDST-1-/- myotubes show a significant 
decrease in the amplitude of calcium spikes and a slower removal of 
cytosolic calcium. These results strongly indicate the involvement of HS 
in skeletal muscle calcium kinetics.
Materials and Methods
Materials
All chemicals used were from Merck (Darmstadt, Germany), unless 
stated otherwise. Bacterial media (2xTY and LB) and cell culture media
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were from Life Technologies (Paisley, Scotland) and tissue culture plas­
tics were from Greiner (Frickenhausen, Germany). Bovine serum albumin 
(fraction V) and NaN3 were obtained from Sigma (St. Louis, MO). Anti- 
c-M yc tag mouse monoclonal IgG (clone 9E10) was from Boehringer 
Mannheim (Mannheim, Germany) and anti-c-M yc  tag goat polyclonal 
IgG (A-14) was from Santa Cruz Biotechnology (Santa Cruz, CA). Alexa 
488-conjugated donkey anti-goat IgG and goat anti-mouse IgG, Alexa 
594-conjugated a-bungarotoxin, Indo-1/AM, and Pluronic F127 were 
purchased from Molecular Probes (Eugene, OR) and Mowiol (4-88) was 
from Calbiochem (La Jolla, CA). All experiments were performed at 
ambient temperature (21OC), unless stated otherwise.
Anti-heparan sulfate antibodies
Preparation of phage display-derived c-Myc-tagged anti-HS antibodies 
AO4B05, AO4B08, AO4F12, RB4CB9, RB4CD12, RB4EA12, and MPB01 
was performed as described (Jenniskens et al., 2000). Control antibody 
MPB01 was randomly picked from phage display 'scFv library #1' 
(Nissim et al., 1994). This antibody does not recognize HS, or heparin, 
and is not reactive with any of the cells or tissues tested (muscle, brain, 
kidney, lung) as judged by ELISA and immunohistochemistry.
Mouse skeletal muscle tissue
C57BL/6 Mice heterozygous for NDST-1 and NDST-2 were intercrossed 
to generate offspring of all genotypes as described (Forsberg et al., 1999; 
Ringvall et al., 2000). The first day of occurrence of a vaginal plug was 
taken as day 0 of gestation (E0). E18.5 (18.5 days in utero) embryos were 
isolated by caesarian delivery and killed by decapitation, in accordance 
with the ethic regulations of the University. Embryos were rinsed in PBS, 
snap-frozen in liquid nitrogen-cooled isopentane, and stored at -80OC.
Immunohistochemistry
5 to 10 |J.m thick cryosections of whole embryos were cut, mounted on 
slides, dried thoroughly, and stored at -80OC until use. Cell cultures 
were washed three times with PBS, dried overnight, and stored at -80OC 
until use. Cryosections and cell cultures were stained with anti-heparan 
sulfate antibodies and a-bungarotoxin as described (Jenniskens et al.,
2000). Photographs were taken, using a constant shutter time, on a Zeiss 
Axioskop immunofluorescence microscope (Göttingen, Germany). For 
each genotype, skeletal muscle specimens of individual embryos of two 
separate litters were studied.
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Primary myoblast culture
To obtain primary myoblast cultures, E18.5 embryos were isolated by 
caesarian delivery, killed by decapitation, and dissected (disposed of 
skin and other organs). Skeletal muscle tissue was isolated from the 
remaining carcasses, triturated with needles and incubated in an enzyme 
solution (300 U collagenase/ml, 0.15% trypsin, and 0.08% BSA in PBS, 
pH 7.3) at 37OC for 15 min. To the cell suspension, containing satellite 
cells (precursors of myoblasts), an equal volume of neutralization solution 
(DMEM/ 50% fetal bovine serum (FBS)) was added. The dissociation 
procedure was repeated three times. Subsequently, cell suspensions were 
sieved through a 40 |j.m cell strainer and cells were collected by 
centrifugation (10 min, 50xg). Cell pellets were resuspended and enriched 
for myoblasts by pre-plating twice for 30 min, after which cells were 
seeded at 5x104 cells per well in a 6 wells format. Primary myoblast cul­
tures were maintained as proliferating cells for up to 6 passages in DMEM 
supplemented with 10% brain extract and 1% Ultroser G (Portiér et al.
1999). Cells were plated at 2x10s (6 wells format) or 5x104 (24 wells format) 
cells per well and grown overnight in proliferation medium to reach 50­
60% confluency the next day. At confluency, culture medium was 
replaced by differentiation medium (DMEM/ 10% brain extract/ 0.4% 
Ultroser G). Differentiation medium was refreshed every second day. 
For immunocytochemistry, H2SO4-etched 13 mm diameter coverslips 
were used in 24 well-format. For measurements of cytosolic calcium, 
cells were plated on H2SO4-etched 24 mm diameter glass coverslips in 6 
well-format. Cultures were grown and differentiated at 37OC in a 
humidified 5% CO2/  95% air atmosphere. For each genotype, primary 
myoblast cultures derived from at least two individual embryos of two 
(NDST-2) or three (wild type and NDST-1) separate litters were studied.
Ratiometric measurements of intracellular calcium with Indo-1
Coverslips with confluent monolayers of primary myoblast cultures, 
differentiated for three days, were washed twice with physiological salt 
solution (PSS; 125 mM NaCl, 10 mM NaHCO3, 1 mM NaH2PO4, 5 mM 
KCl, 2 mM MgSO4, 1.8 mM CaCl2, 10 mM HEPES and 10 mM glucose, 
pH 7.4) and loaded with Indo-1 using an Indo-1/AM solution (5 |J.M 
Indo-1 /AM  and 1 |J.M Pluronic F127 in PSS) for 45 min. Cell loading was 
performed at 37OC in a humidified 5% CO2/  95% air atmosphere. Cells 
were washed twice with PSS, placed in a Leiden chamber (Ince et al., 
1985), and incubated in PSS for another 15 min. The Leiden chamber 
was placed on a Nikon diaphot inverted microscope attached to an OZ 
confocal laser scanning microscope (Noran instruments, Madison, WI). 
Electrical stimulation of myotubes was performed at 15 to 20 V with 10 
ms duration and 0.025 ms delay. Repetitive stimuli were generated at a 
frequency of 1 Hz. Stimulation was performed using a pair of parallel
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oriented platinum electrodes (5 mm interspaced, placed beside the 
monolayer), connected to a Grass SD9 electric pulse generator. Calcium 
free medium was obtained by the use of Ca2+-free PSS, supplemented 
with 1 mM EGTA. For ratiometric Ca2+ recordings, Indo-1 was excited at 
351 nm using a hardware-modified high power argon-ion laser (Cohe­
rent enterprise, Santa Clara, CA). After being separated by a 455 DCLP 
dichroic mirror, Indo-1 fluorescence intensity was collected at 405±45 
and 485±45 nm using photo multipliers. All measurements were 
performed at room temperature, using a Nikon x40 water-immersion 
objective, NA 1.2 with high UV transmission. The estimated laser 
intensity at the end of the objective lens was 28 |J.W. Confocality (optical 
section thickness: 1 to 2 |j.m) was achieved by using a slit width of 100 
|j.m (Koopman et al., 2001). User-based hardware set-up and data 
acquisition was controlled by Intervision software (Version 1.5, Noran 
Instruments), running under IRIX 6.2 on an Indy workstation (Silicon 
Graphics Inc., Mountain view, CA) equipped with 128 MB of RAM. To 
improve signal-to-noise ratio, single full-frame images (512x480 pixels) 
were collected at 30 Hz by averaging of 32 images for each Indo-1 
emission wavelength. Pairs of fluorescence intensities were saved in SGI- 
movie (mv) format, ready for off-line analysis using the Intervision 2D 
software package (Noran Instruments). Regions of interest (ROI) were 
drawn and numerical values were stored in ASCII-format. Additional 
data-analysis was carried out by using O rigin 6.0 (Microcal, 
Northampton, MA), supplemental image analysis and visualization were 
performed with Image Pro-plus 4.1 (Media Cybernetics, Silver Spring, 
MD).
Results
Occurrence of HS epitopes in situ in skeletal muscle
We have previously selected antibodies that recognize specific HS 
epitopes using phage display (van Kuppevelt et al., 1998; Jenniskens et 
al., 2000). Some of these antibodies were used in this study to investigate 
the occurrence of various HS epitopes (AO4B05, AO4B08, AOF412, 
RB4CB9, RB4CD12, and RB4EA12) in intercostal muscle of mouse (E18.5) 
embryos bearing a targeted disruption of the NDST-1 or the NDST-2 
loci (Forsberg et al., 1999; Ringvall et al., 2000). All epitopes studied were 
present in the BL surrounding muscle fibers and/ or nerves of wild type 
embryos (Fig. 1a, e) and in embryo's heterozygous for NDST-1 and 
NDST-2 (data not shown). Staining for HS epitopes in NDST-1-/- muscle 
BL was significantly reduced, except for the neuromuscular region (Fig. 
1c). In contrast, NDST-2-/- muscle BL stained normally (Fig. 1g). The dia-
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Figure 1. Reduction of HS epitopes in NDST-1-/- 
skeletal muscle. Immunofluorescence staining for HS- 
epitope AO4B05 (a, c, e, and g) and acetylcholine 
receptor clusters (b, d, f, and h) in intercostal muscle 
of E18.5 embryos of wild type (a, b, e, and f), NDST-1-/ 
- (c and d), and NDST-2-/- (g and h). Overall staining in 
NDST-1-/- is significantly reduced, as compared to wild 
type and NDST-2-/- staining, except for the BL in the 
NMJs and their direct vicinity (n = 5). Scale bar, 50 jim.
meter of myofibers was slightly less uniform in NDST-1-/- muscle 
compared to other genotypes, whereas the occurrence and size of 
neuromuscular junctions (NMJs) appeared normal.
Culturing of primary myoblasts
Primary myoblast cultures were generated from muscle tissue of E18.5 
embryos. At three days of differentiation, multi-nucleated myotubes were 
present in all cultures. From day three of differentiation onwards, 
spontaneous contractions were regularly observed in wild type and 
heterozygous myotubes, but only occasionally in knock out myotubes. 
In wild type and heterozygous cultures, spontaneous contracting 
myotubes caused monolayers to peel off from the culture plastics, an 
effect which was not observed in NDST-1-/- and NDST-2-/- cultures.
Occurrence of HS epitopes in vitro
To analyze the occurrence of HS epitopes in cultured myotubes, three 
day-differentiated cultures were stained immunologically. All antibodies 
stained the BL of wild type (Fig. 2a, e) and heterozygous (data not shown) 
myotubes. Normal BL staining was present in NDST-2-/- cultures (Fig. 
2g). However, NDST-1-/- cultures showed hardly any HS staining, even
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Figure 2. Reduction of HS epitopes in NDST-1-/- 
primary muscle cell culture. Immunofluorescence 
staining for HS-epitope AO4B05 (a, c, e, and g) and 
acetylcholine receptor clusters (b, d, f, and h) in wild 
type (a, b, e, and f), NDST-1-/- (c and d), and NDST-2-/- 
(g and h) primary muscle culture after three days of 
differentiation. HS staining is absent in NDST-1-/-- 
derived myotubes and mononuclear cells. In contrast, 
NDST-2-/- cultures are not affected. Myotubes in all 
cultures show spontaneous acetylcholine receptors 
clusters (arrows; n = 5). Scale bar, 50 jim.
at sites of spontaneous acetylcholine receptor clustering (Fig. 2c), 
indicating the inability of NDST-1 deficient myotubes to synthesize the 
HS epitopes recognized by the antibodies. The clustering of acetylcholine 
receptors appeared normal in all genotypes, as judged by a-bungarotoxin 
staining (Fig. 2, arrows).
Electrically induced calcium spikes in NDST-1/ -2 affected 
myotubes
Ratiometric measurements of the [Ca2+]. were performed in myotubes of 
all genotypes, using a high-speed UV confocal laser scanning microscope 
and electrical stimulation. Average amplitudes of electrically induced 
calcium spikes decreased gradually in the following order: wild type > 
NDST-2+/- > NDST-2-/- > NDST-1+/- > NDST-1-/-, but only NDST-1-/- 
differed significantly form the wild type (Table 1, Fig. 3). All calcium 
spikes were independent of the presence of calcium in the extracellular 
environment, indicating that the released calcium originated from 
intracellular stores. Upon electrical stimulation, [Ca2+]. reached its maxi­
mum within 99 ms (three data points), after which it rapidly declined to 
a basal level (Fig. 3), with mono-exponential kinetics (Yt= Y0+Ae-t/1 (Yt= 
ratio as a function of time (reflecting the [Ca2+].); Y0= ratio at t=0 (basal 
ratio, reflecting the basal cytosolic [Ca2+]); A= scaling factor; t= time;
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Table 1. Kinetics of electrically induced calcium spikes 
in NDST-1/ -2 affected myotubes.
Genotype n* Am plitude (ratio) Decay constant i  (s)
Wild type 12 1.882 ± 0.255 0.264 ± 0.098
NDST-2+/- 10 1.872 ± 0.335 0.302 ± 0.142
NDST-2-/- 12 1.755 ± 0.242 0.225 ± 0.096
NDST-1+/- 13 1.678 ± 0.092 0.319 ± 0.103
NDST-1-/- 8 1.594 ± 0.108 ** 0.426 ± 0.132 **
Ratiometric measurements of [Ca2+] were performed in myotubes of all 
genotypes, using a high-speed UV co nfocal laser scanning microscope. 
Amplitudes and decay constants of electrically-induced calcium spikes are 
given as average values of the number of myotubes analyzed ± SD.
* Analysis was performed on data obtained from myotubes from separate 
cultures that were derived from individual embryos.
** p<0.01
decay constant)) using the Levenberg-Marquard algorithm (Press et al., 
1992). This mono-exponential description was valid because of the small 
difference between the experimental trace and the fitted exponential 
function (R2 = 0.98) and the small SEM of the average |i (0.26±0.03). The 
mono-exponential kinetics suggest one main [Ca2+] removal process 
(Koopman et al., 2001; Lieste et al., 1998; de Groof et al., 2002), described 
by the decay constant |i, which is inversely proportional to the rate of 
[Ca2+] decline (Table 1). NDST-1-/- myotubes differed significantly from 
wild type myotubes in decay constant (|i; p<0.005). Together with the 
reduced Rmax this indicates that in these myotubes the quantity of 
released calcium and the [Ca2+] removal rate are affected (Table 1; Fig. 
3). By plotting |i as a function of Rmax, it was found that the calcium 
removal rate (i.e. 1/|i) was positively correlated to Rmax. Only in NDST- 
1-/- myotubes calcium spikes were occasionally skipped upon electrical 
stimulation, especially when stimulated at high frequency (>1 Hz).
Discussion
Mice deficient in NDST-1 or NDST-2 were used to study the effect of 
disturbances in HS biosynthesis on excitation-induced calcium spiking. 
Immunostaining of intercostal muscle showed a reduced staining for all 
HS epitopes studied in the BL of NDST-1-/- mice, except for 
neuromuscular regions. In NDST-2-/- and heterozygous mice staining 
was normal. The loss of HS epitopes in NDST-1-deficient muscle indicates 
a major role for NDST-1 in HS biosynthesis. As previously suggested, 
NDST-2 appears to be essential for the synthesis of heparin in mast cells
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Figure 3. Disturbed 
calcium kinetics in NDST-1- 
defective myotubes.
Primary myoblast cultures 
of wild type and NDST-1-/- 
embryos were 
differentiated for three 
days, and Indo-1 ratios of 
electrically induced calcium 
spikes were recorded using 
a high-speed UV confocal 
laser scanning microscope. 
Normalized Indo-1 ratios of 
individual wild type and 
NDST-1-/- primary 
myotubes were averaged 
and plotted against time, 
thus generating 
representative ratio traces 
for both genotypes. Each 
point represents the 
average value (wild type, 
n = 12; NDST-1-/-, n=8).
but may be only marginally involved in HS biosynthesis (Forsberg et al., 
1999; Ringvall et al., 2000). All four NDST-isoform transcripts are pre­
sent in skeletal muscle, NDST-1 and NDST-2 mRNA being more 
abundant than NDST-3 and NDST-4 transcripts (Aikawa et al., 2001). 
Thus, other NDST isoforms may have (partially) compensated for the 
loss of NDST-1, resulting in the low N-sulfation levels of HS detected in 
NDST-1-/- embryos (Ringvall et al., 2000). Although staining for HS 
epitopes was considerably reduced in skeletal muscle from NDST-1-/- 
mice, the neuromuscular region appeared unaffected. Other NDST 
isoforms may be active in this highly specialized area, thus compensating 
for the NDST-1 deficiency. No obvious effects on the presence of HS 
epitopes were seen in mice heterozygous for NDST-1, indicating a 
compensatory effect of the single functional allele present.
In primary myoblast cultures, similar effects were seen with regard 
to the presence of HS epitopes. Staining for HS epitopes in NDST-1-/- 
cultures was strongly reduced, whereas in NDST-2-/- cultures or in cul­
tures derived from heterozygous mice, staining was normal. The 
occurrence and size of acetylcholine receptor clusters appeared similar 
in all genotypes both in vivo  and in vitro, indicating that the loss of either 
enzyme does not interfere with the proper clustering of this receptor.
Calcium kinetics was affected to various degrees in myotubes of 
individual cultures. The rate of [Ca2+]. removal correlated with the 
amplitudes of calcium spikes, both of which were significantly decreased 
for NDST-1-/- myotubes. The lower amplitude in NDST-1-/- myotubes is 
indicative of a lowered calcium flux over the sarcoplasmic reticulum
Time (s)
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membrane. Heparin, a highly sulfated HS, binds with high affinity to 
the extracellular domain of the voltage-dependent L-type Ca2+ channel, 
the dihydropyridine receptor, of skeletal muscle cells (Knaus et al., 1990). 
Upon stimulation, this receptor induces a conformational change in the 
calcium release channel of the sarcoplasmic reticulum (the ryanodine 
receptor), resulting in a calcium flow from the sarcoplasmic reticulum 
to the cytosol. HS may be involved in the correct functioning of the 
dihydropyridine receptor and alterations in HS may reduce the calcium 
flow to the cytosol. Alternatively, the effect of HS may be indirect, e.g. 
by modulating growth factor signaling. The effect of decorin, a dermatan 
sulfate proteoglycan, on calcium kinetics is mediated through the EGF 
receptor (Patel et al., 1998). Also, there may be a lowered calcium 
concentration in the sarcoplasmic reticulum (and thus a lowered cal­
cium flux) as a result of the NDST-1-/- deficiency. Also, the [Ca2+] removal 
rate is affected in NDST-1-/- myotubes. Since this process is mainly 
effectuated by sarcoplasmic reticulum calcium ATPases, an effect of HS 
deficiency on the overall calcium-pumping rate of this ion pump may 
be envisioned. The occurrence of skeletal muscle differentiation 
characteristics such as fusion to multinucleated myotubes, spontaneous 
acetylcholine receptor clustering, and excitability indicate that myotubes 
of all genotypes were differentiated to a similar degree. Therefore, the 
effects observed are not likely the result of disturbed differentiation.
NDST-1-deficient cultures occasionally failed to generate calcium 
spikes upon electrical stimulation. Such aberrant calcium kinetics were 
not observed in any other genotype, arguing for these effects to be a 
result of the loss of this enzyme. NDST-1-/- mice die shortly after birth 
due to respiratory failure. This effect has been attributed to immature 
type II pneumocytes, resulting in shortage of lung surfactant (Fan et al., 
2000). However, the loss of muscle contraction, likely to be the result of 
disturbed calcium kinetics, may also contribute to the lack of pulmonary 
function.
In this study, we report the effects of the deficiency of NDST-1 or 
NDST-2 on electrically-induced calcium spiking in skeletal muscle. The 
results presented here strongly indicate the involvement of HS in skeletal 
muscle calcium kinetics.
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Little is known about the physiological functions of heparan 
sulfates (HS), present in the basal lamina surrounding skeletal 
muscle fibers. Here, we present a new system in which HS is 
phenotypically knocked out by endogenous expression of 
epitope-specific anti-HS antibodies. Single chain antibodies, 
containing an immunoglobulin leader peptide, were produced 
using various expression systems. Antibodies were detected in 
the Golgi apparatus, the site of HS biosynthesis. Likewise, the 
HS-degrading enzyme heparanase was expressed. Endogenous 
expression of antibodies or heparanase in myoblasts resulted 
in HS-defective myotubes. Excitability and calcium kinetics of 
HS-defective myotubes were severely compromised, as 
determined by analysis of electrically induced calcium spikes 
using video-speed UV confocal laser scanning microscopy. 
Phenotypically knocking out of individual HS epitopes resulted 
in specific effects on excitability and calcium kinetics. These 
data indicate important roles for HS in skeletal muscle calcium 
kinetics.
Introduction
Heparan sulfates (HS) are members of the glycosaminoglycan family, 
consisting of repeating disaccharide unit backbones onto which 
modification patterns are superimposed. The addition of sulfate groups 
leads to the generation of specific motifs that make HS a highly versatile, 
protein-binding, cell regulator (Spillmann and Lindahl, 1994; Bernfield 
et al., 1999; Turnbull et al., 2001; Gallagher, 2001).
The basal lamina (BL) and the cell membrane of skeletal muscle cells 
contain various heparan sulfate proteoglycans (HSPGs), which have been 
implicated in developmental and regulatory processes. Regulatory roles 
include the clustering of acetylcholine receptors (Wallace, 1990; Ferns et 
al., 1993; Campanelli et al., 1994; Hoch et al., 1994), the BL-localization of 
certain proteins (Brandan et al., 1985; Patton e t al., 1997), and the 
maintenance of BL integrity (Costell et al., 1999). Unc-52, the Caenorhabditis 
elegans orthologue of perlecan, has important roles in muscle integrity 
(Rogalski et al., 1993). The BL-HSPG perlecan is mutated in Schwartz- 
Jampel syndrome, a human myotonic disorder, implicating a function 
of HSPGs in muscle excitability in men (Nicole et al., 2000).
Due to their location in the muscle BL and on the cell membrane, 
HSPGs may fulfill regulatory functions in skeletal muscle excitation- 
contraction (e-c) coupling. This may be accomplished by binding of cal­
cium, by a direct interaction with ion channels, or by binding to growth 
factors and their receptors. Extracellular heparin, a highly sulfated form
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of HS, interacts with the dihydropyridine receptor (DHPR), an L-type 
calcium channel, and profoundly affects its kinetic properties (Knaus et 
al., 1990; Lacinova et al., 1993; Martinez et al., 1996). The ryanodine 
receptor (RyR) is activated by heparin in v itro  (Ritov e t al., 1985; 
Bezprozvanny et al., 1993), whereas the structurally similar inositol 
trisphosphate receptor is inhibited (Gosh et al., 1988; Kobayashi et al., 
1988). Decorin, a small leucine-rich (dermatan sulfate) proteoglycan, 
mediates increases in cytosolic calcium through the epidermal growth 
factor receptor (Patel et al., 1998). Intracellular application of heparin 
blocks e-c coupling in an activation-dependent manner in toad, but not 
in rat muscle fibers (Lamb et al., 1994).
Little is known about the precise functions of HS epitopes in muscle 
physiology. For molecules like HS, which are not genetically encoded, it 
has been difficult to generate dominant negative in vitro or in vivo re­
search systems (Lander and Selleck, 2000, Iozzo, 2001). Recently, we 
selected single chain variable fragment (scFv) antibodies directed against 
specific HS epitopes, and showed HS epitopes to be differentially 
distributed in muscle and nerve BL (van Kuppevelt et al., 1998; Jenniskens 
et al., 2000).
In this study, we have used the DNA encoding these antibodies to 
produce intracellular antibodies (intrabodies (Biocca and Cattaneo, 1995; 
Marasco, 1997)) to phenotypically knock out specific HS epitopes in 
myoblasts. A cDNA encoding the HS-degrading enzyme heparanase 
(Hulett et al., 1999; Vlodavsky et al., 1999) was used likewise, thus 
generating HS-defective myoblasts. Using video-speed UV confocal la­
ser scanning microscopy to measure electrically induced changes in 
cytosolic calcium concentration ([Ca2+]t), we show that excitability and 
calcium kinetics are severely impaired in HS-defective myotubes that 
differentiated from transfected myoblasts. To our knowledge, this is the 
first time a physiological role for HS epitopes in excitation-induced cal­
cium spiking is demonstrated.
Materials and Methods
Materials
Mice (C3H, male, 70 d) and rats (Wistar, 10 d) were obtained from the 
University of Nijmegen Central Animal Laboratory. C2C12 (CRL1772) 
skeletal muscle cell line was purchased from American Type Culture 
Collection (Rockville, MD). Glycosaminoglycan-deficient myoblast (S27) 
cell line was a generous gift of Dr. Z. Hall (Dept. of Physiology, University 
of California, San Francisco, CA). Anti-syndecan antibody (2E9; 
syndecan-1 and -3) was a kind gift of Dr. G. David (Center for Human
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Genetics, University of Leuven, Leuven, Belgium). Anti-perlecan anti­
body (EY-90) was a kind gift of Dr. D. Noonan (Dept. of Chemical 
Carcinogenesis, ICT, Genova, Italy).
All chemicals used were from Merck (Darmstadt, Germany), unless 
stated otherwise. Bacterial media (2xTY and LB), cell culture media, 
OptiMEM, LipofectAMIN/ PLUS reagents, and Geneticin G418 were 
from Life Technologies (Paisley, Scotland); tissue culture plastics from 
Greiner (Frickenhausen, Germany). Bovine serum albumin (fraction V), 
Cy3-labelled P5D4, and NaN3 were obtained from Sigma (St. Louis, Mo); 
Anti-c-Myc tag mouse monoclonal IgG (clone 9E10) from Boehringer 
Mannheim (Mannheim, Germany); anti-c-Myc tag goat polyclonal IgG 
(A-14) from Santa Cruz Biotechnology (Santa Cruz, CA); Alexa 488- 
conjugated donkey anti-goat IgG, donkey anti-sheep IgG, and goat anti­
mouse IgG, Alexa 594-conjugated goat anti-mouse IgG, Alexa 594- 
conjugated a-bungarotoxin, NBD C6-Ceramide (N-1154), Indo-1/AM, 
and Pluronic F127 from Molecular Probes (Eugene, OR); Mowiol (4-88) 
from Calbiochem (La Jolla, CA). Polymerase chain reaction (PCR) 
chemicals, Taq polymerase (DNA polymerase from Thermus aquaticus), 
and Pfu-Taq polymerase were obtained from Promega (Madison, WI); 
PCR primers and synthetic oligonucleotides from Biolegio (Malden, The 
Netherlands); Ecdysone-inducible eukaryotic expression system, high 
level eukaryotic expression vector pcDNA3.1, Zeocin, Muresterone A, 
and Ponasterone A from Invitrogen (Groningen, The Netherlands); 
bicistronic vector pIRES2-EGFP from Clontech (Palo Alto, Ca); 
Restriction enzymes and buffers from New England Biolabs (Beverly, 
MA); Unique site elimination kit from Amersham Pharmacia (Roosend­
aal, The Netherlands); ABI Prism Big Dye Terminator Cycle Sequencing 
Ready Reaction Kit from PE Applied Biosystems (Norwalk, CT).
All experiments were performed at ambient temperature (21OC), 
unless stated otherwise.
Generation of anti-HS antibody expression constructs
For the inducible expression of scFv antibody fragments, an Ecdysone- 
inducible eukaryotic expression system, consisting of vectors pVgRXR 
and pIND, was used (No et al., 1996; Fig. 1). To allow NcoI-NotI cloning 
of antibody-coding fragments, two NcoI restriction sites in the pIND 
vector (at nucleotides 1544 and 2279) were eliminated by site directed 
mutagenesis using the unique site elimination kit with oligonucleotides 
pINDmutNco-1544: 5'-CTCCGCCCCATGC*CTGACTAATTTT- 
TTTTATTTATGC-3' and pINDmutNco-2279: 5'-GAGGATCTC- 
GTCGTGACA*CATGGCGATGCCTGCTTGC-3', following the 
manufacturer's protocol, to generate pINDmutNcoI. An immunoglobulin 
leader sequence (Ig-lead) cassette, compiled of two complementary 
oligonucleotides Ig-lead-codogene (sense): 5'-AGCTTATGGG-
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ATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAG- 
GTGTCCACTCCATGGGATCCGAT-3' and Ig-lead-noncodogene 
(antisense): 5'-ATCGGATCCCATGGAGTGGACACCTGTAGCTG- 
TTGCTACCAAGAAGAGGATGATACAGCTCCATCCCATA-3', was 
inserted into the multiple cloning site of H in d III/ EcoRV-digested 
pINDmutNcoI to form pIND/Ig-lead. These oligonucleotides annealed 
to form an Ig-lead cassette bordered on the 5' end by a HindIII, and on 
the 3' end by an EcoRV  restriction site. In this cassette, the first three 
nucleotides following the HindIII restriction recognition site form the 
initiation codon (ATG) used for translation. As a marker for expressed 
proteins, a VSV tag was cloned in frame with the Ig-lead sequence. 
Complementary oligonucleotides VSV-codogene (sense): 5'-ATCGCG- 
GCCGCATATACAGACATAGAGATGAACCGACTTGGAAAGTGAGC- 
3' and VSV-noncodogene (antisense): 5'-TCGAGCTCACTTTCCA- 
AGTCGGTTCATCTCTATGTCTGTATATGCGGCCGCGAT-3' were 
annealed and inserted into pIND/Ig-lead as an EcoRV-XhoI cassette, 
generating pIND/Ig-lead/VSV. The VSV cassette contains an opal stop 
codon (TGA) directly following the VSV tag coding sequence, to 
terminate protein synthesis. Ig and VSV cassettes were constructed such 
that NcoI-NotI scFv cassettes could be cloned into pIND/Ig-lead/VSV 
in frame, with only a stretch of three alanine codons inserted between 
the scFv fragment and the VSV tag. ScFv coding regions were digested 
from original pHEN clones (Jenniskens et al., 2000) as N coI-N otI  
fragments, and inserted in between the Ig and VSV sequences, to generate 
pIND/Ig-lead/scFv/VSV clones. In this study, the following anti-HS 
scFv antibodies were used (Table 1): A04B05, A04B08, AO4F12, RB4CB9, 
RB4CD12, and RB4EA12. As a control, a scFv antibody (MPB01), which 
does not recognize HS, nor heparin, nor any cellular structure was used 
(see below). Next to construction in the pIND vector, Ig-lead/scFv/VSV 
cassettes were cloned into pcDNA3.1 and pIRES2-EGFP as NheI-XhoI 
fragments (containing the full-length expression cassette, including start 
and stop codons) to generate high expression and bicistronic expression 
systems, respectively.
Generation of human heparanase expression construct
Human heparanase cDNA (AF/44325) was amplified from the original 
clone (Vlodavski et al., 1999), using Pfu-Taq polymerase and primers Hep- 
s3 (sense): 5'-CCCAGGTGAGCCCACCATGGTGCTGCGCTCG- 
AAGCC-3' and Hep-a1 (antisense): 5'-AATATCTGCGGCCGCGAC- 
TAGTATATTTTATTTTCAGATGCA-3'. Via their non-complementary 
regions, these oligonucleotides introduced restriction sites at both sides 
of the heparanase-coding region: at the 5' end, an NcoI site was introduced 
and at the 3' end, a N o t l  site was generated. The PCR product was 
digested with NcoI and NotI, and ligated in similarly digested pIND/Ig-
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lead/VSV, generating pIND/Ig-lead/Hep/VSV. In the construct thus 
obtained, the heparanase-coding region directly followed the Ig sequence, 
and amino acid #2 of the enzyme was mutated from a leucine (CTG) to 
a valine (GTG). The two in frame stop codons (opal (TGA) and ochre 
(TAA)) directly following the coding region are conserved.
Cell culture, transfection, and induction
C2C12 cells were maintained as proliferating myoblasts in DMEM 
supplemented with 10% fetal bovine serum (FBS). CHO and COS-7 cells 
were cultured in M505 medium (50% DMEM, 50% Ham's F12 nutrient 
medium). Cells were plated at 2x10s (6 wells format) or 5x104 (24 wells 
format) cells per well and grown overnight in proliferation medium 
(DMEM/ 10% FBS), to reach 50-60% confluency the next day. For 
measurements of intracellular calcium, cells were plated on H2SO4-etched 
24 mm diam eter glass coverslips in 6 w ell-form at. For 
immunocytochemistry, 13 mm diameter coverslips were used in 24 well- 
format. For transfection, two solutions were prepared (volumes are given 
per well in 24 well format; for 6 well-format, all volumes are to be mul­
tiplied by 4): (solution 1) 110 |J.l OptiMEM, 1.5 |J.l PLUS reagent, and 600 
ng plasmid DNA (A260/  280 >1.8), and (solution 2) 110 |J.l OptiMEM and 2 
|j.l LipofectAMIN. After 15 min, solutions 1 and 2 were mixed, and 
incubated for another 15 min. Meanwhile, half-confluent cultures were 
washed three times with OptiMEM. 300 |j.l OptiMEM was left on the 
culture, and the transfection solution was added. After 4 h incubation, 
the transfection medium was substituted with DMEM/ 10% FBS, and 
cells were allowed to recover overnight. For the Ecdysone-inducible 
eukaryotic expression system, a mix of pIND/Ig-lead/scFv/VSV, pIND/ 
EGFP, and pVgRXR plasmids (in the ratio 6:2:2) was used. Induction 
was achieved the next day by applying Muresterone A or Ponasterone 
A, at a final concentration of 5 or 10 mM respectively, to the culture 
medium. PIRES2 and pcDNA 3.1 constructs were transfected separately. 
At confluency, one day post transfection, C2C12 culture medium was 
replaced by differentiation medium UBE (DMEM/ 10% brain extract/ 
0.4% Ultroser G (Portier et al., 1999)), supplemented with Muresterone 
A or Ponasterone A if necessary. Cultures were grown, transfected, and 
differentiated at 37OC in a humidified 5% CO2/  95% air atmosphere. 
Differentiation medium was refreshed every second day.
Following validation of the expression system in transiently 
transfected cells, stably transfected C2C12 cell lines were prepared using 
the pcDNA3.1-based expression system. Although antibody-encoding 
mRNA could be detected in stably transfected cells by RT-PCR, no 
antibodies could be detected neither with immunocytological nor with 
immunoblotting techniques. We therefore did not pursue this.
PHENOTYPIC HEPARAN SULFATE KNOCK OUT MYOTUBES |l 139
Ratiometric measurements of intracellular calcium with Indo-1
Coverslips with confluent monolayers of C2C12 myotubes, differentiated 
for three days, were washed twice with physiological salt solution (PSS; 
125 mM NaCl, 10 mM NaHCO3, 1 mM NaH2PO4, 5 mM KCl, 2 mM 
MgSO4, 1.8 mM CaCl2, 10 mM HEPES and 10 m M glucose, pH 7.4) and 
loaded with Indo-1 using an Indo-1/AM solution (5 |J.M Indo-1/AM 
and 1 |J.M Pluronic F127 in PSS) for 45 min. Cell loading was performed 
at 37OC in a humidified 5% CO2/  95% air atmosphere. Cells were washed 
twice with PSS, placed in a Leiden chamber (Ince e t al., 1985), and 
incubated in PSS for another 15 min. The Leiden chamber was placed on 
a Nikon diaphot inverted microscope attached to an OZ confocal laser 
scanning microscope (Noran instruments, Madison, WI). Electrical 
stimulation of myotubes was performed at 15 to 20 V with 10 ms duration 
and 0.025 ms delay. Repetitive stimuli were generated at a frequency of 
1 Hz. Stimulation was performed using a pair of parallel oriented 
platinum electrodes (5 mm interspaced, placed beside the monolayer), 
connected to a Grass SD9 electric pulse generator. Calcium free medium 
was obtained by the use of Ca2+-free PSS, supplemented with 1 mM 
EGTA. Identification of EGFP-positive cells was performed by collecting 
fluorescence above 500 nm (500 LP filter), after excitation at 488 nm with 
an argon-ion laser (Omnichrome, Chino, CA). For ratiometric Ca2+ 
recordings, Indo-1 was excited at 351 nm using a hardware-modified 
high power argon-ion laser (Coherent enterprise, Santa Clara, CA). After 
being separated by a 455 DCLP dichroic mirror, Indo-1 fluorescence 
intensity was collected at 405±45 and 485±45 nm using photo multipliers. 
All measurements were performed at room temperature, using a Nikon 
x40, water-immersion objective, NA 1.2 with high UV transmission. The 
estimated laser intensity at the end of the objective lens was 28 |J.W. 
Confocality (optical section thickness: 1 to 2 |j.m) was achieved by using 
a slit width of 100 |j.m (Koopman et al., 2001). User-based hardware set­
up and data acquisition was controlled by Intervision software (Version 
1.5, Noran Instruments), running under IRIX 6.2 on an Indy workstation 
(Silicon Graphics Inc., Mountain view, CA) equipped with 128 Mb of 
RAM. To improve signal-to-noise ratio, single full-frame images (512x480 
pixels) were collected at 30 Hz by averaging of 32 images for each Indo-
1 emission wavelength. Pairs of fluorescence intensities were saved in 
SGI-movie (mv) format, ready for off-line analysis using the Intervision 
2D software package (Noran Instruments). Regions of interest (ROI) were 
drawn and numerical values were stored in ASCII-format. Additional 
data-analysis was carried out by using O rigin 6.0 (Microcal, 
Northampton, MA), supplemental image analysis and visualization were 
performed with Image Pro-plus 4.1 (Media Cybernetics, Silver Spring, 
MD). To ensure the correct functioning of the stimulatory electric field, 
only measurements containing at least one excitable myotube were 
analyzed.
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Anti-heparan sulfate antibodies
Preparation of c-M yc-tagged anti-HS antibodies (periplasmic fractions) 
A04B05, A04B08, AO4F12, RB4CB9, RB4CD12, RB4EA12, and control 
antibody MPB01 was performed as described previously (Jenniskens et 
al., 2000). Antibody MPB01 was randomly picked from scFv library #1 
(Nissim et al., 1994). This antibody does not recognize HS, nor heparin, 
and is not reactive with any of the cells or tissues tested (muscle, brain, 
kidney, lung) by ELISA and IFA techniques. This control antibody was 
used in all three expression systems.
Immunohistochemistry
Cell cultures were washed three times with PBS, dried overnight, and 
stored at -80OC until use. Cell cultures were rehydrated in PBS for 10 
min. After 20 min blocking in PBS containing 0.1% (w/v) BSA, fixed 
cultures were incubated with c-M yc-tagged anti-HS antibodies overnight. 
Bound c-Myc-tagged and endogenously produced VSV-tagged anti-HS 
antibodies were visualized using anti-c-M yc  goat polyclonal A-14 and 
anti-VSV monoclonal P5D4 antibodies for 90 min, followed by Alexa 
594-conjugated donkey anti-goat IgG and Alexa 488-conjugated goat anti­
mouse IgG (60 min each). Perlecan and syndecan were visualized 
together with VSV-tagged intrabodies in a similar way, using Cy3- 
labelled P5D4 for VSV staining, antibody EY-90 for perlecan, and 
syndecan-1 and -3 antibody 2E9. Following each incubation, cultures
Table 1. Complementarity determining region 3 
(CDR3) sequences and preferred HS sequences of the 
anti-HS antibodies that were cloned in eukaryotic 
expression constructs.
Antibody CDR3 sequence Preferred HS sequence
AO4B05 LKQQGIS NDa
AO4B08 SLRMNGWRAHQ GlcNS6S-IdoUA2S-GlcNS6S
AO4F12 AMTQKKPRKLSL NDa
RB4CB9 HAPLRNTRTNT b
RB4CD12 GMRPRL GlcNS6S-IdoUA2S-GlcNS6Sc
RB4EA12 RRYALDY GlcNS6S-IdoUA-GlcNS6S
MPB01 PKRTRN not reactive with HS
CDR3 sequences are shown in single-letter amino acid code. The preferred HS sequence was deduced 
as described in Dennissen et al., 2002. Antibodies RB4CB9 and RB4CD12 (previously selected against 
human skeletal muscle GAGs) are identical to HS4E4 and HS3A8 (selected against a kidney HS 
preparation), respectively.
a Antibodies AO4B05 and AO4F12 recognize different HS epitopes, as deduced by their differential 
reactivity in ELISA assay and different staining patterns in Torpedo marmarota electric organ 
(Jenniskens et al., 2000)
b Preferred sequence is not known, N-sulfation is indispensable, 6-O-sulfation is likely to be inhibitory 
c Antibodies aO4B08 and RB4CD12 recognize different HS epitopes, as deduced by their differential 
reactivity in ELISA assay and different staining patterns in muscle and kidney (Jenniskens et a l., 
2000; Dennissen et al., 2002)
ND: not determined.
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Figure 1. Construction of 
the vectors for antibody 
expression. Initially, the 
pIND expression vector was 
adapted by elimination of 
two NcoI sites of the 
original pIND vector (at 
nucleotides 1544 and 
2279). Next, an 
immunoglobulin leader 
cassette (Ig-lead (single­
letter amino acid code);
MGWSCIILFLVATATGVHS, 
bold) and a VSV cassette 
(VSV tag (single-letter 
amino acid code);
YTDIEMNRLGK, bold) were 
inserted in the multiple cloning site as HindIII-EcoRV 
and EcoRV-XhoI fragments respectively (DNA sequence 
is depicted in lower case), generating pIND/Ig-lead/ 
VSV. Ig-lead and VSV cassettes were constructed such 
that scFv cassettes, NcoI-NotI digested from original 
pHEN clones (Jenniskens et al., 2000), can be inserted 
in frame into pIND/Ig-lead/VSV (NcoI and NotI 
recognition sequences are in bold and underlined). The 
first codon following the HindIII recognition site 
(following an in frame opal codon (tga) at nucleotides 
432-434) is the translation initiation codon (atg; bold, 
italics) and the opal codon (tga; bold, italics) 
downstream of the VSV-tag sequence functions as stop 
codon. The Ig-lead/scFv/VSV expression cassettes 
were cloned into pIRES2/EGFP and pcDNA3.1 vectors 
as NheI-XhoI fragments.
were washed three times 10 min with PBS. Finally, cultures were fixed 
in 100% methanol, dried, and embedded in Mowiol (10% (w/v) in 0.1 M 
Tris-HCl, pH 8.5/ 25% (v/v) glycerol/ 2.5% (w/v) NaN3). As a control, 
primary, secondary or conjugated antibodies were omitted. All 
incubations were performed at ambient temperature (21OC). Photographs 
were taken, using a constant shutter time, on a Zeiss Axioskop 
immunofluorescence microscope (Göttingen, Germany). Confocal ima­
ges were made on a Nikon Diaphot inverted microscope attached to a 
BioRad MRC1024 ES confocal laserscanning microscope (Hemel 
Hempstead, UK). Digital images were processed using Confocal 
Assistant 4.02 and Adobe Photoshop 6.0 software.
430 440  450  460  470  480
GAAGAGAACT CTGAATACTT TCAACAAGTT ACCGAGAAAG AAGAACTCAC ACACAGÇTAG 
Ecdysone priming site t Nhel
4 90  500  510  520  530  540
M G W S C I  I L F  L V A T  A
CGTTTAAACT TA a g c t t a t g  ggatggagct gtatcatcct cttcttggta gcaacagcta 
Î HindIII Ig leader
550 560  570  58 0  590  600
T G V H S M G  S D I A A A Y T D I  E  M N
caggtgtcca c t c c a t g g g a  tccqatatcg c g g c c g c a t a  tacagacata gagatgaacc 
T NcoI T BamHI t  EcoR\/tNot[ VSV tag
610  620 630  640 650 660
R L G K Opal
gacttggaaa gfcgagcTCGA GTCTAGAGGG CCCGTTTAAA CCCGCTGATC AGCCTCGACT 
ÎXhol BGH
670  680 690  700
GTGCCTTCTA GTTGCCAGCC ATCTGTTGTT TGCCCCTCCC 
priming site
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Results
Anti-HS intrabody and heparanase expression systems
Phage display-derived antibodies have the advantage of the direct 
availability of the genetic material coding for the antibody in a single 
chain variable fragment (scFv) conformation. In this study we used 
several anti-HS antibodies from scFv library #1, selected against skeletal 
muscle-HS (Table 1; Jenniskens et al., 2000). From the original pHEN 
plasmid, the scFv antibody-coding region was excised, provided with 
an immunoglobulin leader sequence (Ig-lead), and cloned into three dif­
ferent eukaryotic expression vectors. Plasmid pcDNA3.1 was used for 
high-level expression, pIRES2-EGFP was used for bicistronic expression 
together with cytosolic enhanced green fluorescent protein (EGFP), and 
pIND was used for Ecdysone-inducible expression (see Methods, Fig. 1, 
and Table 1). All three expression systems were used in this study, and 
the results obtained were similar.
The immunoglobulin leader peptide was used to guide the anti-HS 
antibodies to the secretory pathway through the lumen of the Golgi 
apparatus. This approach was based on the assumption that antibodies 
may bind their HS epitopes while these are being synthesized in the 
lumen of this organelle. For all three expression systems, antibodies were 
found in cytosolic granules as demonstrated in CHO, COS-7, and C2C12 
(myoblast) cells. In these cells a polarized, peri-nuclear expression was 
observed, which colocalized with NBD C6-ceramide staining, a selective 
dye for the Golgi network (Fig. 2).
Figure 2. Golgi location of 
anti-HS antibodies. COS-7 
cells were transfected with 
the ecdyson-inducible 
expression vector encoding 
anti-HS antibody AO4BÜ5. 
Antibodies could be 
detected by immunologic 
detection of their VSV-tag
(a) and were shown to 
colocalize with the Golgi 
network as visualized by 
NBD C6-ceramide staining
(b). Sim ilar results were
obtained for all antibodies. Arrows point at cell margin; 
N, nucleus. Scale bar, 10 jam.
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Figure 3. Proliferation and 
differentiation of C2C12 
myoblasts expressing 
control antibody MPB01 
and cytosolic EGFP. C2C12 
myoblasts were transfected 
with ecdyson-inducible 
expression vectors, 
encoding control antibody 
MPB01 and cytosolic EGFP, 
at 50-60% confluency.
Transfected myoblasts 
display EGFP expression 
(arrows) as early as two 
hours post transfection (a).
At confluency, myoblasts 
align and stretch (b). After 
two days of differentiation, 
myoblasts have fused to 
form myotubes (c, arrows).
After five days of differentiation, myotubes dominate 
the culture (d, arrows), oriented in the parallel pattern 
typical for highly differentiated cultures. Expression of 
control antibody MPB01 and concomitant cytosolic 
expression of EGFP have no adverse effects on in vitro 
myogenesis. Scale bar, 100 am.
Transfection efficiency in C2C12 myoblasts was 15-20%. Transfected 
myoblasts fused with neighboring wild type myoblasts to form 
morphologically normal myotubes (studied for all anti-HS antibodies; 
Fig. 3). Transfected myotubes showed EGFP distributed throughout the 
cytosol, whereas endogenously expressed VSV-tagged anti-HS 
antibodies were contained in Golgi vesicles, similar as in myoblasts. Both 
transfected and non-transfected myotubes contained 5 to 10 nuclei and 
displayed clusters of acetylcholine receptors (as visualized by a- 
bungarotoxin staining, data not shown). Also, in both transfected and in 
non-transfected myotubes, electrical excitability was first observed at 
day three of differentiation. These data indicate that differentiation of 
transfected (hybrid) myotubes resembles that of wild type myotubes.
Expression of anti-HS intrabodies or heparanase results in 
phenotypic HS-knock out myotubes
Endogenous expression of each anti-HS antibody blocks the specific 
epitope recognized by this antibody. This could be demonstrated by 
visualizing the endogenously expressed, VSV-tagged anti-HS 
intrabodies, which were located within Golgi vesicles, in transiently 
transfected C2C12 myoblasts (Fig. 4a1-a6). Simultaneously, using a c-M yc-
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Figure 4. Expression of 
anti-HS intrabodies blocks 
the expression of the 
involved HS epitope at the 
cell surface. C2C12 
myoblasts were transfected 
with ecdysone-inducible 
expression vectors 
encoding VSV-tagged anti- 
HS antibody A04B05 (a1-
3) or AO4F12 (a4-6). 
Antibodies were detected in 
cytosolic granules, most 
likely complexed with the 
HS epitope to which they 
bind. Counter-staining for 
BL-HS using c-Myc-tagged 
A04B05 (b1-3) and 
AO4F12 (b4-6) reveals the 
presence of these HS 
epitopes at the surface of 
non-transfected cells, but 
not at the surface of 
transfected cells. The 
merge of images a and b 
(c1-6) shows in green the 
VSV-tagged intrabodies and 
in red the extracellular HS 
epitopes. Similar results 
were obtained for all 
antibodies. Scale bar, 25 
am.
tagged antibody against the same HS epitope, this epitope could not be 
detected in the extracellular matrix surrounding these cells (Fig. 4b1- 
b6). Using antibody-expressing C2C12 myoblasts, it was shown that 
phenotypic knocking out of one HS epitope does not necessarily impede 
the functional synthesis of another epitope, thus providing evidence for 
the presence of unique epitopes on separate HS molecules (Fig. 5a-d). 
This effect was studied and observed for HS epitopes A04B05, AO4F12, 
and RB4CD12.
In the direct vicinity of transfected myotubes, the staining intensity 
of extracellular HS with c-Myc-tagged antibodies against the same HS 
epitope was less intense. Also, anti-VSV staining for intrabodies often
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Figure 5. Phenotypically 
knocking out one HS 
epitope does not impede 
the cell surface expression 
of another epitope. C2C12 
myoblasts were transfected 
with ecdyson-inducible 
expression vectors 
encoding anti-HS antibody 
A04B05 and cytosolic EGFP 
(a-d). Transfected cultures 
were FACS sorted to obtain 
homogeneous populations 
of A04B05-expressing and 
of control myoblasts, using 
EGFP expression as a 
selection marker for 
transfected cells. Control 
myoblasts (a and c) 
differentiated into
myotubes with BL staining for HS epitopes A04B05 (a) 
and A04F12 (c). In contrast, homogenous cultures of 
myotubes endogenously expressing antibody A04B05 
(b and d) showed no BL staining for the A04B05 
epitope, the antibody-HS complex being localized in the 
peri-nuclear Golgi-region (b). In contrast, HS epitope 
A04F12 could readily be detected in the BL (d). Similar 
results were obtained for any combination of antibodies 
A04B05, A04F12, and RB4CD12. Scale bar, 50 am.
resulted in labeling of BL-resident HS epitopes of surrounding myotubes, 
indicating that a part of these antibodies are secreted and are reactive 
with HS epitopes in the extracellular environment (see e.g. Fig. 4c3). The 
occurrence of HSPG core proteins on the surface and in the BL of 
transfected myotubes was examined for syndecan and perlecan, 
respectively (fig. 6). Elimination of HS epitopes A04B05, AO4F12, or 
RB4CD12 had no effect on the occurrence and distribution of the core 
proteins.
Similar to the expression of anti-HS antibodies, human heparanase 
could be functionally expressed in C2C12 cultures. By ELISA assay, a 
modest heparanase activity was detected in the culture supernatant of 
transfected cultures, indicating the secretion of functional heparanase 
by myoblasts. Moreover, heparanase expressing myoblasts stained poorly 
for any of the HS epitopes used in this study (results not shown). Hybrid 
myotubes were formed, with morphological characteristics similar to 
wild type and anti-HS antibody-transfected myotubes.
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Table 2. The effect of endogenous expression of anti- 
HS intrabodies and heparanase on the excitability of 3 
day-differentiated C2C12 myotubes.
Culture n Excitability (%)
C2Ci2 Mocka 14 36
C2C12 MPB01b 21 29
C2Ci2 AO4B05 14 21
C2C12 AO4B08 19 11
C2C12 AO4F12 13 8
C2C12 RB4CB9 15 0*
C2C12 RB4CD12 20 5*
C2C12 RB4EA12 23 17
C2C12 H.Hep 50 6*
Cytosolic calcium spikes of individual EGFP-positive C2C12 myotubes were monitored upon electric 
stimulation. The percentage of myotubes that respond ed to stimuli by generating calcium spikes (i.e. 
excitable) was determined. n represents the number of myotubes analyzed. 
a Transfected with either pIRES2-EGFP, or with pVgRXR, pIND/EGFP, and pIND/Ig-lead/VSV (both 
lacking anti-HS antibodies or heparanase)
b Transfected with either pIRES2/MPB01-EGFP, or with pVgRXR, pIND/EGFP, and pIND/Ig-lead/MPB01/ 
VSV
* P value < 0.05 (against C2Ci2 MPB01).
Excitation-induced calcium spiking is disrupted in HS-knock out 
myotubes
To examine the effect of the changes in cellular HS composition on cal­
cium kinetics, ratiometric measurements of [Ca2+] were performed in 
EGFP-positive myotubes of transiently transfected cultures after 3 days 
of differentiation. In these myotubes, the expression of EGFP is linked 
directly to antibody expression levels. We did not observe differences in 
calcium kinetics in myotubes with high EGFP expression levels 
(determined optically), as compared to myotubes with low or moderate 
EGFP expression. Indo-1 ratio signals were recorded within a region of 
interest (ROI) of individual myotubes using a high-speed UV confocal 
laser scanning microscope.
After 3 days of differentiation, 36% of the mock-transfected EGFP- 
positive myotubes responded to electrical stimuli by generating calcium 
spikes (Table 2). Upon co-expression of control antibody MPB01, the 
percentage excitable EGFP-positive myotubes was 29%. The kinetics of 
the calcium spikes of both control myotubes (Fig. 7a, trace 1) were 
identical to wild type calcium spikes, and no spontaneous calcium spikes 
were recorded. [Ca2+] reached its maximum within 99 ms (three data 
points), after which it rapidly declined to basal level.
Expression of anti-HS antibodies or heparanase resulted in a marked 
decrease in the excitability of myotubes (Table 2). Moreover, all excitable 
EGFP-positive myotubes responded aberrantly to excitatory stimuli, in 
contrast to mock and MPB01-transfected myotubes, which in all 
recordings showed wild type responses. Anomalies included: (1) fre­
quent skipping of calcium spikes upon electrical stimulation, (2) 
considerably slow decay resulting in an elevated plateau at high
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Figure 6. Expression 
and distribution of the 
core proteins of HSPGs 
syndecan and perlecan 
is not affected in HS- 
knock out myotubes.
Wild type C2C12 
myoblasts (a) were 
transfected with a 
bicistronic expression 
vector encoding anti-HS 
antibody AO4F12 (b-d) 
and cytosolic EGFP. 
Subsequently, cultures 
were stained for 
syndecan (a1, c1) or 
perlecan (a2, c2). 
Transfected myotubes 
were identified by 
staining for the VSV-tag, 
present in the anti-HS 
antibodies (b).
Expression of anti-HS 
antibodies does not 
affect the expression 
and distribution of either 
HSPG core protein (c). 
The merge (d) of images 
b and c shows in red the 
VSV-tagged intrabodies 
and in green the 
extracellular core 
proteins. Similar results 
were obtained for 
antibodies AO4B05 and 
RB4CD12. Scale bar, 50 
|im (a); 20 |im (b-d).
m m j j f l i
b1
V . . V ' «  V
i "
• •
4
b2
,  '  • ,  V
■ # ? * *  ■
.  •  >  - g ,  <7 ~ 7 - 
/ ^  % t  *■*' . 1 i
d 1  w
" i  'ü 
f" .s * , • F % . % •  '  •
d2
Ä r
^  : r { -  ' '  -  *  ■
‘ ' i ' ;
frequency stimulation, (3) differences in amplitudes, (4) spontaneous 
generation of calcium spikes, (5) continuous firing, and (6) fluctuations 
in basal [Ca2+] (Fig. 7b). Skipping of calcium spikes was observed most 
often in myotubes expressing heparanase and anti-HS antibodies AO4B05 
and RB4EA12. Differences in amplitudes of calcium spikes were more 
frequently observed in AO4B08 and RB4EA12 expressing myotubes. 
Spontaneous generation of calcium spikes, in irregular or regular 
patterns, occurred most often in myotubes expressing AO4B05 and 
heparanase. Periodical fluctuations in the basal [Ca2+] occurred especially 
upon expression of heparanase and anti-HS antibodies AO4B08 and 
RB4CD12. All calcium spikes were independent of the presence of cal­
cium in the extracellular environment, indicating that the released cal­
cium originated from intracellular stores (data not shown).
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Figure 7. Ratiometric measurements of cytosolic 
calcium in transfected C2C12 myotubes. C2C12 myoblasts 
were transfected with a bicistronic expression vector, 
encoding control antibody MPB01 and cytosolic EGFP
(a), or with an expression vector encoding an anti-HS 
antibody or heparanase combined with cytosolic EGFP
(b). Upon confluency, C2C12 myotubes were 
differentiated for 3 days. Regions of interest (ROIs) 
were drawn on EGFP images (488 nm) of the myotubes 
(exemplified by the ROIs in a and b). Changes in 
intracellular calcium were measured in ROIs, corrected 
for background, and plotted against time as ratio 
values (405 nm/ 485 nm); bars below ratio traces 
indicate time points of electrical stimulation. Excitable 
myotubes transfected with control-antibody MPB01 
show wild type calcium spikes upon stimulation (a; 
trace 1). Myotubes transfected with anti-HS antibodies 
or with heparanase gave on no occasion wild type 
calcium spikes, but displayed six types of anomalies (b; 
traces 1-6): (1) frequent skipping of calcium spikes 
upon electrical stimulation, (2) considerably slow decay 
resulting in an elevated plateau at high frequency 
stimulation, (3) differences in amplitudes, (4) 
spontaneous generation of calcium spikes, (5) 
continuous firing, and (6) fluctuations in basal [Ca2+]. 
The table in the right panel depicts the occurrence of 
the anomalies for each expressed protein. Individual 
405 nm and 485 nm signals are depicted for the 
underlined part of each trace. The physiological 
relevance of the ratio traces is demonstrated by the 
rise of the 405 nm signal (calcium-bound Indo-1), 
simultaneous with the decline of the 485 nm signal 
(calcium-unbound Indo-1). Similar results were 
obtained using either the ecdysone-inducible or the 
bicistronic expression system.
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Excitation-induced calcium spiking is disrupted in mutant GAG- 
deficient myotubes
To verify the relationship between HS depletion and its effects on 
excitation-induced calcium spiking, we measured the calcium kinetics 
of myotubes of the C2C12-derived myoblast cell line S27 (Gordon and Hall, 
1989; Bowen et al., 1996). S27 myoblasts differentiate normally, but are 
defective in GAG biosynthesis (shorter, undersulfated GAG chains are 
formed). The expression of HSPG core proteins (as judged on basis of 
the perlecan core protein) is normal. Staining for HS epitopes, applying 
the same antibodies as used in this study, is negative (Jenniskens et al.,
2000). Only few (approximately 2%) S27 myotubes were excitable, and 
those that could be triggered generated modest calcium spikes (Fig. 8). 
Excitable S27 myotubes had a very low signal to noise ratio, in contrast to 
wild type myotubes that displayed sharp calcium spikes.
Figure 8. Ratiometric 
measurements of cytosolic 
calcium in wild type and in 
GAG-deficient myotubes.
Wild type (a; C2C12) and 
GAG-deficient (b; S27) 
myotubes were 
differentiated for 3 days.
Regions of interest (ROIs) 
were drawn on Indo-1 
images (485 nm) of the 
myotubes (exemplified by 
the ROIs in a and b).
Changes in intracellular 
calcium were measured in 
ROIs, corrected for 
background, and plotted 
against time as ratio values 
(405 nm/ 485 nm); bars 
below ratio traces indicate 
time points of electrical 
stimulation. Upon 
stimulation, excitable wild 
type myotubes showed 
sharp calcium spikes (a; 
trace). Only few S27 
myotubes were excitable, 
and these showed minor 
calcium fluxes with a very 
low signal to noise ratio (b; 
trace). Individual 405 nm
and 485 nm signals are depicted for the underlined 
part of each trace. The physiological relevance of the 
ratio traces is demonstrated by the rise of the 405 nm 
signal (calcium-bound Indo-1), simultaneous with the 
decline of the 485 nm signal (calcium-unbound Indo- 
1). The table depicts the number of excitable myotubes 
as a percentage of the total number measured; C2C12, 
n = 1875; S27, n = 140.
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Discussion
With the generation of a panel of antibodies that recognize specific, 
discretely located HS epitopes in skeletal muscle (Jenniskens et al., 2000), 
we recently developed tools appropriate for in vitro studying of the 
physiological roles of HS epitopes. In this paper, we report on the 
intracellular expression of these antibodies and of the HS-degrading 
enzyme heparanase, resulting in phenotypic knock out of HS in the C2C12 
myoblast cell line. We show that the calcium kinetics in HS-defective 
myotubes is impaired, indicating that HS epitopes have a role in the 
proper functioning of excitation-induced calcium spiking in skeletal 
muscle.
Expression of anti-HS intrabodies and heparanase in the C2C12 
myoblast cell line was accomplished by either of three expression 
systems: (1) pcDNA3.1 for high-level expression, (2) pIRES2-EGFP for 
bicistronic expression together with cytosolic EGFP in transient 
transfectants, and (3) pIND of the Ecdysone-inducible eukaryotic 
expression system for inducible expression together with cytosolic EGFP 
in transient transfectants. All three expression systems gave essentially 
the same results. Using an inducible expression system, we anticipated 
on a possible future implementation of the system in a transgenic mouse 
model, thus enabling the regulation of expression of the antibodies in 
vivo  in time. Whereas stably transfected myoblasts were unable to pro­
duce detectable quantities of antibodies using either expression system, 
transiently transfected myoblasts expressed antibodies in amounts 
sufficient for immunologic detection and for studying their physiological 
effects. We therefore did not pursue the generation of stably transfected 
cell lines, but studied the effects of the expression of anti-HS antibodies 
in transiently transfected cells. Differences in expression levels are 
probably caused by the presence of multiple copies of the expression 
constructs in transient transfectants as compared to stably transfected 
myoblasts, or by the lack of transcriptional activity due to the place of 
insertion in the genome.
Targeting of the intrabodies to the secretory pathway was realized 
by using an immunoglobulin leader peptide. Anti-HS intrabodies bind 
to HS epitopes in the Golgi lumen, and the antibody-HS complexes 
formed may either be secreted into the extracellular environment or 
recognized and degraded by the cellular quality control system. Unbound 
antibodies are secreted and bind to HS epitopes on cells surrounding 
transfectants. Endogenously expressed heparanase possibly acts in a 
similar fashion, digesting HS within the Golgi lumen and being secreted 
to the extracellular space in an active conformation. The effect of the 
expression of anti-HS intrabodies or heparanase is the inactivation of 
newly formed HS, resulting in phenotypic HS-knock out myoblasts.
Blocking one HS-epitope with a specific antibody may result in the 
removal of the whole HS chain, possibly harboring other HS-epitopes.
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However, our results show that knocking out one HS epitope does not 
necessarily interfere with the synthesis of another epitope, arguing for 
the occurrence of individual epitopes on physically separated HS 
molecules. This phenomenon, however, was not investigated further. 
Phenotypic knock out of HS epitopes did not interfere with the occurrence 
and distribution of cell surface and BL-resident HSPG core proteins. HS- 
knock out myotubes stained normally for syndecan and perlecan, 
respectively, and did not have either core protein retained within the 
Golgi apparatus. This situation is analogous to effects seen in xyloside- 
treated cells (Rapraeger et al., 1996), in which proteoglycan core proteins 
have shorter or no GAG chains and are transported and located similar 
to intact proteoglycans. Blocking or digestion of (a specific) HS epitope(s) 
within the Golgi apparatus apparently does not necessarily interfere with 
the proper routing of the HSPG core protein. In this context, it will be 
interesting to investigate whether the HS epitopes are specific for 
individual HS chains and for certain HSPG core proteins.
Cytosolic co-expression of the bioluminescent protein EGFP was used 
to identify transfected myotubes. Since myotubes are formed by the 
fusion of neighboring myoblasts, heterogeneous syncytia originate from 
both transfected and non-transfected myoblasts. The dilution of EGFP-, 
antibody-, and heparanase-coding vectors due to myoblast fusion and 
the degradation over time by nucleases may result in less effective 
expression levels of these proteins. Moreover, the synthesis of HSPGs 
from various nuclei w ithin a myotube may compensate for the 
phenotypic HS-knock out effectuated by the expression of antibodies or 
enzyme. Three days of differentiation was determined as an optimum 
between the myotube maturation grade and the dilution and degradation 
of the transfected plasmids. At this stage, excitable myotubes occurred 
for the first time (simultaneously) in both wild type and in transfected 
myoblast cultures, indicating a similar level of differentiation. EGFP- 
negative myotubes may prove to be falsely negative since their HS 
epitopes may be blocked by antibodies or digested by heparanase 
secreted by neighboring (transfected) myotubes. Hence, mock transfected 
and control antibody-transfected EGFP-positive myotubes were used 
as a control, rather than EGFP-negative myotubes neighboring 
transfected myotubes.
The effect of the depletion of HS-epitopes was evaluated by 
ratiometric measurements of the [Ca2+] on transfected myotubes, using 
a high-speed UV confocal laser scanning microscope. A considerable 
portion of control antibody-transfected myotubes could be triggered to 
generate calcium spikes, all of which had calcium kinetics identical to 
wild type myotubes. Upon the expression of anti-HS intrabodies or 
heparanase, the percentage of excitable myotubes was significantly 
reduced. Concomitantly, various anomalies in calcium signaling were 
noticed, whereas wild type calcium spikes were never observed. Excitable 
hybrid myotubes appeared to differentiate normally, as judged by their
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general appearence, the number of nuclei per myotube, the occurence of 
spontaneous acetylcholine receptor clustering, and the first occurrence 
of excitability. In wild type myoblast cultures all excitable myotubes 
displayed mature calcium kinetics and no aberrant calcium kinetics were 
observed. Since (for both wild type and hybrid myotubes) poor 
differentiation results in no excitability at all rather than aberrant cal­
cium kinetics, the anomalies observed in hybrid myotubes are likely to 
be the result of the affected HS composition, rather than the result of a 
disturbance in differentiation.
In line with these results are the data obtained from calcium 
measurements in the GAG-deficient myoblast cell line S27. Although the 
primary defect is unknown, the S27 cell line is defective in GAG 
biosynthesis but forms morphologically normal myotubes. The calcium 
kinetics in S27 myotubes is severely disturbed, further indicating an ef­
fect of GAGs in excitation-induced calcium kinetics. Finally, aberrant 
calcium kinetics are observed in myotubes derived from myoblast cul­
tures from mice carrying targeted disruptions in the gene encoding N- 
deacety lase /N  -sulfotransferase-1, an enzyme involved in HS 
biosynthesis (Jenniskens et al., submitted). Together, these data indicate 
a role for HS in skeletal muscle calcium kinetics.
N on-excitable HS-defective m yotubes frequently  showed 
spontaneous fluctuations of the [Ca2+], either as periodical elevations of 
the resting [Ca2+]t, or as autonomously generated calcium spikes, 
indicating a d isturbed calcium regulation. In absence of HS, 
dihydropyridine receptor-ryanodine receptor coupling appears to be 
affected and the myotube cell membrane seems to adopt an autonomous 
membrane oscillatory activity, triggering periodical calcium spikes. The 
effect of HS on excitation-induced calcium spiking may be mediated 
through direct or indirect regulatory interactions with ion channels in 
the cell membrane, like voltage-gated sodium channels or DHPRs, as 
has been described for extracellular heparin (Knaus et al., 1990; Knaus et 
al., 1992; Martinez et al., 1996). Lamb and coworkers (1994) found a 
negative regulatory effect of intracellular heparin, most likely by acting 
on the DHPR voltage sensor. HS, which is less sulfated than heparin, 
might act in a similar way. Since specific aberrations in calcium kinetics 
preferentially occur upon the elimination of certain HS-epitopes, it is 
tempting to attribute these effects to the HS-sequences involved. For 
instance, expression of antibody AO4B08, which recognizes HS sequences 
containing 2-O-sulfated iduronic acid residues, has a different effect than 
RB4EA12, which preferentially recognizes unsulfated iduronic acid 
residues. The expression of heparanase brought about all anomalies in 
calcium kinetics that were observed for individual antibodies, often 
combined in one recording. This may be due to the relatively broad HS- 
degrading activity of the enzyme (Vlodavsky and Friedmann, 2001), in 
contrast to the antibodies that recognize specific HS epitopes. In all cases, 
calcium spikes occurred both in the presence and in the absence of
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extracellular calcium, indicating that released calcium originated from 
intracellular stores.
Taken together, these data indicate specific functions of HS epitopes 
in skeletal muscle calcium kinetics. The antibody-based expression 
systems presented here, add a powerful tool to the repertoire available 
in the quest for improving our understanding of the HS structure- 
function relationship. Next to the generation of cell lines or mice defective 
in HS synthesis, it has now become possible to phenotypically knock 
out specific HS epitopes, enabling the detailed study of the functions of 
HS epitopes in cellular physiology in vitro  and in the future perhaps in 
v ivo . Using this expression system in skeletal muscle cell culture, we 
show for the first time a functional role for HS epitopes in myotube 
excitation-induced calcium spiking.
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Here we report on the identification of a unique glycosamino­
glycan (GAG) epitope, localized in the sarcoplasmic reticulum 
of mammalian skeletal muscle. Antibody RB4CG9, which inter­
acts with this GAG epitope, was selected by phage display 
against a GAG preparation derived from skeletal muscle. This 
antibody reacts with heparin and with the unusual GAG acharan 
sulfate (AS) but not with other GAGs. AS is a heparan sulfate­
like glycopolymer consisting of GlcNAc-IduA2S disaccharides. 
The antibody does not react with N-sulfated, N-deacetylated, 
nor with 2-O-desulfated AS, indicating GlcNAc-IduA2S to be of 
major importance in the epitope. Functional depletion of this 
GAG epitope in myotubes, by expression of antibody RB4CG9 
in C2C12 myoblast cultures, severely affects myotube excitability 
and alters the kinetics of electrically-induced calcium spikes. 
They show a significantly lower amplitude of calcium spikes, 
and frequently undershoots below basal cytosolic calcium le­
vel. Moreover, the reuptake rate of cytosolic calcium is strongly 
increased, arguing for a role of this uniquely located GAG epitope 
in the kinetics of sarcoplasmic reticulum calcium ATPase.
Introduction
Contraction of skeletal muscle follows upon calcium release from 
sarcoplasmic stores in response to depolarization of the sarcolemma. 
This signaling process is called excitation-contraction (e-c) coupling, and 
depends on intracellular junctions between invaginations of the 
sarcolemma (the transverse (T) tubules) and cellular calcium stores (the 
sarcoplasmic reticulum (SR)). These two membranous systems meet in 
so called triads, where a flattened portion of the T-tubule is flanked on 
both sides by terminal cisternae of the SR. Dihydropyridine receptors 
(DHPRs), located in the junctional T-tubular membrane, function as vol­
tage sensors and activate the facing ryanodine receptors (RyRs) in the 
SR terminal cisternae to release calcium into the sarcoplasm. Following 
its release, calcium triggers muscle contraction and is pumped back into 
the SR by calcium ATPases (SERCAs), which are located throughout the 
SR membrane (Franzini-Armstrong, 1972; Franzini-Armstrong, 1986; 
Hille, 1992; Flucher and Franzini-Armstrong, 1996).
T-tubules and SR develop simultaneously during myogenesis. 
Concomitantly, the interactions are formed between the proteins of both 
membrane systems in the triad (Franzini-Armstrong, 1991; Flucher, 1992; 
Flucher et al., 1992; 1994). Mature triads contain several proteins that are 
specifically located in the membrane or lumen of either the T-tubules or 
the SR. Whereas most of these proteins are thought to be involved in e­
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c coupling, few have been studied in detail. The integral SR membrane 
proteins triadin and junctin, and the SR luminal calcium binding protein 
calsequestrin are shown to mutually interact and to associate with the 
RyR, possibly regulating its activity (Guo and Campbell, 1995; Zhang et 
al., 1997; Ohkura et al., 1998; Caswell et al., 1999; Shin et al., 2000). SERCA 
activity in skeletal muscle is regulated by two related small SR- 
transmembrane proteins: phospholamban (in type I fibers) and sarcolipin 
(in type II fibers; Aubier and Viires, 1998; East, 2000).
Proteoglycans, consisting of a core protein and a glycosaminoglycan 
(GAG) moiety, are present in the extracellular matrix and at the surface 
of virtually all cell types. GAGs are negatively charged polysaccharides, 
which bind and modulate a large number of proteins and are able to 
bind cations, notably calcium (Lerner and Torchia, 1986). The large 
number of modifications in GAG chains makes them a highly versatile 
group of cell-regulatory molecules (Spillmann and Lindahl, 1994; Bern­
field et al, 1999; Turnbull et al., 2001, Gallagher, 2001). To our knowledge, 
no proteoglycans have been described to be located within the lumen of 
cellular organelles, except for the Golgi apparatus where the GAG 
moieties are synthesized and in the nucleus where GAGs are present 
possibly associated with the process of growth factor internalization.
In this paper, we report the presence of a unique GAG epitope within 
the SR of the skeletal muscle. We demonstrate that the functional 
depletion of this epitope results in drastic changes of calcium kinetics. 
Therefore, we hypothesize a novel role of GAGs in skeletal muscle cal­
cium kinetics.
Materials and Methods
Materials
Synthetic single chain variable fragment (scFv) library #1 (Nissim et al., 
1994) was generously provided by Dr. G. Winter (Cambridge University, 
Cambridge, United Kingdom). Human skeletal muscle samples 
(diaphragm, m. quadriceps, and m. soleus) were generously provided by 
Prof. Dr. D. Ruiter (Department of Pathology, University of Nijmegen, 
Nijmegen, The Netherlands). Frogs (Xenopus laevis, young adult) were a 
kind gift of Dr. R. Kuiper (Department of Molecular Animal Physiology, 
University of Nijmegen, Nijmegen, The Netherlands). Creatine kinase 
knock out mice were provided by Dr. Frank Oerlemans (Department of 
Cell Biology, University of Nijmegen, Nijmegen, The Netherlands). Anti- 
SERCA-1/ -2 polyclonal rabbit anti-rat antibody was a kind gift of Dr. J. 
Timmermans (Department of Physiology, University of Nijmegen,
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Nijmegen, The Netherlands); mouse monoclonal anti-chicken SERCA-1 
IgG (5D2) was a kind gift of Dr. D. Fambrough (Department of 
Embryology, Carnegie Institution of Washington, Baltimore, MD). Mice 
(C3H and C57BL/6) and rats (Wistar, male, 10 d; six weeks) were 
obtained from the University of Nijmegen Central Animal Laboratory. 
C2C12 (CRL1772) skeletal muscle cell line was purchased from American 
Ty pe Culture Collection (Rockville, MD).
All chemicals used were from Merck (Darmstadt, Germany), unless 
stated otherwise. Bacterial media (2xTY and LB), cell culture media, 
OptiMEM, and LipofectAMIN/ PLUS reagents were obtained from Life 
Technologies (Paisley, Scotland); tissue culture plastics from Greiner 
(Frickenhausen, Germany). Chondroitinase ABC (from Proteus vulgaris, 
EC 4.2.2.4) was from Seikagaku Kogyo Co. (Tokyo, Japan). Heparinase 
III (from Flavobacterium heparinum, EC 4.2.2.8), heparan sulfate from 
bovine kidney and from porcine intestinal mucosa, heparin from porcine 
intestinal mucosa, chondroitin 4-sulfate and chondroitin 6-sulfate from 
bovine trachea, dermatan sulfate from porcine intestinal mucosa, bovine 
serum albumin (fraction V), 3,3'diaminobenzidine-4HCl (DAB), anti­
desmin rabbit monoclonal IgG, and NaN3 were obtained from Sigma 
(St. Louis, MO). AS was isolated as described (Kim et al., 1996). Anti-c- 
M yc  mouse monoclonal IgG (clone 9E10) and anti-VSV antibody (clone 
P5D4) were purchased from Boehringer Mannheim (Mannheim, 
Germany). Anti-c-Myc goat polyclonal IgG (A-14), anti-dihydropyridine 
receptor goat polyclonal IgG (N-19), and anti-ryanodine receptor goat 
polyclonal IgG (N-19) were from Santa Cruz Biotechnology (Santa Cruz, 
CA). Biotin-conjugated donkey-anti-mouse, Vectastain ABC Elite kit was 
from Vector Laboratories (Burlingame, CA). Alexa 488-conjugated 
donkey anti-goat IgG and goat anti-mouse IgG, NBD C6-Ceramide (N- 
1154), Indo-1/AM and Pluronic F127 were purchased from Molecular 
Probes (Eugene, OR). Mowiol (4-88) was obtained from Calbiochem (La 
Jolla, CA). Polymerase chain reaction (PCR) chemicals and Taq 
polymerase (DNA polymerase from Thermus aquaticus) were from 
Promega (Madison, WI), PCR primers and synthetic oligonucleotides 
were obtained from Biolegio (Malden, The Netherlands). Eukaryotic 
expression vector pIRES2-EGFP was obtained from Clontech (Palo Alto, 
CA). Restriction enzymes and buffers were purchased from New Eng­
land Biolabs (Beverly, MA). Plasmid DNA isolation kit was purchased 
from Qiagen (Hilden, Germany). ABI Prism Big Dye Terminator Cycle 
Sequencing Ready Reaction Kit was from PE Applied Biosystems (Nor­
walk, CT).
All experiments were performed at ambient temperature (21OC), 
unless stated otherwise.
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Selection of antibody RB4CG9
Anti-GAG scFv antibody RB4CG9 was selected against GAG 
preparations of human skeletal muscle. Selection and characterization 
of antibody RB4CG9, and preparation of antibodies (periplasmic fraction) 
were performed as described previously (van Kuppevelt et al., 1998; 
Jenniskens et al., 2000). Briefly, synthetic scFv library #1 (containing 
approximately 108 different scFv antibody clones) was subjected to 
panning against an immobilized skeletal m uscle-derived GAG 
preparation (isolated from human diaphragm, m. quadriceps, and m. 
soleus). After four rounds of panning, single colonies were picked and 
the antibodies expressed by individual clones were evaluated for 
reactivity against various GAGs by ELISA. Subsequently, staining 
patterns of these antibodies were evaluated by immunohistochemistry 
on longitudinal cryosections of skeletal muscle.
Cell culture, transfection, and ratiometric measurements of 
intracellular calcium
Generation of the RB4CG9 expressing pIRES eukaryotic expression 
vector, cell culture, transfection, and ratiometric calcium measurements 
were carried out as described (Jenniskens et al., 2002). In short, C2C12 
myoblast cultures were transfected with pIRES expression constructs 
resulting in the expression of VSV-tagged MPB01 (control) or RB4CG9 
antibodies within the Golgi apparatus, concomitant with cytosolic 
expression of enhanced green fluorescent protein (EGFP). Using video­
speed UV confocal laser scanning microscopy, changes in cytosolic cal­
cium concentration upon electric stimulation were monitored as Indo-1 
ratios in EGFP positive myotubes. Additional off-line data analysis was 
perform ed using the O rigin 6.0 software package (Microcal, 
Northampton, MA).
Pre- and postnatal mouse tissue
C3H mice were bred under standard conditions and monitored for 
vaginal plugs twice a day. The first day of occurrence of a vaginal plug 
was taken as day 0 of gestation (E0). Pregnant mice were quarantinised 
and kept solitary until the litter had reached the indicated E-number 
(12, 13, 14, 15, 16, 17, 18, and 20 days in utero). Mice were anesthetized, 
killed by cervical dislocation, and embryos were isolated either with 
(E12 and 13) or without (E14-E20) the surrounding uteric tissue, rinsed 
in PBS, snap-frozen in liquid nitrogen-cooled isopentane, and stored at 
-80OC. Birth occurred on average at day E20 (P0). Mice of postnatal day
2 (P2) were anesthetized prior to freezing. Adult muscle specimens were 
isolated from the pregnant females that were killed. For each
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developmental stage, at least three individual mice, derived from two 
separate litters, were studied.
Immunohistochemistry
Skeletal muscle tissue specimens were snap-frozen in liquid nitrogen- 
cooled isopentane and stored at -80OC. 3 or 5 |j.m thick (muscle speci­
mens) or 5 to 10 |J.m thick (mouse embryos and newborns) cryosections 
were cut, mounted on slides, dried thoroughly, and stored at -80OC until 
use. Tissue cultures were washed three times with PBS, dried overnight, 
and stored at -80OC. Cryosections or tissue cultures were stained as 
described previously (Jenniskens et al., 2000; Jenniskens et al., 2002). 
Confocal images were made on a Nikon Diaphot inverted microscope 
attached to a BioRad MRC1024 ES confocal laser scanning microscope 
(Hemel Hepstead, UK). Digital images were processed using Confocal 
Assistant 4.02 and Adobe Photoshop 6.0 software.
Electron microscopy
Frogs (Xenopus laevis) were anesthetized with MS 222 and perfused with 
0.9% NaCl, followed by Bouin fixative (9% (v/v) paraformaldehyde, 
3% (w/v) picric acid, 5% (v/v) acetic acid). Skeletal muscle samples were 
taken and immersed overnight in Bouin fixative at 4OC. After washing 
in 0.1 M phosphate buffer, pH 7.4 (2 times 1 h), 75 |j.m sections were cut 
using a Leica VT1000S vibratome. Sections were rinsed three times in 
PBS, pH 7.4 (20 min each), incubated for 60 min in PBS containing 0.1% 
(w/v) BSA, followed by free floating overnight incubation with VSV- 
tagged anti-GAG antibody RB4CG9. After rinsing three times in PBS, 
sections were incubated with anti-VSV antibody P5D4 for 90 min, rinsed 
three times, and incubated with biotin-conjugated donkey-anti-mouse 
antibody for 60 min. Subsequently, sections were incubated in a solution 
of avidin and biotinylated horseradish peroxidase for two hours, followed 
by a 0.02% DAB solution in 0.05 M Tris/ 3E-3% H2O2 for 10 min. The 
substrate reaction was stopped by rinsing twice in PBS (5 min each), 
followed by 0.1 M phosphate buffer (1 h). As a control, a phage display- 
derived antibody that does not react with HS was used (MPB01). Next, 
sections were osmicated for one hour in 1% osmiumtetroxide and rinsed 
again in 0.1 M phosphate buffer. Sections were dehydrated in a grade 
series of ethanol, embedded in epon 812 via propylene oxide and 
mounted in epon 812. After polymerization, a Reichert Ultracut-E was 
used to cut 80 nm thick sections, which were examined under a Jeol 
1010 electron microscope.
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Results
Selection of the RB4CG9 antibody
Antibody RB4CG9 was obtained by phage display as described 
(Jenniskens et al., 2000). Four rounds of panning were performed against 
a GAG preparation derived from human skeletal muscle (combined 
diaphragm, m. quadriceps, and m. soleus). Selection resulted in the isolation 
of two identical scFv antibodies designated RB4CG9. RB4CG9 is a 
member of VH family 4 (DP segment 67) and bears the complementarity 
determining region 3 (a major determinant in antigen specificity) amino 
acid sequence LRSVSPGY.
RB4CG9 recognizes a rare GAG epitope
In ELISA, antibody RB4CG9 showed no reactivity with K5 (heparosan, 
the precursor polysaccharide of heparan sulfate (HS)), chondroitin sulfate 
(CS), and dermatan sulfate (DS). Immunoreactivity was seen with GAG 
preparations from mammalian skeletal muscle and with heparin. 
Surprisingly, RB4CG9 also showed reactivity with acharan sulfate (AS), 
a HS-like GAG isolated from the giant African snail (Achatina fulica), 
which mainly consists of GlcNAc-IduA2S disaccharides (Kim et al., 1996).
Table 1. Evaluation of RB4CG9 specificity by ELISA
GAG preparation Reactivity
K5 capsular polysaccharide (E. co li) -
AS (Achina fulicka) ++
N-sulfated AS -
N-deacetylated AS -
2-O-desulfated AS -
CS (bovine trachea) -
DS (porcine intestinal mucosa) -
HS (bovine kidney) -
HS (porcine intestinal mucosa) -
HS (human lung) -
Heparin (porcine intestinal mucosa) + +
GAG preparation (human diaphragm) + +
GAG preparation (human m.quadriceps) +
GAG preparation (rat diaphragm) + +
GAG preparation (rat m.quadriceps) +
GAG preparation (rabbit diaphragm) + +
GAG preparation (rabbit m.quadriceps) +
GAG preparation (mouse total skeletal muscle) + +
AS after heparinase treatmentc +
Heparin after heparinase treatmentc ±
GAG preparations after heparinase treatmentc ±
GAG preparations after Chondroitinase ABC treatment + +
RB4CG9 antibodies were applied to GAG preparations immobilized on microtiter plates. Bound 
antibodies were detected using anti-c-Myc mouse monoclonal antibody 9E10, followed by alkaline 
phosphatase-conjugated rabbit anti-mouse IgG, after which enzymatic activity was measured using 
p-nitrophenyl as a substrate. Reactivity: ++, strong; + , moderate; ±, low; -, absent (n = 5). 
a Similar to the HS precursor polysaccharide (heparosan) 
b AS, acharan sulfate; a HS-like Gag  
c digested with heparanase I, II, and III
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RB4CG9 had no reactivity with N-sulfated, deacetylated, or 2-O- 
desulfated AS, or with HS from sources other than muscle tissue (Table 
1). Treatment of GAG preparations with chondroitinase ABC (digests 
CS and DS) did not interfere with immunoreactivity. Treatment with a 
combination of heparinases I (digests HS/ heparin at HNS6X-I2S), II (digests 
AS and HS/ heparin at HNY6X-G/I2S), and III (digests HS/ heparin at 
HNAc-I/ HNY6X-G (X, sulfated or unsubstituted; Y, sulfated or acetylated)) 
diminished reactivity, arguing for a HS-like nature of the RB4CG9 GAG­
antigen.
Unique location of the RB4CG9 epitope in skeletal muscle
In immunohistochemistry, antibody RB4CG9 reacted only with skeletal 
muscle tissue. Studies on longitudinal cryosections of muscle specimens 
of various species (frog, rat, mouse, rabbit, and human) revealed a distinct 
cross-striation after staining with the RB4CG9 antibody. RB4CG9 
reactivity appeared in bands, approximately 2 |j.m interspersed, 
transversely oriented to the longitudinal direction of muscle fibers (Fig. 
1a).
Figure 1. Immunolocali- 
sation of GAG epitope 
RB4CG9 in adult and 
developing skeletal muscle. 
Longitudinal cryosections of 
adult mouse m. soleus (a), 
cross cryosections of m. 
quadriceps (b), and 
cryosections of myogenic 
regions of fetal mice at 
embryonic days E14 (c and 
e) and E20 (birth; d and f) 
were stained for GAG 
epitope RB4CG9. Regular 
cross striation, 
approximately 2 |im 
interspersed, was observed 
(a). In muscle specimens 
composed of different fiber 
types, a differential staining 
was observed (b). Cross (c 
and d) and longitudinal (e 
and f) cryosections of 
mouse fetal myogenic 
regions showed GAG 
epitope RB4CG9 to be 
present near the 
sarcolemma of primary 
myotubes in a punctuate 
pattern at E14 (c and e), and cross striated throughout 
muscle fibers at E20 (d and f). Scale bar, 30 |im (a); 
500 |im (b); 50 |im (c-f).
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Colocalization studies in various postural muscles (m. extensor digitorum  
longus; m. soleus; m. quadriceps) with antibodies against myosin fast, 
SERCA-1, and SERCA-1/ -2 showed that antibody RB4CG9 has a strong 
preference for slow myofibers (type I; oxidative), as compared to fast 
myofibers (type II; glycolytic; Fig. 1b).
Figure 2. Immunolocalisation of GAG epitope RB4CG9 
in skeletal muscle. Longitudinal cryosections of rat 
skeletal muscle were stained for GAG epitope RB4CG9 
(a1-c1), RyR (a2), SERCA (b2), and desmin (c2). 
Merged images are shown in color (a3-c3), of which 
enlargements are shown in the far right panel (a4-c4). 
GAG epitope RB4CG9 (large arrows to the left of panels
4) is flanked by RyR (small arrows to the right of 
panels a4), and alternates with bands with no staining, 
suggesting the presence of this GAG epitope over 
either the longitudinal or the fenestrated SR. Note the 
double cross-striated bands when stained for RyR (a2), 
due to the presence of two triads per sarcomere. An 
overlap in location with SERCA (small arrows to the 
right of panel b4) and with desmin (small arrows to the 
right of panel c4) confirms the location of this GAG 
epitope over the fenestrated SR. Scale bar, 20 |im (1­
3); 2.5 M*m (4).
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In cryosections of whole mouse embryos RB4CG9 reacted with 
myogenic regions only (Fig. 1). At embryonic day 12, antibody RB4CG9 
stained the periphery of developing primary myotubes. Ongoing 
myogenesis and the concomitant development of the muscle triad 
membranous systems resulted in a punctuate staining pattern with anti­
body RB4CG9 near the sarcolemma of primary myotubes at E14 (Fig. 1c 
and 1e), which developed to a cross-striation of the entire muscle fiber 
at E20 (Fig. 1d and 1f) and in further stages of development.
GAG epitope RB4CG9 was moderately detectable in cultured C2C12 
myotubes; small intracellular granules could be stained, together with a 
general cytoplasmic staining. Under the culturing conditions used, C2C12 
myotubes did not reach a differentiation stage in which RB4CG9 cross- 
striation became visible (data not shown).
Immunohistochemical localization of GAG epitope RB4CG9
Staining of skeletal muscle with antibody RB4CG9 resulted in a highly 
ordered pattern of transversely oriented bands. To investigate whether 
this GAG epitope occurs associated with either of the membrane systems 
of the triad, we performed colocalization studies of RB4CG9 with 
sarcomeric proteins and with several ion channels of the e-c coupling 
system. Skeletal muscle of mammals contains two triads per sarcomere, 
located at the A-I junction (reviewed in Franzini-Armstrong, 1972). In 
rat RB4CG9 did not colocalize with the DHPR nor with the RyR (fig. 2 
a1-a4). With SERCA, an overlap was found (fig. 2b1-b4), whereas 
RB4CG9 staining also colocalized with desmin, indicating a distribution 
over the Z-line (fig. 2c1-c4). A sarcomeric band that was flanked by RyR 
and negative for desmin did not stain with antibody RB4CG9. Similar 
staining patterns were obtained for mouse, rabbit, and human skeletal 
muscle. In frog skeletal muscle only one triad is present per sarcomere, 
which is located at the Z-line. Here, RB4CG9 staining overlapped with 
SERCA (data not shown).
Since colocalization studies suggested the presence of GAG epitope 
RB4CG9 in muscle SR, we looked into greater detail to the subcellular 
location. Immuno electron microscopy on frog skeletal muscle using 
RB4CG9 indicated the presence of the GAG epitope within the 
sarcoplasmic reticulum (Fig. 3b). In mammalian muscle, however, we 
could not achieve electron microscopic immunostaining with this anti­
body. We therefore performed immunostaining on skeletal muscle from 
mice double mutant for the mitochondrial and cytosolic creatine kinase 
loci (creatine kinase-/-; Steeghs et al., 1997). Creatine kinase-/- muscle 
displays longitudinally oriented tubular aggregates consisting of SR-ter­
minal cisternae, which were strongly stained with antibody RB4CG9 (Fig. 
3a).
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Figure 3. GAG epitope 
RB4CG9 is located in the 
SR of skeletal muscle.
Longitudinal cryosections 
of m. soleus of creatine 
kinase-knock out mouse 
(a) were stained for GAG 
epitope RB4CG9. RB4CG9 
staining results in an 
ordered pattern of 
transversely oriented 
bands as well as 
longitudinally oriented 
tubular structures that 
represent aggregates of 
SR-terminal cisternae, 
which are present in 
skeletal muscle of creatine 
kinase-knock out mice 
(Steeghs et al., 1997; 
arrows in a). Immuno- 
electron microscopical 
localization of GAG epitope 
RB4CG9 in frog skeletal 
muscle (b) confirms that 
GAG epitope RB4CG9 is 
present within the 
sarcoplasmic reticulum. SR, sarcoplasmic 
T-tubule. Scale bar, 20 |im (a); 0.1 |im (b
Phenotypic knock out of GAG epitope RB4CG9 leads to aberrant 
calcium kinetics in cultured myotubes
The SR location of GAG epitope RB4CG9 prompted us to study its 
possible involvement in calcium kinetics in C2C12 myotubes. For this, we 
used a pIRES-based eukaryotic expression system adapted for expression 
of anti-HS antibodies within the Golgi apparatus, simultaneously with 
cytosolic expression of EGFP (Jenniskens et al., 2002). Previously, we 
have shown that the expression of anti-HS antibodies can be used to 
phenotypically knock out HS epitopes, resulting in myotubes with a 
defective HS composition. In transfected myoblasts, RB4CG9 antibodies 
were detected within the Golgi apparatus, as was confirmed with C6- 
Ceramide, and in cytosolic vesicles (Fig. 4a, insert). Transfected myoblasts 
fused with non-transfected neighboring myoblasts to form EGFP-positive 
myotubes, which could be used for Indo-1 ratiometric measurements of 
the intracellular calcium concentration ([Ca2+];), using a high-speed UV 
confocal laser scanning microscope. Under the conditions used in this 
study, 32% of the myotubes transfected with vectors encoding EGFP, or 
EGFP plus control antibody MPB01 was excitable (Table 2). Upon the 
expression of anti-GAG antibody RB4CG9, the amount of excitable EGFP- 
positive myotubes was significantly reduced to 8%.
).
reticulum; T,
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Table 2. The effect of endogenous expression of anti­
GAG antibody RB4CG9 on 3 day-differentiated C2C12 
myotubes.
Calcium spike kinetics
Transfected myotube n Excitability (%) n Amplitude (ratio) Rate constant i  (s)
C2Ci2 Control3 
C2C12 RB4CG9
35
37
32
8*
12
8
2.04 ± 0.34 0.30 ± 0.04 
1.50 ± 0.25** 0.14 ± 0.03**
Ratiometric measurements of [Ca2+]. were performed upon electric stimulation of individual EGFP-positive 
C2C12 myotubes. The overall percenta ge of myotubes that responded to stimuli by generating calcium 
spikes (i.e. excitable) was determined in transfected cultures. The kinetics of individual calcium spikes 
were analyzed for a number of spikes from separate measurements of multiple recording sessions. n 
represents the number of individual cells of which calcium transients were monitored (overall) or the 
number of individual calcium spikes that were analyzed (calcium spike kinetics). 
a Expressing either cytosolic EGFP alone, or cytosolic EGFP and control antibody MPB01 
* P value <0.05 
** P value <0.001
Calcium spikes of RB4CG9-expressing excitable myotubes (Fig. 4a) 
had significantly lower amplitudes as compared to control myotubes 
and frequently showed undershoots during decline to basal level (Fig. 
4b and 4c). Moreover, individual calcium spikes differed in amplitude 
when compared to each other and occasionally failed to be generated 
upon stimulation. Spontaneous fluctuations of the resting [Ca2+] were 
frequently observed in RB4CG9-expressing myotubes, in contrast to 
control-transfected myotubes. Electric stimulation often triggered 
RB4CG9-expressing myotubes to generate a series of oscillatory calcium 
spikes. Spontaneous generation of calcium spikes was seldom seen, as 
in control myotubes. Removal of extracellular calcium neither affected 
the occurrence nor the amplitudes of induced calcium spikes (data not 
shown).
Calcium spikes of control-transfected myotubes were selected from 
individual measurements of multiple recording sessions, and averaged 
out to generate a mean wild type calcium spike (Fig. 4c). Similarly, a 
mean RB4CG9 calcium spike was derived from measurements of RB4CG9 
expressing myotubes. Individual analysis of the spikes showed that upon 
electrical stimulation maximum [Ca2+] levels were reached within 99 
ms (three data points), after which they rapidly declined to basal level. 
In control myotubes a significantly higher rise in Indo-1 ratio (2.04±0.34) 
was observed, as compared to RB4CG9-expressing myotubes (1.50±0.25 
(p<0.003); Table 2). The decline of [Ca2+] to basal level could be described 
by a mono-exponential function (Yt= Y0+Ae-t/i (Yt= ratio as a function of 
time; Y0= ratio at t=0 (basal ratio); A= scaling factor; t= time; |J= decay 
constant)), for both control and RB4CG9 expressing myotubes, using 
the Levenberg-Marquard algorithm (Press, 1995). The small difference 
between the experimental trace and the exponential fit showed this 
description to be valid (R2=0.99). These mono-exponential kinetics 
suggest one main calcium reuptake process (Lieste et al., 1998; Koop-
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man et al., 2001; de Groof et al., 2001), described by a decay constant i ,  
which is inversely proportional to the rate of [Ca2+]. decline (Table 2). 
Fitting of the [Ca2+]. decline of the individual recordings resulted in an 
average decay constant for control myotubes of 0.30s ±0.04 (n=12) and 
for RB4CG9 expressing myotubes of 0.14s ±0.03 (n=8), indicating a sig­
nificant (p<0.001) decrease of the decay constant upon depletion of this 
GAG epitope (Table 2). Following decline to basal [Ca2+]. level, RB4CG9- 
transfected myotubes showed an undershoot that gradually returned to 
basal level. When plotting the derivative of the decay phase of the mean 
calcium spike Indo-1 ratios (d[Ca2+]./dt) against the normalized Indo-1 
ratio (Fig. 4d), the decline of the linear fit through the data points 
correlates with the [Ca2+]. removal speed. Since the decline of this linear 
fit is more steep for RB4CG9 transfected myotubes, it can be concluded 
that the [Ca2+]. removal speed its increased upon depletion of GAG 
epitope RB4CG 9.
-0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 
Time (s)
Figure 4. Ratiometric measurements of cytosolic 
calcium in control and RB4CG9 transfected C2C12 
myotubes. C2C12 myoblasts were transfected with
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expression vectors, encoding control antibody MPB01 
or anti-GAG antibody RB4CG9, combined with cytosolic 
EGFP. The insert in panel a shows the expression of 
VSV-tagged antibodies within the Golgi apparatus (dark 
staining). Upon confluency, C2C12 myotubes were 
differentiated for 3 days. Regions of interest (ROIs) 
were drawn on EGFP images (488 nm) of the myotubes 
(exemplified by the ROI in a). Changes in intracellular 
calcium were measured in ROIs, corrected for 
background, and plotted against time as ratio values 
(405 nm/ 485 nm; b); bars below ratio traces indicate 
time points of electrical stimulation. Individual 405 nm 
and 485 nm signals are depicted for the underlined 
part of each trace. The physiological relevance of the 
ratio traces is demonstrated by the rise of the 405 nm 
signal (calcium-bound Indo-1), simultaneous with the 
decline of the 485 nm signal (calcium-unbound Indo- 
1). Excitable myotubes transfected with control- 
antibody MPB01 showed wild type calcium spikes upon 
stimulation (b; Control). Myotubes transfected with 
anti-GAG antibody RB4CG9 had substantially lower 
amplitudes and showed undershoots in returning to 
basal [Ca2+] (b; RB4CG9). Calcium spikes of control 
and RB4CG9-expressing myotubes were selected from 
individual measurements of multiple recording sessions 
and averaged to generate mean calcium spikes (c). By 
plotting the derivative of the decay-phase (insert) of 
the mean calcium spikes against the normalized Indo-1 
ratio, it can be illustrated that the mono-exponential 
rate constant i  decreases upon depletion of GAG 
epitope RB4CG9 (d; the insert indicates the data points 
(taken from c) used for analysis). Since i  is inversely 
proportional to the calcium removal speed, the 
intracellular calcium removal kinetics are accelerated in 
the absence of GAG epitope RB4CG9.
Discussion
Antibody RB4CG9 was selected by phage display against GAG 
preparations derived from human skeletal muscle. In ELISA, the anti­
body was reactive with GAG preparations from skeletal muscle, with 
heparin (a highly sulfated form of HS), and with AS. AS is a HS-like 
GAG, composed of GlcNAc-IduA2S as basic disaccharide units, of which 
about 10% is N-sulfated. Fully N-sulfated AS, however, does not react 
with antibody RB4CG9, nor do N-deacetylated and 2-O-desulfated AS. 
This indicates that GlcNAc-IduA2S sequences are involved in the 
formation of the epitope defined by antibody RB4CG9. Reactivity with 
skeletal muscle GAG preparations, heparin, and AS in ELISA was 
diminished by heparanase digestion, indicating the HS-like nature of 
the antigen.
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In immunofluorescence studies, the antibody reacted exclusively with 
skeletal muscle cells. Colocalization studies in various adult postural 
muscles showed GAG epitope RB4CG9 to be predominantly present in 
type I (oxidative; 'slow-twitch') muscle fibers, as compared to type II 
(glycolytic; 'fast-twitch') fibers. The distinct distribution of RB4CG9 
argues for an involvement of this GAG epitope in muscle-specific 
properties, possibly by fine-tuning the physiological requirements.
During in vivo  myogenesis, RB4CG9 initially stained the periphery 
of developing primary myotubes, eventually resulting in cross-striation 
of full-grown muscle fibers. Colocalization studies of GAG epitope 
RB4CG9 with sarcomeric proteins and with several ion channels of the 
e-c coupling system in mammals and frog, studies on creatine kinase7- 
mice, and immuno electron microscopy studies all indicated GAG epitope 
RB4CG9 to be present in the SR. More specific, GAG epitope RB4CG9 is 
located in the fenestrated SR and the terminal cisternae (Fig. 5).
The unusual subcellular distribution of GAG epitope RB4CG9 
partially overlaps with the recently published locations of y-sarcoglycan 
in the SR membrane (Ueda et al., 2001). This sarcoglycan isoform is a 
type II transmembrane glycoprotein and a member of the dystrophin 
complex. y-sarcoglycan is located in the SR terminal cisternae and 
throughout the fenestrated SR. Mutations in y-sarcoglycan are causal 
for severe childhood autosomal recessive muscular dystrophy (Noguchi 
et al., 1995; McNally et al., 1996). 5-sarcoglycan is restricted to the SR 
terminal cisternae and is mutated in autosomal recessive limb-girdle 
muscular dystrophy (Jung et al., 1996; Nigro et al., 1996). However, we 
could not locate any putative heparin/ HS binding motif in neither 5- 
nor y-sarcoglycan, leaving us with no clue as to a possible interaction of 
GAG epitope RB4CG9 with these proteins.
The strict location of GAG epitope RB4CG9 within the SR may indicate 
a function for GAGs in this organelle. This GAG epitope may be involved 
in maintaining the integrity of the SR lumen against mechanic or osmotic 
forces, as was proposed for CS in T-tubules (Davis and Carlson, 1994). 
Being negatively charged, GAGs may be involved in the sequestering of 
calcium within the SR, as was shown for the SR-resident protein 
calsequestrin (MacLennan and Wong, 1971; MacLennan et al., 1983; 
Lerner and Torchia, 1986). Interestingly, one of the proposed functions 
of AS in the giant African snail (Achatina fulica) is the binding of bivalent 
cations such as calcium (Kim et al., 1996). Possibly, by affecting the local 
calcium concentration near regulatory SR-luminal sites of RyRs or 
SERCAs, GAGs may regulate the activity of these proteins, similar to 
the previously proposed mechanism for heparin-stimulated RyR activity 
(Men'shikova et al., 1986; Bezprozvanny et al., 1993). Another possibility 
is the involvement of GAG epitope RB4CG9 in e-c coupling via direct or 
indirect interactions with SERCA or ion channels. Such interactions have 
been shown for heparin in DHPR activity (Knaus et al., 1990; Martinez et 
al., 1996) and for the SR-resident proteins calsequestrin and triadin in
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Figure 5. Proposed 
location of GAG epitope 
RB4CG9 in mammalian 
skeletal muscle, based on 
immunofluorescent and on 
electron microscopic 
studies. GAG epitope 
RB4CG9 is present within 
the fenestrated SR and in 
the non-junctional side of 
the SR-terminal cisternae.
their regulation of the RyR (Guo and Campbell, 1995; Ohkura et a l, 1998). 
To evaluate possible interactions between GAGs and SR-proteins, we 
screened several SR-resident proteins and ion channels involved in e-c 
coupling for putative HS/ heparin-binding consensus motifs. Amino 
acid sequences of calsequestrin (accession number P07221), junctate 
(NP_004309), junctin (AAG16983), phosphoglucomutase (P00949), d- 
sarcoglycan (AAC50921), g-sarcoglycan (AAC50269), sarcoplasmic 
reticulum glycoprotein (AAA60730), triadin (AF220558, AJ243303, 
AJ243304), DHPR-alpha1 (AAB37235), D H PR -alpha2/delta 
(NM_000722), RyR1 (NM_000540), RyR3 (NM_001036), SERCA1 
(A48849), and SERCA2 (NM_001681) were analyzed for the occurrence 
of HS/ heparin-binding consensus motifs: XBBXBX in ß-strands and 
XBBBXXBX in a-helices (Cardin and W eintraub, 1989), 
XBBXXBBBXXBBX (Sobel et al., 1992), and TXXBXXTBXXXTBB (Hileman 
et al., 1998; (X, any amino acid; B, basic amino acid (H, K, R); T, turn)). 
Multiple XBBXBX and XBBBXXBX motifs were present in most of the 
proteins m entioned above, except for the sarcoglycans. 
XBBXXBBBXXBBX and TXXBXXTBXXXTBB motifs were not found in 
any of these proteins. In SERCA1, a XBBXBX motif was found starting at 
amino acid 682, located in a turn in the cytosolic phosphorylation domain. 
RyR1 and RyR3 contain multiple XBBXBX and XBBBXXBX motifs, but 
these are located at the cytosolic side. It will be interesting to study 
interactions between GAG epitope RB4CG9 and SR resident proteins in 
future studies.
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Previously, we have shown that expression of anti-HS antibodies in 
cell culture leads to the phenotypic knock out of the HS-epitopes involved 
(Jenniskens et al., 2002). Endogenous expression of anti-GAG antibody 
RB4CG9 in transiently transfected C2C12 myoblast culture resulted in a 
marked decrease in the number of excitable myotubes and in altered 
kinetics of electrically induced calcium spikes. Depletion of GAG epitope 
RB4CG9 resulted in 50% reduced amplitudes of calcium spikes and a 
doubled [Ca2+] removal speed. Since calcium removal kinetics could be 
fitted with a mono-exponential function, the transport of calcium from 
the cytosol to the SR is most likely mediated by one main removal process, 
namely SERCA activity. The anomalies induced by the absence of GAG 
epitope RB4CG9 may be explained by an involvement of this GAG 
epitope in mediating SERCA activity, possibly in combination with 
phospholamban or sarcolipin. One can envisage the binding of calcium 
to the negatively charged GAG molecules after its arrival in the SR. An 
increase in GAG-bound calcium in the vicinity of the SERCAs may be 
sensed and may result in a lower pumping speed. In absence of GAG 
epitope RB4CG9, this negative feedback mechanism is absent, leading 
to unrestrained calcium pumping, eventually resulting in an undershoot 
of [Ca2+] below the basal level. The mechanism responsible for the re­
turn of [Ca2+] from the undershoot to basal level remains unclear, but 
may reflect an intrinsic activity of RyRs to balance the resting [Ca2+]r 
In this paper we describe a unique HS-like GAG epitope, likely 
containing GlcNAc-IduA2S sequences, that specifically localizes in the 
skeletal muscle fenestrated SR and the terminal cisternae. To our 
knowledge for the first time, a tissue-specific GAG epitope is shown to 
be located within an organelle other than the nucleus or Golgi apparatus. 
Depletion of GAG epitope RB4CG9 by endogenous expression of the 
RB4CG9 antibody results in altered calcium kinetics in myotubes in vitro, 
indicating a role for this GAG epitope in skeletal muscle calcium kine­
tics.
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Chapter ß
Survey and Summary

Background and aim of the study
Heparan sulfate proteoglycans (HSPGs) are major components of the 
skeletal muscle cell surface and of the basal lamina (BL) surrounding 
muscle cells. HSPGs consist of a protein core to which multiple heparan 
sulfate (HS) chains are attached. Individual HSPGs, notably agrin and 
perlecan, have been intensely studied in recent years. However, these 
studies focused on the protein core, ignoring the HS moiety mainly 
because of a lack of appropriate tools. Previously, it was shown that 
antibodies specific for unique HS epitopes can be selected by means of 
phage display. The aim of the study described here was to select 
antibodies against skeletal muscle HS, to investigate the occurrence of 
specific HS epitopes in muscle, and to analyze the involvement of HS in 
muscle development and physiology.
Spatiotemporal occurrence of HS epitopes in 
skeletal muscle
Anti-HS antibodies were selected by phage display against HS from 
skeletal muscle, as described in chapter 2. Using these antibodies, several 
distinct HS epitopes were shown to be differentially distributed in skeletal 
muscle. Whereas some HS epitopes were generally present in muscle 
BL, others had a more restricted distribution, especially with regard to 
the NMJ. Both in situ  and in vitro, some HS epitopes colocalized with 
acetylcholine receptor clusters.
In chapter 3 the epitopes recognized by anti-HS phage display 
antibodies are characterized in more detail. The topological distribution 
of HS epitopes is tightly regulated and antibodies recognize chemically 
different HS epitopes, the position of sulfate groups being of major 
importance.
Chapter 4 describes in detail the distribution of HS epitopes in skeletal 
muscle during embryogenesis in the mouse. The spatiotemporal 
expression of various HS epitopes changes markedly during muscle 
development. This dynamic regulation may create a specific extracellular 
microenvironment, necessary for the correct sequence of events in 
myogenesis and synaptogenesis, and argues for roles of individual HS 
epitopes in underlying developmental processes.
A functional role for HS in muscle calcium kinetics
Chapter 5 describes changes in calcium kinetics in cultured primary 
myotubes of mice carrying a targeted disruption of a gene encoding an
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enzyme involved in HS synthesis. Muscle cells of mice knock out for N- 
deacetylase/N-sulfotransferase-1 show changes in HS composition, as 
determined by immuno staining, as well as a significant change in the 
kinetics of calcium spikes. Upon electrical excitation, a lower flux of cal­
cium over the SR membrane and a slower decay to basal [Ca2+] were 
observed as compared to wild type myotubes. The relationship 
demonstrated between changes in HS and in calcium kinetics is in 
accordance with the data presented in the following two chapters.
Apart from their obvious use in immunohistochemistry, phage 
display-derived antibodies can be used in expression studies. In chapter
6 novel eukaryotic expression systems are described, in which anti-HS 
antibodies are expressed as intrabodies in the C2C12 myoblast cell line. 
Targeting of anti-HS antibodies or the HS-degrading enzyme heparanase 
to the secretory pathway through the Golgi apparatus results in a 
phenotypic knock out of HS at the cellular surface. Myoblasts expressing 
either antibodies or heparanase form myotubes that are defective in HS. 
These myotubes are seriously affected in their calcium kinetics.
A rare HS-like glycosaminoglycan (GAG), which is unique for skeletal 
muscle tissue and which is located in the sarcoplasmic reticulum, is 
described in chapter 7. Antibodies against this GAG were selected against 
skeletal muscle GAG preparations by means of phage display. Using 
the previously described expression systems (chapter 6), this molecule 
can be knocked out in cultured myotubes, resulting in dramatic changes 
of the kinetics of electrically induced calcium spikes. This GAG is unique 
in its muscle specificity, in its intracellular location, and in the effects of 
its role in calcium kinetics. The data presented in these chapters argue 
for the involvement of HS in skeletal muscle calcium kinetics.
Future research
The results presented in this thesis offer new insights in the diversity, 
topology and function of HS epitopes. The preferential binding of anti- 
HS antibodies to defined synthetic oligosaccharides were established. It 
remains to be elucidated whether these HS epitopes are unique for 
specific core proteins. Moreover, it is a major challenge to elucidate the 
monosaccharide sequences of the HS epitopes recognized by the 
anibodies.
Knocking out of HS at the cellular surface by the expression of epitope- 
specific anti-HS intrabodies or by the HS-degrading enzyme heparanase 
offers a new and powerful tool to investigate the roles of HS. The use of 
universal eukaryotic expression vectors with strong viral promoters 
allows the general application of these systems in many fields in which 
GAG are involved. These systems may prove to be valuable in many in 
vitro  studies in which the roles of HS or specific HS epitopes are studied
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apart from the core protein to which they are attached.
An antibody expression system that can be induced to various levels 
in vitro, is described in chapter 6. This system may also prove to be useful 
for in vivo  HS research. The inducible expression of anti-HS intrabodies 
or heparanases by the oral addition of the inducing agent ecdyson, may 
enable the temporal knock out of HS epitopes in vivo  at any time point. 
Such studies may attribute to a better insight in the roles of HS epitopes 
in developmental or physiological processes. Similar techniques may 
also be used to study the function of other GAGs.
The identification of a rare, muscle-specific GAG species, which is 
located within the sarcoplasmic reticulum and has a function in cellular 
physiology, seems in contradiction with the current view of GAGs being 
present in the extracellular environment only (except for the presence of 
HS in the nucleus). It would be interesting to further investigate the na­
ture of this GAG, and to elucidate its mechanism of action in muscle 
calcium kinetics.
The functional properties of the cellular HS epitopes should be 
analyzed in more detail. Next to the developmental and physiological 
functions described in this study, the involvement of the cellular HS 
constitution in pathological conditions is of special interest. Since HSPGs 
have been involved in interstitial myopathies (e.g. Schwartz-Jampel 
syndrome, Silverman-Handmaker dyssegmental dysplasia, Simpson- 
Golabi-Behmel syndrome), it will be interesting to investigate the role of 
the HS moieties in these disorders. The antibodies and expression systems 
described in this thesis may facilitate new approaches for this purpose.
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Chapter 9
Samenvatting in het 
Nederlands

Achtergrond en doelstelling van het onderzoek
Spieren zijn organen die zijn gespecialiseerd in het ontwikkelen van de 
mechanische kracht die tot beweging leidt. Skeletspieren zijn aan beide 
uiteinden door middel van pezen bevestigd aan de botten van het ske­
let. De gecoördineerde bewegingen van een organisme worden moge­
lijk gemaakt doordat individuele spiervezels worden geïnnerveerd door 
motorneuronen in zogenaamde neuromusculaire juncties (NMJs).
Tussen de individuele vezels waaruit skeletspier is opgebouwd be­
vindt zich een laag vezel-achtig materiaal; de extracellulaire matrix 
(ECM). Deze matrix vormt een structureel verbindingsweefsel dat be­
langrijke functies heeft bij: (a) het ontstaan van spierweefsel tijdens de 
embryonale ontwikkeling, (b) het herstel van spierweefsel na beschadi­
ging en (c) de verdeling van de mechanische krachten die op de spierve­
zels komen te staan bij contractie. Een specifieke structuur binnen de 
ECM is de basale lamina (BL), die de individuele spiervezels omgeeft. 
De BL is continu over het gehele oppervlak van de spiervezel, ook in 
NMJs waar deze structuur de ruimte tussen de uitloper van het 
motorneuron en de spiervezel vult.
Heparan sulfaat-proteoglycanen (HSPGs) zijn belangrijke componen­
ten van de BL en het celoppervlak van de skeletspier. HSPGs bestaan uit 
een eiwitketen met daaraan gekoppeld een of meer heparan sulfaat (HS) 
moleculen. Individuele HSPGs, met name agrine en perlecan, zijn in de 
afgelopen jaren intensief bestudeerd. Deze studies richtten zich echter 
op de eiwitketens van deze moleculen, aangezien er nauwelijks metho­
den waren om de HS moleculen te onderzoeken. In voorgaand onder­
zoek is aangetoond dat het mogelijk is om antilichamen te selecteren die 
specifiek bepaalde epitopen op HS moleculen herkennen. Het doel van 
het in dit proefschrift beschreven onderzoek was om antilichamen te 
selecteren tegen HS geïsoleerd uit skeletspier, de distributie van speci­
fieke HS epitopen in spier BL te onderzoeken en de betrokkenheid van 
HS bij de ontwikkeling en de fysiologie van de spier te analyseren.
De distributie van HS-epitopen in skeletspier
In hoofdstuk 2 is beschreven hoe met behulp van 'phage display' epitoop- 
specifieke antilichamen zijn geselecteerd tegen HS geïsoleerd uit skelet- 
spier. Gebruikmakend van deze antilichamen werd aangetoond dat in­
dividuele HS-epitopen verschillend voorkomen in spier BL. Sommige 
HS epitopen zijn aanwezig in de gehele BL, terwijl andere HS epitopen 
slechts beperkt voorkomen, in het bijzonder met betrekking tot de NMJ. 
Verschillende HS epitopen colocaliseren met acetylcholine receptor clus­
ters zowel in situ  als in vitro.
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In hoofdstuk 3 worden de epitopen bestudeerd die worden herkend 
door de anti-HS antilichamen. De verschillende HS epitopen vertonen 
een gereguleerde topologische verdeling en zijn ook chemisch verschil­
lend. De positie van de sulfaatgroepen is het belangrijkst.
Hoofdstuk 4 beschrijft in detail het voorkomen van HS epitopen in 
skeletspier tijdens de embryogenese in de muis. Er wordt aangetoond 
dat gedurende de ontwikkeling van de spier de spatio-temporele ex­
pressie van de verschillende HS epitopen in hoge mate is gereguleerd. 
Deze dynamische distributie van HS epitopen kan een specifiek extra- 
cellulair microklimaat creëren, dat nodig is voor de verschillende pro­
cessen tijdens de myogenese en synaptogenese.
Een rol voor HS in de calciumhuishouding van spier
In hoofdstuk 5 worden veranderingen beschreven in de calciumkinetiek 
van gekweekte primaire spiercellen van muizen met een defect in een 
gen coderend voor een eiwit dat is betrokken bij de synthese van HS. 
Spiercellen van muizen knock-out voor het enzym N-deacetylase/N- 
sulfotransferase-1 vertonen duidelijk minder reactie met anti-HS antili- 
chamen. Ook worden significante veranderingen in de kinetiek van 
calciumtransiënten waargenomen. Na electrische stimulatie is er een 
verminderde flux van calcium over de membraan van het sarcoplasma- 
tisch reticulum en een langzamere daling naar de basaalwaarde verge­
leken met wildtype spiercellen. In overeenstemming met de data gepre­
senteerd in het volgende hoofdstuk wordt een verband beschreven tus­
sen veranderingen in HS in de spier en in de calciumkinetiek.
In hoofdstuk  6 worden nieuwe expressiesystemen beschreven, 
waarin anti-HS antilichamen als zogenaamde intrabodies tot expressie 
worden gebracht in een C2C12 myoblast-cellijn. Door endogene expres­
sie van anti-HS antilichamen of van het HS-afbrekende enzym 
heparanase kan worden voorkomen dat HS epitopen aan het cellulaire 
oppervlak tot expressie komen. Als gevolg hiervan ontstaan er spier­
cellen die aangedaan zijn in hun oppervlakte HS. Deze cellen vertonen 
verschillende afwijkingen in hun calciumhuishouding.
Een zeldzaam HS-achtig glycosaminoglycan (GAG), dat specifiek is 
voor skeletspier en is gelocaliseerd in het sarcoplasmatisch reticulum 
wordt beschreven in hoofdstuk 7. Een antilichaam hiertegen werd ge­
selecteerd tegen GAGs geïsoleerd uit skeletspier. Dit molecuul kan 
deficiënt gemaaktworden in gekweekte C2C12 spiercellen door expressie 
van het antilichaam met behulp van de eerder beschreven expressie- 
systemen. Het gevolg hiervan is dat de kinetiek van electrisch-geïndu- 
ceerde calciumfluxen significant verandert.
De in deze hoofdstukken beschreven resultaten wijzen op een rol 
voor HS bij de calciumhuishouding in skeletspier.
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List of abbreviations
ACh acetylcholine
AChE acetylcholine esterase
AChR acetylcholine receptor
AP action potential
AS acharan sulfate
BL basal lamina
[Ca2+]j cytosolic Ca2+ concentration
CDR3 complementarity determining region 3
CHO Chinese hamster ovary
CK creatine kinase
CS chondroitin sulfate
DHPR dihydropyridine receptor
DS dermatan sulfate
e-c coupling excitation-contraction coupling
ECM extracellular matrix
EDL extensor digitorum longus
EGFP enhanced green fluorescent protein
ELISA enzyme linked immunosorbent assay
EPP endplate potential
GAG glycosaminoglycan
Gal D-galactose
GalNAc N-acetyl-D-galactosamine
GlcA D-glucuronic acid
GlcNAc N-acetyl-D-glucosamine
HA hyaluronic acid
Hep heparin
HS heparan sulfate
HS2ST heparan sulfate 2-O-sulfotransferase
HS6ST heparan sulfate 6-O-sulfotransferase
HSPG heparan sulfate proteoglycan
IduA L-iduronic acid
IFA immunofluorescence assay
KS keratan sulfate
MuSK muscle-specific kinase
NDST N-deacetylase/N-sulfotransferase
NMJ neuromuscular junction
3-OST heparan sulfate glucosaminyl 3-O-sulfotransferase
ROI region of interest
RyR ryanodine receptor
sBL synaptic basal lamina
scFv single chain variable fragment
SERCA sarcoplasmic reticulum calcium ATPase
SR sarcoplasmic reticulum
T-tubule transverse tubule
VgNa+Ch voltage gated Na+channel
Xyl D-xylose
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